#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Association of Magnetoencephalographically Measured High-Frequency Oscillations in Visual Cortex With Circuit Dysfunctions in Local and Large-scale Networks During Emerging Psychosis
#Text=Key Points
#Text=Question
#Text=Are high-frequency oscillations in visual cortex impaired during early stages of psychosis?
1-1	0-11	Association	_	
1-2	12-14	of	_	
1-3	15-42	Magnetoencephalographically	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[1]	
1-4	43-51	Measured	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[1]	
1-5	52-66	High-Frequency	_	
1-6	67-79	Oscillations	_	
1-7	80-82	in	_	
1-8	83-89	Visual	_	
1-9	90-96	Cortex	_	
1-10	97-101	With	_	
1-11	102-109	Circuit	_	
1-12	110-122	Dysfunctions	_	
1-13	123-125	in	_	
1-14	126-131	Local	_	
1-15	132-135	and	_	
1-16	136-147	Large-scale	_	
1-17	148-156	Networks	_	
1-18	157-163	During	_	
1-19	164-172	Emerging	_	
1-20	173-182	Psychosis	_	
1-21	183-186	Key	_	
1-22	187-193	Points	_	
1-23	194-202	Question	_	
1-24	203-206	Are	_	
1-25	207-221	high-frequency	_	
1-26	222-234	oscillations	_	
1-27	235-237	in	_	
1-28	238-244	visual	_	
1-29	245-251	cortex	_	
1-30	252-260	impaired	_	
1-31	261-267	during	_	
1-32	268-273	early	_	
1-33	274-280	stages	_	
1-34	281-283	of	_	
1-35	284-293	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder	
1-36	293-294	?	_	

#Text=Findings
#Text=In this cross-sectional study, there were significant impairments in the variability, power, and connectivity of neural oscillations during visual processing in clinical high-risk participants and patients with first-episode psychosis that were associated with impaired functioning and cognitive deficits.
2-1	295-303	Findings	_	
2-2	304-306	In	_	
2-3	307-311	this	_	
2-4	312-327	cross-sectional	_	
2-5	328-333	study	_	
2-6	333-334	,	_	
2-7	335-340	there	_	
2-8	341-345	were	_	
2-9	346-357	significant	_	
2-10	358-369	impairments	_	
2-11	370-372	in	_	
2-12	373-376	the	_	
2-13	377-388	variability	_	
2-14	388-389	,	_	
2-15	390-395	power	_	
2-16	395-396	,	_	
2-17	397-400	and	_	
2-18	401-413	connectivity	_	
2-19	414-416	of	_	
2-20	417-423	neural	_	
2-21	424-436	oscillations	_	
2-22	437-443	during	_	
2-23	444-450	visual	_	
2-24	451-461	processing	_	
2-25	462-464	in	_	
2-26	465-473	clinical	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[2]	
2-27	474-483	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[2]	
2-28	484-496	participants	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[2]	
2-29	497-500	and	_	
2-30	501-509	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
2-31	510-514	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
2-32	515-528	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
2-33	529-538	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[3]	
2-34	539-543	that	_	
2-35	544-548	were	_	
2-36	549-559	associated	_	
2-37	560-564	with	_	
2-38	565-573	impaired	_	
2-39	574-585	functioning	_	
2-40	586-589	and	_	
2-41	590-599	cognitive	_	
2-42	600-608	deficits	_	
2-43	608-609	.	_	

#Text=Moreover, the increased variability of γ-band oscillations in visual cortex was also associated with the persistence of subthreshold psychotic symptoms in clinical high-risk participants.
3-1	610-618	Moreover	_	
3-2	618-619	,	_	
3-3	620-623	the	_	
3-4	624-633	increased	_	
3-5	634-645	variability	_	
3-6	646-648	of	_	
3-7	649-655	γ-band	_	
3-8	656-668	oscillations	_	
3-9	669-671	in	_	
3-10	672-678	visual	_	
3-11	679-685	cortex	_	
3-12	686-689	was	_	
3-13	690-694	also	_	
3-14	695-705	associated	_	
3-15	706-710	with	_	
3-16	711-714	the	_	
3-17	715-726	persistence	_	
3-18	727-729	of	_	
3-19	730-742	subthreshold	_	
3-20	743-752	psychotic	_	
3-21	753-761	symptoms	_	
3-22	762-764	in	_	
3-23	765-773	clinical	_	
3-24	774-783	high-risk	_	
3-25	784-796	participants	_	
3-26	796-797	.	_	

#Text=Meaning
#Text=Impaired high-frequency oscillations in visual cortex are an important aspect of circuit dysfunction, which could constitute a biomarker for clinical staging of emerging psychosis.
4-1	798-805	Meaning	_	
4-2	806-814	Impaired	_	
4-3	815-829	high-frequency	_	
4-4	830-842	oscillations	_	
4-5	843-845	in	_	
4-6	846-852	visual	_	
4-7	853-859	cortex	_	
4-8	860-863	are	_	
4-9	864-866	an	_	
4-10	867-876	important	_	
4-11	877-883	aspect	_	
4-12	884-886	of	_	
4-13	887-894	circuit	_	
4-14	895-906	dysfunction	_	
4-15	906-907	,	_	
4-16	908-913	which	_	
4-17	914-919	could	_	
4-18	920-930	constitute	_	
4-19	931-932	a	_	
4-20	933-942	biomarker	_	
4-21	943-946	for	_	
4-22	947-955	clinical	_	
4-23	956-963	staging	_	
4-24	964-966	of	_	
4-25	967-975	emerging	_	
4-26	976-985	psychosis	_	
4-27	985-986	.	_	

#Text=Importance
#Text=Psychotic disorders are characterized by impairments in neural oscillations, but the nature of the deficit, the trajectory across illness stages, and functional relevance remain unclear.
5-1	987-997	Importance	_	
5-2	998-1007	Psychotic	_	
5-3	1008-1017	disorders	_	
5-4	1018-1021	are	_	
5-5	1022-1035	characterized	_	
5-6	1036-1038	by	_	
5-7	1039-1050	impairments	_	
5-8	1051-1053	in	_	
5-9	1054-1060	neural	_	
5-10	1061-1073	oscillations	_	
5-11	1073-1074	,	_	
5-12	1075-1078	but	_	
5-13	1079-1082	the	_	
5-14	1083-1089	nature	_	
5-15	1090-1092	of	_	
5-16	1093-1096	the	_	
5-17	1097-1104	deficit	_	
5-18	1104-1105	,	_	
5-19	1106-1109	the	_	
5-20	1110-1120	trajectory	_	
5-21	1121-1127	across	_	
5-22	1128-1135	illness	_	
5-23	1136-1142	stages	_	
5-24	1142-1143	,	_	
5-25	1144-1147	and	_	
5-26	1148-1158	functional	_	
5-27	1159-1168	relevance	_	
5-28	1169-1175	remain	_	
5-29	1176-1183	unclear	_	
5-30	1183-1184	.	_	

#Text=Objectives
#Text=To examine whether changes in spectral power, phase locking, and functional connectivity in visual cortex are present during emerging psychosis and whether these abnormalities are associated with clinical outcomes.
6-1	1185-1195	Objectives	_	
6-2	1196-1198	To	_	
6-3	1199-1206	examine	_	
6-4	1207-1214	whether	_	
6-5	1215-1222	changes	_	
6-6	1223-1225	in	_	
6-7	1226-1234	spectral	_	
6-8	1235-1240	power	_	
6-9	1240-1241	,	_	
6-10	1242-1247	phase	_	
6-11	1248-1255	locking	_	
6-12	1255-1256	,	_	
6-13	1257-1260	and	_	
6-14	1261-1271	functional	_	
6-15	1272-1284	connectivity	_	
6-16	1285-1287	in	_	
6-17	1288-1294	visual	_	
6-18	1295-1301	cortex	_	
6-19	1302-1305	are	_	
6-20	1306-1313	present	_	
6-21	1314-1320	during	_	
6-22	1321-1329	emerging	_	
6-23	1330-1339	psychosis	_	
6-24	1340-1343	and	_	
6-25	1344-1351	whether	_	
6-26	1352-1357	these	_	
6-27	1358-1371	abnormalities	_	
6-28	1372-1375	are	_	
6-29	1376-1386	associated	_	
6-30	1387-1391	with	_	
6-31	1392-1400	clinical	_	
6-32	1401-1409	outcomes	_	
6-33	1409-1410	.	_	

#Text=Design, Setting, and Participants
#Text=In this cross-sectional study, participants meeting clinical high-risk criteria for psychosis, participants with first-episode psychosis, participants with affective disorders and substance abuse, and a group of control participants were recruited.
7-1	1411-1417	Design	_	
7-2	1417-1418	,	_	
7-3	1419-1426	Setting	_	
7-4	1426-1427	,	_	
7-5	1428-1431	and	_	
7-6	1432-1444	Participants	_	
7-7	1445-1447	In	_	
7-8	1448-1452	this	_	
7-9	1453-1468	cross-sectional	_	
7-10	1469-1474	study	_	
7-11	1474-1475	,	_	
7-12	1476-1488	participants	_	
7-13	1489-1496	meeting	_	
7-14	1497-1505	clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[4]	
7-15	1506-1515	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[4]	
7-16	1516-1524	criteria	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[4]	
7-17	1525-1528	for	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[4]	
7-18	1529-1538	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[4]	
7-19	1538-1539	,	_	
7-20	1540-1552	participants	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]	
7-21	1553-1557	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]	
7-22	1558-1571	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]	
7-23	1572-1581	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]	
7-24	1581-1582	,	_	
7-25	1583-1595	participants	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[6]	
7-26	1596-1600	with	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[6]	
7-27	1601-1610	affective	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[6]	
7-28	1611-1620	disorders	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[6]	
7-29	1621-1624	and	_	
7-30	1625-1634	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
7-31	1635-1640	abuse	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
7-32	1640-1641	,	_	
7-33	1642-1645	and	_	
7-34	1646-1647	a	_	
7-35	1648-1653	group	_	
7-36	1654-1656	of	_	
7-37	1657-1664	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
7-38	1665-1677	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
7-39	1678-1682	were	_	
7-40	1683-1692	recruited	_	
7-41	1692-1693	.	_	

#Text=Participants underwent measurements with magnetoencephalography and magnetic resonance imaging.
8-1	1694-1706	Participants	_	
8-2	1707-1716	underwent	_	
8-3	1717-1729	measurements	_	
8-4	1730-1734	with	_	
8-5	1735-1757	magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
8-6	1758-1761	and	_	
8-7	1762-1770	magnetic	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[9]	
8-8	1771-1780	resonance	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[9]	
8-9	1781-1788	imaging	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[9]	
8-10	1788-1789	.	_	

#Text=Data analysis was carried out between 2018 and 2019.
9-1	1790-1794	Data	_	
9-2	1795-1803	analysis	_	
9-3	1804-1807	was	_	
9-4	1808-1815	carried	_	
9-5	1816-1819	out	_	
9-6	1820-1827	between	_	
9-7	1828-1832	2018	_	
9-8	1833-1836	and	_	
9-9	1837-1841	2019	_	
9-10	1841-1842	.	_	

#Text=Main Outcomes and Measures
#Text=Magnetoencephalographical activity was examined in the 1- to 90-Hz frequency range in combination with source reconstruction during a visual grating task.
10-1	1843-1847	Main	_	
10-2	1848-1856	Outcomes	_	
10-3	1857-1860	and	_	
10-4	1861-1869	Measures	_	
10-5	1870-1895	Magnetoencephalographical	_	
10-6	1896-1904	activity	_	
10-7	1905-1908	was	_	
10-8	1909-1917	examined	_	
10-9	1918-1920	in	_	
10-10	1921-1924	the	_	
10-11	1925-1926	1	_	
10-12	1926-1927	-	_	
10-13	1928-1930	to	_	
10-14	1931-1933	90	_	
10-15	1933-1934	-	_	
10-16	1934-1936	Hz	_	
10-17	1937-1946	frequency	_	
10-18	1947-1952	range	_	
10-19	1953-1955	in	_	
10-20	1956-1967	combination	_	
10-21	1968-1972	with	_	
10-22	1973-1979	source	_	
10-23	1980-1994	reconstruction	_	
10-24	1995-2001	during	_	
10-25	2002-2003	a	_	
10-26	2004-2010	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
10-27	2011-2018	grating	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
10-28	2019-2023	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
10-29	2023-2024	.	_	

#Text=Event-related fields, power modulation, intertrial phase consistency, and connectivity measures in visual and frontal cortices were associated with neuropsychological scores, psychosocial functioning, and clinical symptoms as well as persistence of subthreshold psychotic symptoms at 12 months.
11-1	2025-2038	Event-related	_	
11-2	2039-2045	fields	_	
11-3	2045-2046	,	_	
11-4	2047-2052	power	_	
11-5	2053-2063	modulation	_	
11-6	2063-2064	,	_	
11-7	2065-2075	intertrial	_	
11-8	2076-2081	phase	_	
11-9	2082-2093	consistency	_	
11-10	2093-2094	,	_	
11-11	2095-2098	and	_	
11-12	2099-2111	connectivity	_	
11-13	2112-2120	measures	_	
11-14	2121-2123	in	_	
11-15	2124-2130	visual	_	
11-16	2131-2134	and	_	
11-17	2135-2142	frontal	_	
11-18	2143-2151	cortices	_	
11-19	2152-2156	were	_	
11-20	2157-2167	associated	_	
11-21	2168-2172	with	_	
11-22	2173-2191	neuropsychological	_	
11-23	2192-2198	scores	_	
11-24	2198-2199	,	_	
11-25	2200-2212	psychosocial	_	
11-26	2213-2224	functioning	_	
11-27	2224-2225	,	_	
11-28	2226-2229	and	_	
11-29	2230-2238	clinical	_	
11-30	2239-2247	symptoms	_	
11-31	2248-2250	as	_	
11-32	2251-2255	well	_	
11-33	2256-2258	as	_	
11-34	2259-2270	persistence	_	
11-35	2271-2273	of	_	
11-36	2274-2286	subthreshold	_	
11-37	2287-2296	psychotic	_	
11-38	2297-2305	symptoms	_	
11-39	2306-2308	at	_	
11-40	2309-2311	12	_	
11-41	2312-2318	months	_	
11-42	2318-2319	.	_	

#Text=Results
#Text=The study participants included those meeting clinical high-risk criteria for psychosis (n = 119; mean [SD] age, 22 [4.4] years; 32 men), 26 patients with first-episode psychosis (mean [SD] age, 24 [4.2] years; 16 men), 38 participants with affective disorders and substance abuse (mean [SD] age, 23 [4.7] years; 11 men), and 49 control participants (mean age [SD], 23 [3.6] years; 16 men).
12-1	2320-2327	Results	_	
12-2	2328-2331	The	_	
12-3	2332-2337	study	_	
12-4	2338-2350	participants	_	
12-5	2351-2359	included	_	
12-6	2360-2365	those	_	
12-7	2366-2373	meeting	_	
12-8	2374-2382	clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[11]	
12-9	2383-2392	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[11]	
12-10	2393-2401	criteria	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[11]	
12-11	2402-2405	for	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[11]	
12-12	2406-2415	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[11]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]	
12-13	2416-2417	(	_	
12-14	2417-2418	n	_	
12-15	2419-2420	=	_	
12-16	2421-2424	119	_	
12-17	2424-2425	;	_	
12-18	2426-2430	mean	_	
12-19	2431-2432	[	_	
12-20	2432-2434	SD	_	
12-21	2434-2435	]	_	
12-22	2436-2439	age	_	
12-23	2439-2440	,	_	
12-24	2441-2443	22	_	
12-25	2444-2445	[	_	
12-26	2445-2448	4.4	_	
12-27	2448-2449	]	_	
12-28	2450-2455	years	_	
12-29	2455-2456	;	_	
12-30	2457-2459	32	_	
12-31	2460-2463	men	_	
12-32	2463-2464	)	_	
12-33	2464-2465	,	_	
12-34	2466-2468	26	_	
12-35	2469-2477	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[13]	
12-36	2478-2482	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[13]	
12-37	2483-2496	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[13]	
12-38	2497-2506	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[13]	
12-39	2507-2508	(	_	
12-40	2508-2512	mean	_	
12-41	2513-2514	[	_	
12-42	2514-2516	SD	_	
12-43	2516-2517	]	_	
12-44	2518-2521	age	_	
12-45	2521-2522	,	_	
12-46	2523-2525	24	_	
12-47	2526-2527	[	_	
12-48	2527-2530	4.2	_	
12-49	2530-2531	]	_	
12-50	2532-2537	years	_	
12-51	2537-2538	;	_	
12-52	2539-2541	16	_	
12-53	2542-2545	men	_	
12-54	2545-2546	)	_	
12-55	2546-2547	,	_	
12-56	2548-2550	38	_	
12-57	2551-2563	participants	_	
12-58	2564-2568	with	_	
12-59	2569-2578	affective	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[14]	
12-60	2579-2588	disorders	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[14]	
12-61	2589-2592	and	_	
12-62	2593-2602	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
12-63	2603-2608	abuse	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
12-64	2609-2610	(	_	
12-65	2610-2614	mean	_	
12-66	2615-2616	[	_	
12-67	2616-2618	SD	_	
12-68	2618-2619	]	_	
12-69	2620-2623	age	_	
12-70	2623-2624	,	_	
12-71	2625-2627	23	_	
12-72	2628-2629	[	_	
12-73	2629-2632	4.7	_	
12-74	2632-2633	]	_	
12-75	2634-2639	years	_	
12-76	2639-2640	;	_	
12-77	2641-2643	11	_	
12-78	2644-2647	men	_	
12-79	2647-2648	)	_	
12-80	2648-2649	,	_	
12-81	2650-2653	and	_	
12-82	2654-2656	49	_	
12-83	2657-2664	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
12-84	2665-2677	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
12-85	2678-2679	(	_	
12-86	2679-2683	mean	_	
12-87	2684-2687	age	_	
12-88	2688-2689	[	_	
12-89	2689-2691	SD	_	
12-90	2691-2692	]	_	
12-91	2692-2693	,	_	
12-92	2694-2696	23	_	
12-93	2697-2698	[	_	
12-94	2698-2701	3.6	_	
12-95	2701-2702	]	_	
12-96	2703-2708	years	_	
12-97	2708-2709	;	_	
12-98	2710-2712	16	_	
12-99	2713-2716	men	_	
12-100	2716-2717	)	_	
12-101	2717-2718	.	_	

#Text=Clinical high-risk participants and patients with first-episode psychosis were characterized by reduced phase consistency of β/γ-band oscillations in visual cortex (d = 0.63/d = 0.93).
13-1	2719-2727	Clinical	_	
13-2	2728-2737	high-risk	_	
13-3	2738-2750	participants	_	
13-4	2751-2754	and	_	
13-5	2755-2763	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[17]	
13-6	2764-2768	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[17]	
13-7	2769-2782	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[17]	
13-8	2783-2792	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[17]	
13-9	2793-2797	were	_	
13-10	2798-2811	characterized	_	
13-11	2812-2814	by	_	
13-12	2815-2822	reduced	_	
13-13	2823-2828	phase	_	
13-14	2829-2840	consistency	_	
13-15	2841-2843	of	_	
13-16	2844-2845	β	_	
13-17	2845-2846	/	_	
13-18	2846-2852	γ-band	_	
13-19	2853-2865	oscillations	_	
13-20	2866-2868	in	_	
13-21	2869-2875	visual	_	
13-22	2876-2882	cortex	_	
13-23	2883-2884	(	_	
13-24	2884-2885	d	_	
13-25	2886-2887	=	_	
13-26	2888-2892	0.63	_	
13-27	2892-2893	/	_	
13-28	2893-2894	d	_	
13-29	2895-2896	=	_	
13-30	2897-2901	0.93	_	
13-31	2901-2902	)	_	
13-32	2902-2903	.	_	

#Text=Moreover, the first-episode psychosis group was also characterized by reduced occipital γ-band power (d = 1.14) and altered visual cortex connectivity (d = 0.74-0.84).
14-1	2904-2912	Moreover	_	
14-2	2912-2913	,	_	
14-3	2914-2917	the	_	
14-4	2918-2931	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[18]	
14-5	2932-2941	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[18]	
14-6	2942-2947	group	_	
14-7	2948-2951	was	_	
14-8	2952-2956	also	_	
14-9	2957-2970	characterized	_	
14-10	2971-2973	by	_	
14-11	2974-2981	reduced	_	
14-12	2982-2991	occipital	_	
14-13	2992-2998	γ-band	_	
14-14	2999-3004	power	_	
14-15	3005-3006	(	_	
14-16	3006-3007	d	_	
14-17	3008-3009	=	_	
14-18	3010-3014	1.14	_	
14-19	3014-3015	)	_	
14-20	3016-3019	and	_	
14-21	3020-3027	altered	_	
14-22	3028-3034	visual	_	
14-23	3035-3041	cortex	_	
14-24	3042-3054	connectivity	_	
14-25	3055-3056	(	_	
14-26	3056-3057	d	_	
14-27	3058-3059	=	_	
14-28	3060-3064	0.74	_	
14-29	3064-3065	-	_	
14-30	3065-3069	0.84	_	
14-31	3069-3070	)	_	
14-32	3070-3071	.	_	

#Text=Impaired fronto-occipital connectivity was present in both clinical high-risk participants (d = 0.54) and patients with first-episode psychosis (d = 0.84).
15-1	3072-3080	Impaired	_	
15-2	3081-3097	fronto-occipital	_	
15-3	3098-3110	connectivity	_	
15-4	3111-3114	was	_	
15-5	3115-3122	present	_	
15-6	3123-3125	in	_	
15-7	3126-3130	both	_	
15-8	3131-3139	clinical	_	
15-9	3140-3149	high-risk	_	
15-10	3150-3162	participants	_	
15-11	3163-3164	(	_	
15-12	3164-3165	d	_	
15-13	3166-3167	=	_	
15-14	3168-3172	0.54	_	
15-15	3172-3173	)	_	
15-16	3174-3177	and	_	
15-17	3178-3186	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[19]	
15-18	3187-3191	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[19]	
15-19	3192-3205	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[19]	
15-20	3206-3215	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[19]	
15-21	3216-3217	(	_	
15-22	3217-3218	d	_	
15-23	3219-3220	=	_	
15-24	3221-3225	0.84	_	
15-25	3225-3226	)	_	
15-26	3226-3227	.	_	

#Text=Importantly, reductions in intertrial phase coherence predicted persistence of subthreshold psychosis in clinical high-risk participants (receiver operating characteristic area under curve = 0.728; 95% CI, 0.612-0.841; P = .001).
16-1	3228-3239	Importantly	_	
16-2	3239-3240	,	_	
16-3	3241-3251	reductions	_	
16-4	3252-3254	in	_	
16-5	3255-3265	intertrial	_	
16-6	3266-3271	phase	_	
16-7	3272-3281	coherence	_	
16-8	3282-3291	predicted	_	
16-9	3292-3303	persistence	_	
16-10	3304-3306	of	_	
16-11	3307-3319	subthreshold	_	
16-12	3320-3329	psychosis	_	
16-13	3330-3332	in	_	
16-14	3333-3341	clinical	_	
16-15	3342-3351	high-risk	_	
16-16	3352-3364	participants	_	
16-17	3365-3366	(	_	
16-18	3366-3374	receiver	_	
16-19	3375-3384	operating	_	
16-20	3385-3399	characteristic	_	
16-21	3400-3404	area	_	
16-22	3405-3410	under	_	
16-23	3411-3416	curve	_	
16-24	3417-3418	=	_	
16-25	3419-3424	0.728	_	
16-26	3424-3425	;	_	
16-27	3426-3429	95%	_	
16-28	3430-3432	CI	_	
16-29	3432-3433	,	_	
16-30	3434-3439	0.612	_	
16-31	3439-3440	-	_	
16-32	3440-3445	0.841	_	
16-33	3445-3446	;	_	
16-34	3447-3448	P	_	
16-35	3449-3450	=	_	
16-36	3451-3455	.001	_	
16-37	3455-3456	)	_	
16-38	3456-3457	.	_	

#Text=Conclusions and Relevance
#Text=High-frequency oscillations are impaired in the visual cortex during emerging psychosis and may be linked to behavioral and clinical impairments.
17-1	3458-3469	Conclusions	_	
17-2	3470-3473	and	_	
17-3	3474-3483	Relevance	_	
17-4	3484-3498	High-frequency	_	
17-5	3499-3511	oscillations	_	
17-6	3512-3515	are	_	
17-7	3516-3524	impaired	_	
17-8	3525-3527	in	_	
17-9	3528-3531	the	_	
17-10	3532-3538	visual	_	
17-11	3539-3545	cortex	_	
17-12	3546-3552	during	_	
17-13	3553-3561	emerging	_	
17-14	3562-3571	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis	
17-15	3572-3575	and	_	
17-16	3576-3579	may	_	
17-17	3580-3582	be	_	
17-18	3583-3589	linked	_	
17-19	3590-3592	to	_	
17-20	3593-3603	behavioral	_	
17-21	3604-3607	and	_	
17-22	3608-3616	clinical	_	
17-23	3617-3628	impairments	_	
17-24	3628-3629	.	_	

#Text=Impaired phase consistency of γ-band oscillations was also associated with the persistence of subthreshold psychosis, suggesting that magnetoencephalographical measured neural oscillations could constitute a biomarker for clinical staging of emerging psychosis.
18-1	3630-3638	Impaired	_	
18-2	3639-3644	phase	_	
18-3	3645-3656	consistency	_	
18-4	3657-3659	of	_	
18-5	3660-3666	γ-band	_	
18-6	3667-3679	oscillations	_	
18-7	3680-3683	was	_	
18-8	3684-3688	also	_	
18-9	3689-3699	associated	_	
18-10	3700-3704	with	_	
18-11	3705-3708	the	_	
18-12	3709-3720	persistence	_	
18-13	3721-3723	of	_	
18-14	3724-3736	subthreshold	_	
18-15	3737-3746	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis	
18-16	3746-3747	,	_	
18-17	3748-3758	suggesting	_	
18-18	3759-3763	that	_	
18-19	3764-3789	magnetoencephalographical	_	
18-20	3790-3798	measured	_	
18-21	3799-3805	neural	_	
18-22	3806-3818	oscillations	_	
18-23	3819-3824	could	_	
18-24	3825-3835	constitute	_	
18-25	3836-3837	a	_	
18-26	3838-3847	biomarker	_	
18-27	3848-3851	for	_	
18-28	3852-3860	clinical	_	
18-29	3861-3868	staging	_	
18-30	3869-3871	of	_	
18-31	3872-3880	emerging	_	
18-32	3881-3890	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis	
18-33	3890-3891	.	_	

#Text=This study examines whether changes in spectral power, phase locking, and functional connectivity in visual cortex are present during emerging psychosis and whether these abnormalities are associated with clinical outcomes.
19-1	3892-3896	This	_	
19-2	3897-3902	study	_	
19-3	3903-3911	examines	_	
19-4	3912-3919	whether	_	
19-5	3920-3927	changes	_	
19-6	3928-3930	in	_	
19-7	3931-3939	spectral	_	
19-8	3940-3945	power	_	
19-9	3945-3946	,	_	
19-10	3947-3952	phase	_	
19-11	3953-3960	locking	_	
19-12	3960-3961	,	_	
19-13	3962-3965	and	_	
19-14	3966-3976	functional	_	
19-15	3977-3989	connectivity	_	
19-16	3990-3992	in	_	
19-17	3993-3999	visual	_	
19-18	4000-4006	cortex	_	
19-19	4007-4010	are	_	
19-20	4011-4018	present	_	
19-21	4019-4025	during	_	
19-22	4026-4034	emerging	_	
19-23	4035-4044	psychosis	_	
19-24	4045-4048	and	_	
19-25	4049-4056	whether	_	
19-26	4057-4062	these	_	
19-27	4063-4076	abnormalities	_	
19-28	4077-4080	are	_	
19-29	4081-4091	associated	_	
19-30	4092-4096	with	_	
19-31	4097-4105	clinical	_	
19-32	4106-4114	outcomes	_	
19-33	4114-4115	.	_	

#Text=Introduction
#Text=Neural oscillations are a crucial aspect of normal brain functioning owing to their role in facilitating communication between neuronal populations, a process that is closely linked to the integrity of sensory and cognitive processes.
20-1	4116-4128	Introduction	_	
20-2	4129-4135	Neural	_	
20-3	4136-4148	oscillations	_	
20-4	4149-4152	are	_	
20-5	4153-4154	a	_	
20-6	4155-4162	crucial	_	
20-7	4163-4169	aspect	_	
20-8	4170-4172	of	_	
20-9	4173-4179	normal	_	
20-10	4180-4185	brain	_	
20-11	4186-4197	functioning	_	
20-12	4198-4203	owing	_	
20-13	4204-4206	to	_	
20-14	4207-4212	their	_	
20-15	4213-4217	role	_	
20-16	4218-4220	in	_	
20-17	4221-4233	facilitating	_	
20-18	4234-4247	communication	_	
20-19	4248-4255	between	_	
20-20	4256-4264	neuronal	_	
20-21	4265-4276	populations	_	
20-22	4276-4277	,	_	
20-23	4278-4279	a	_	
20-24	4280-4287	process	_	
20-25	4288-4292	that	_	
20-26	4293-4295	is	_	
20-27	4296-4303	closely	_	
20-28	4304-4310	linked	_	
20-29	4311-4313	to	_	
20-30	4314-4317	the	_	
20-31	4318-4327	integrity	_	
20-32	4328-4330	of	_	
20-33	4331-4338	sensory	_	
20-34	4339-4342	and	_	
20-35	4343-4352	cognitive	_	
20-36	4353-4362	processes	_	
20-37	4362-4363	.	_	

#Text=There is emerging evidence that psychotic disorders with pronounced cognitive impairments, such as schizophrenia, involve aberrant neuronal oscillations, but the nature of the impairment, the onset of deficits, and clinical relevance remain unclear.
#Text=β/γ-Band oscillations but also lower frequencies are impaired during sensory and cognitive tasks in schizophrenia.
21-1	4364-4369	There	_	
21-2	4370-4372	is	_	
21-3	4373-4381	emerging	_	
21-4	4382-4390	evidence	_	
21-5	4391-4395	that	_	
21-6	4396-4405	psychotic	_	
21-7	4406-4415	disorders	_	
21-8	4416-4420	with	_	
21-9	4421-4431	pronounced	_	
21-10	4432-4441	cognitive	_	
21-11	4442-4453	impairments	_	
21-12	4453-4454	,	_	
21-13	4455-4459	such	_	
21-14	4460-4462	as	_	
21-15	4463-4476	schizophrenia	_	
21-16	4476-4477	,	_	
21-17	4478-4485	involve	_	
21-18	4486-4494	aberrant	_	
21-19	4495-4503	neuronal	_	
21-20	4504-4516	oscillations	_	
21-21	4516-4517	,	_	
21-22	4518-4521	but	_	
21-23	4522-4525	the	_	
21-24	4526-4532	nature	_	
21-25	4533-4535	of	_	
21-26	4536-4539	the	_	
21-27	4540-4550	impairment	_	
21-28	4550-4551	,	_	
21-29	4552-4555	the	_	
21-30	4556-4561	onset	_	
21-31	4562-4564	of	_	
21-32	4565-4573	deficits	_	
21-33	4573-4574	,	_	
21-34	4575-4578	and	_	
21-35	4579-4587	clinical	_	
21-36	4588-4597	relevance	_	
21-37	4598-4604	remain	_	
21-38	4605-4612	unclear	_	
21-39	4612-4613	.	_	
21-40	4614-4615	β	_	
21-41	4615-4616	/	_	
21-42	4616-4622	γ-Band	_	
21-43	4623-4635	oscillations	_	
21-44	4636-4639	but	_	
21-45	4640-4644	also	_	
21-46	4645-4650	lower	_	
21-47	4651-4662	frequencies	_	
21-48	4663-4666	are	_	
21-49	4667-4675	impaired	_	
21-50	4676-4682	during	_	
21-51	4683-4690	sensory	_	
21-52	4691-4694	and	_	
21-53	4695-4704	cognitive	_	
21-54	4705-4710	tasks	_	
21-55	4711-4713	in	_	
21-56	4714-4727	schizophrenia	_	
21-57	4727-4728	.	_	

#Text=During normal brain functioning, inhibition of excitatory pyramidal cells through different classes of aminobutyric acid (GABA)ergic interneurons lead to the emergence of neural oscillations.
22-1	4729-4735	During	_	
22-2	4736-4742	normal	_	
22-3	4743-4748	brain	_	
22-4	4749-4760	functioning	_	
22-5	4760-4761	,	_	
22-6	4762-4772	inhibition	_	
22-7	4773-4775	of	_	
22-8	4776-4786	excitatory	_	
22-9	4787-4796	pyramidal	_	
22-10	4797-4802	cells	_	
22-11	4803-4810	through	_	
22-12	4811-4820	different	_	
22-13	4821-4828	classes	_	
22-14	4829-4831	of	_	
22-15	4832-4844	aminobutyric	_	
22-16	4845-4849	acid	_	
22-17	4850-4851	(	_	
22-18	4851-4855	GABA	_	
22-19	4855-4856	)	_	
22-20	4856-4861	ergic	_	
22-21	4862-4874	interneurons	_	
22-22	4875-4879	lead	_	
22-23	4880-4882	to	_	
22-24	4883-4886	the	_	
22-25	4887-4896	emergence	_	
22-26	4897-4899	of	_	
22-27	4900-4906	neural	_	
22-28	4907-4919	oscillations	_	
22-29	4919-4920	.	_	

#Text=Converging evidence from genetics, postmortem data, and brain imaging have highlighted that GABAergic as well as glutamatergic neurotransmission is impaired in schizophrenia, supporting the possibility that measurements with electro/magnetoencephalography (EEG/MEG) could be important for translational research aimed at identifying circuit mechanisms in the disorder.
23-1	4921-4931	Converging	_	
23-2	4932-4940	evidence	_	
23-3	4941-4945	from	_	
23-4	4946-4954	genetics	_	
23-5	4954-4955	,	_	
23-6	4956-4966	postmortem	_	
23-7	4967-4971	data	_	
23-8	4971-4972	,	_	
23-9	4973-4976	and	_	
23-10	4977-4982	brain	_	
23-11	4983-4990	imaging	_	
23-12	4991-4995	have	_	
23-13	4996-5007	highlighted	_	
23-14	5008-5012	that	_	
23-15	5013-5022	GABAergic	_	
23-16	5023-5025	as	_	
23-17	5026-5030	well	_	
23-18	5031-5033	as	_	
23-19	5034-5047	glutamatergic	_	
23-20	5048-5065	neurotransmission	_	
23-21	5066-5068	is	_	
23-22	5069-5077	impaired	_	
23-23	5078-5080	in	_	
23-24	5081-5094	schizophrenia	_	
23-25	5094-5095	,	_	
23-26	5096-5106	supporting	_	
23-27	5107-5110	the	_	
23-28	5111-5122	possibility	_	
23-29	5123-5127	that	_	
23-30	5128-5140	measurements	_	
23-31	5141-5145	with	_	
23-32	5146-5153	electro	_	
23-33	5153-5154	/	_	
23-34	5154-5176	magnetoencephalography	_	
23-35	5177-5178	(	_	
23-36	5178-5181	EEG	_	
23-37	5181-5182	/	_	
23-38	5182-5185	MEG	_	
23-39	5185-5186	)	_	
23-40	5187-5192	could	_	
23-41	5193-5195	be	_	
23-42	5196-5205	important	_	
23-43	5206-5209	for	_	
23-44	5210-5223	translational	_	
23-45	5224-5232	research	_	
23-46	5233-5238	aimed	_	
23-47	5239-5241	at	_	
23-48	5242-5253	identifying	_	
23-49	5254-5261	circuit	_	
23-50	5262-5272	mechanisms	_	
23-51	5273-5275	in	_	
23-52	5276-5279	the	_	
23-53	5280-5288	disorder	_	
23-54	5288-5289	.	_	

#Text=Critical questions concerning the role of neural oscillations in the pathophysiology of schizophrenia are the onset of abnormalities, the nature of the deficit, and functional relevance.
24-1	5290-5298	Critical	_	
24-2	5299-5308	questions	_	
24-3	5309-5319	concerning	_	
24-4	5320-5323	the	_	
24-5	5324-5328	role	_	
24-6	5329-5331	of	_	
24-7	5332-5338	neural	_	
24-8	5339-5351	oscillations	_	
24-9	5352-5354	in	_	
24-10	5355-5358	the	_	
24-11	5359-5374	pathophysiology	_	
24-12	5375-5377	of	_	
24-13	5378-5391	schizophrenia	_	
24-14	5392-5395	are	_	
24-15	5396-5399	the	_	
24-16	5400-5405	onset	_	
24-17	5406-5408	of	_	
24-18	5409-5422	abnormalities	_	
24-19	5422-5423	,	_	
24-20	5424-5427	the	_	
24-21	5428-5434	nature	_	
24-22	5435-5437	of	_	
24-23	5438-5441	the	_	
24-24	5442-5449	deficit	_	
24-25	5449-5450	,	_	
24-26	5451-5454	and	_	
24-27	5455-5465	functional	_	
24-28	5466-5475	relevance	_	
24-29	5475-5476	.	_	

#Text=Early signs of psychosis as well as associated cognitive deficits are already present several years prior to the full emergence of schizophrenia, and thus, research efforts have shifted the focus toward identifying circuit abnormalities and biomarkers in participants who are at risk for the development of psychotic disorders that could allow for early intervention and clinical staging.
25-1	5477-5482	Early	_	
25-2	5483-5488	signs	_	
25-3	5489-5491	of	_	
25-4	5492-5501	psychosis	_	
25-5	5502-5504	as	_	
25-6	5505-5509	well	_	
25-7	5510-5512	as	_	
25-8	5513-5523	associated	_	
25-9	5524-5533	cognitive	_	
25-10	5534-5542	deficits	_	
25-11	5543-5546	are	_	
25-12	5547-5554	already	_	
25-13	5555-5562	present	_	
25-14	5563-5570	several	_	
25-15	5571-5576	years	_	
25-16	5577-5582	prior	_	
25-17	5583-5585	to	_	
25-18	5586-5589	the	_	
25-19	5590-5594	full	_	
25-20	5595-5604	emergence	_	
25-21	5605-5607	of	_	
25-22	5608-5621	schizophrenia	_	
25-23	5621-5622	,	_	
25-24	5623-5626	and	_	
25-25	5627-5631	thus	_	
25-26	5631-5632	,	_	
25-27	5633-5641	research	_	
25-28	5642-5649	efforts	_	
25-29	5650-5654	have	_	
25-30	5655-5662	shifted	_	
25-31	5663-5666	the	_	
25-32	5667-5672	focus	_	
25-33	5673-5679	toward	_	
25-34	5680-5691	identifying	_	
25-35	5692-5699	circuit	_	
25-36	5700-5713	abnormalities	_	
25-37	5714-5717	and	_	
25-38	5718-5728	biomarkers	_	
25-39	5729-5731	in	_	
25-40	5732-5744	participants	_	
25-41	5745-5748	who	_	
25-42	5749-5752	are	_	
25-43	5753-5755	at	_	
25-44	5756-5760	risk	_	
25-45	5761-5764	for	_	
25-46	5765-5768	the	_	
25-47	5769-5780	development	_	
25-48	5781-5783	of	_	
25-49	5784-5793	psychotic	_	
25-50	5794-5803	disorders	_	
25-51	5804-5808	that	_	
25-52	5809-5814	could	_	
25-53	5815-5820	allow	_	
25-54	5821-5824	for	_	
25-55	5825-5830	early	_	
25-56	5831-5843	intervention	_	
25-57	5844-5847	and	_	
25-58	5848-5856	clinical	_	
25-59	5857-5864	staging	_	
25-60	5864-5865	.	_	

#Text=There is only limited evidence available on alterations of neural oscillations in individuals meeting clinical high-risk criteria for psychosis (CHR-P).
26-1	5866-5871	There	_	
26-2	5872-5874	is	_	
26-3	5875-5879	only	_	
26-4	5880-5887	limited	_	
26-5	5888-5896	evidence	_	
26-6	5897-5906	available	_	
26-7	5907-5909	on	_	
26-8	5910-5921	alterations	_	
26-9	5922-5924	of	_	
26-10	5925-5931	neural	_	
26-11	5932-5944	oscillations	_	
26-12	5945-5947	in	_	
26-13	5948-5959	individuals	_	
26-14	5960-5967	meeting	_	
26-15	5968-5976	clinical	_	
26-16	5977-5986	high-risk	_	
26-17	5987-5995	criteria	_	
26-18	5996-5999	for	_	
26-19	6000-6009	psychosis	_	
26-20	6010-6011	(	_	
26-21	6011-6016	CHR-P	_	
26-22	6016-6017	)	_	
26-23	6017-6018	.	_	

#Text=To address this fundamental question, we applied a state-of-the-art MEG approach to examine low-frequency and high-frequency oscillations during a visual paradigm in CHR-P participants, patients with first-episode psychosis (FEP), and participants with substance-related and affective disorders.
27-1	6019-6021	To	_	
27-2	6022-6029	address	_	
27-3	6030-6034	this	_	
27-4	6035-6046	fundamental	_	
27-5	6047-6055	question	_	
27-6	6055-6056	,	_	
27-7	6057-6059	we	_	
27-8	6060-6067	applied	_	
27-9	6068-6069	a	_	
27-10	6070-6086	state-of-the-art	_	
27-11	6087-6090	MEG	_	
27-12	6091-6099	approach	_	
27-13	6100-6102	to	_	
27-14	6103-6110	examine	_	
27-15	6111-6124	low-frequency	_	
27-16	6125-6128	and	_	
27-17	6129-6143	high-frequency	_	
27-18	6144-6156	oscillations	_	
27-19	6157-6163	during	_	
27-20	6164-6165	a	_	
27-21	6166-6172	visual	_	
27-22	6173-6181	paradigm	_	
27-23	6182-6184	in	_	
27-24	6185-6190	CHR-P	_	
27-25	6191-6203	participants	_	
27-26	6203-6204	,	_	
27-27	6205-6213	patients	_	
27-28	6214-6218	with	_	
27-29	6219-6232	first-episode	_	
27-30	6233-6242	psychosis	_	
27-31	6243-6244	(	_	
27-32	6244-6247	FEP	_	
27-33	6247-6248	)	_	
27-34	6248-6249	,	_	
27-35	6250-6253	and	_	
27-36	6254-6266	participants	_	
27-37	6267-6271	with	_	
27-38	6272-6289	substance-related	_	
27-39	6290-6293	and	_	
27-40	6294-6303	affective	_	
27-41	6304-6313	disorders	_	
27-42	6313-6314	.	_	

#Text=Magnetoencephalography is characterized by an improved signal-to-noise ratio for measurements of high-frequency oscillations compared with EEG and is ideally suited for source reconstruction, allowing the identification of anatomical layout of generators with high spatial resolution.
28-1	6315-6337	Magnetoencephalography	_	
28-2	6338-6340	is	_	
28-3	6341-6354	characterized	_	
28-4	6355-6357	by	_	
28-5	6358-6360	an	_	
28-6	6361-6369	improved	_	
28-7	6370-6385	signal-to-noise	_	
28-8	6386-6391	ratio	_	
28-9	6392-6395	for	_	
28-10	6396-6408	measurements	_	
28-11	6409-6411	of	_	
28-12	6412-6426	high-frequency	_	
28-13	6427-6439	oscillations	_	
28-14	6440-6448	compared	_	
28-15	6449-6453	with	_	
28-16	6454-6457	EEG	_	
28-17	6458-6461	and	_	
28-18	6462-6464	is	_	
28-19	6465-6472	ideally	_	
28-20	6473-6479	suited	_	
28-21	6480-6483	for	_	
28-22	6484-6490	source	_	
28-23	6491-6505	reconstruction	_	
28-24	6505-6506	,	_	
28-25	6507-6515	allowing	_	
28-26	6516-6519	the	_	
28-27	6520-6534	identification	_	
28-28	6535-6537	of	_	
28-29	6538-6548	anatomical	_	
28-30	6549-6555	layout	_	
28-31	6556-6558	of	_	
28-32	6559-6569	generators	_	
28-33	6570-6574	with	_	
28-34	6575-6579	high	_	
28-35	6580-6587	spatial	_	
28-36	6588-6598	resolution	_	
28-37	6598-6599	.	_	

#Text=Based on models of developing psychosis that have highlighted the central role of visual deficits during the early stages of psychosis that predict transition to psychosis as well as the importance of high-frequency oscillations for the integrity of visual perception, we predicted that CHR-P participants would be characterized by a circumscribed dysfunction of β/γ-band oscillations in visual cortex that would be linked to clinical outcomes.
29-1	6600-6605	Based	_	
29-2	6606-6608	on	_	
29-3	6609-6615	models	_	
29-4	6616-6618	of	_	
29-5	6619-6629	developing	_	
29-6	6630-6639	psychosis	_	
29-7	6640-6644	that	_	
29-8	6645-6649	have	_	
29-9	6650-6661	highlighted	_	
29-10	6662-6665	the	_	
29-11	6666-6673	central	_	
29-12	6674-6678	role	_	
29-13	6679-6681	of	_	
29-14	6682-6688	visual	_	
29-15	6689-6697	deficits	_	
29-16	6698-6704	during	_	
29-17	6705-6708	the	_	
29-18	6709-6714	early	_	
29-19	6715-6721	stages	_	
29-20	6722-6724	of	_	
29-21	6725-6734	psychosis	_	
29-22	6735-6739	that	_	
29-23	6740-6747	predict	_	
29-24	6748-6758	transition	_	
29-25	6759-6761	to	_	
29-26	6762-6771	psychosis	_	
29-27	6772-6774	as	_	
29-28	6775-6779	well	_	
29-29	6780-6782	as	_	
29-30	6783-6786	the	_	
29-31	6787-6797	importance	_	
29-32	6798-6800	of	_	
29-33	6801-6815	high-frequency	_	
29-34	6816-6828	oscillations	_	
29-35	6829-6832	for	_	
29-36	6833-6836	the	_	
29-37	6837-6846	integrity	_	
29-38	6847-6849	of	_	
29-39	6850-6856	visual	_	
29-40	6857-6867	perception	_	
29-41	6867-6868	,	_	
29-42	6869-6871	we	_	
29-43	6872-6881	predicted	_	
29-44	6882-6886	that	_	
29-45	6887-6892	CHR-P	_	
29-46	6893-6905	participants	_	
29-47	6906-6911	would	_	
29-48	6912-6914	be	_	
29-49	6915-6928	characterized	_	
29-50	6929-6931	by	_	
29-51	6932-6933	a	_	
29-52	6934-6947	circumscribed	_	
29-53	6948-6959	dysfunction	_	
29-54	6960-6962	of	_	
29-55	6963-6964	β	_	
29-56	6964-6965	/	_	
29-57	6965-6971	γ-band	_	
29-58	6972-6984	oscillations	_	
29-59	6985-6987	in	_	
29-60	6988-6994	visual	_	
29-61	6995-7001	cortex	_	
29-62	7002-7006	that	_	
29-63	7007-7012	would	_	
29-64	7013-7015	be	_	
29-65	7016-7022	linked	_	
29-66	7023-7025	to	_	
29-67	7026-7034	clinical	_	
29-68	7035-7043	outcomes	_	
29-69	7043-7044	.	_	

#Text=Specifically, we focused on the persistence of attenuated psychotic symptoms (APS) because there is evidence to suggest that persistent APS are associated with poor outcomes and cognitive deficits in CHR-P populations.
30-1	7045-7057	Specifically	_	
30-2	7057-7058	,	_	
30-3	7059-7061	we	_	
30-4	7062-7069	focused	_	
30-5	7070-7072	on	_	
30-6	7073-7076	the	_	
30-7	7077-7088	persistence	_	
30-8	7089-7091	of	_	
30-9	7092-7102	attenuated	_	
30-10	7103-7112	psychotic	_	
30-11	7113-7121	symptoms	_	
30-12	7122-7123	(	_	
30-13	7123-7126	APS	_	
30-14	7126-7127	)	_	
30-15	7128-7135	because	_	
30-16	7136-7141	there	_	
30-17	7142-7144	is	_	
30-18	7145-7153	evidence	_	
30-19	7154-7156	to	_	
30-20	7157-7164	suggest	_	
30-21	7165-7169	that	_	
30-22	7170-7180	persistent	_	
30-23	7181-7184	APS	_	
30-24	7185-7188	are	_	
30-25	7189-7199	associated	_	
30-26	7200-7204	with	_	
30-27	7205-7209	poor	_	
30-28	7210-7218	outcomes	_	
30-29	7219-7222	and	_	
30-30	7223-7232	cognitive	_	
30-31	7233-7241	deficits	_	
30-32	7242-7244	in	_	
30-33	7245-7250	CHR-P	_	
30-34	7251-7262	populations	_	
30-35	7262-7263	.	_	

#Text=Patients with FEP, on the other hand, would involve large-scale dysfunctions of induced oscillations and effective connectivity between frontal and visual areas, consistent with a disconnection syndrome.
31-1	7264-7272	Patients	_	
31-2	7273-7277	with	_	
31-3	7278-7281	FEP	_	
31-4	7281-7282	,	_	
31-5	7283-7285	on	_	
31-6	7286-7289	the	_	
31-7	7290-7295	other	_	
31-8	7296-7300	hand	_	
31-9	7300-7301	,	_	
31-10	7302-7307	would	_	
31-11	7308-7315	involve	_	
31-12	7316-7327	large-scale	_	
31-13	7328-7340	dysfunctions	_	
31-14	7341-7343	of	_	
31-15	7344-7351	induced	_	
31-16	7352-7364	oscillations	_	
31-17	7365-7368	and	_	
31-18	7369-7378	effective	_	
31-19	7379-7391	connectivity	_	
31-20	7392-7399	between	_	
31-21	7400-7407	frontal	_	
31-22	7408-7411	and	_	
31-23	7412-7418	visual	_	
31-24	7419-7424	areas	_	
31-25	7424-7425	,	_	
31-26	7426-7436	consistent	_	
31-27	7437-7441	with	_	
31-28	7442-7443	a	_	
31-29	7444-7457	disconnection	_	
31-30	7458-7466	syndrome	_	
31-31	7466-7467	.	_	

#Text=Methods
#Text=Participants
#Text=Four groups of participants (total n = 232) were recruited: (1) participants meeting CHR-P criteria (n = 119) from the ongoing Youth Mental Health Risk and Resilience (YouR) Study; (2) 38 participants who did not meet CHR-P criteria (CHR-N) and were characterized by nonpsychotic disorders, such as affective disorders (n = 11), anxiety disorders (n = 16), eating disorders (n = 1), and/or substance abuse (n = 10); (3) 26 patients with FEP (13 antipsychotic-naive); and (4) 49 healthy control individuals (HC) without an axis I diagnosis or family history of psychotic disorders.
32-1	7468-7475	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
32-2	7476-7488	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-3	7489-7493	Four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-4	7494-7500	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-5	7501-7503	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-6	7504-7516	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-7	7517-7518	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-8	7518-7523	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-9	7524-7525	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-10	7526-7527	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-11	7528-7531	232	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-12	7531-7532	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-13	7533-7537	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-14	7538-7547	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-15	7547-7548	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-16	7549-7550	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-17	7550-7551	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-18	7551-7552	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-19	7553-7565	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[21]	
32-20	7566-7573	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[21]	
32-21	7574-7579	CHR-P	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[21]	
32-22	7580-7588	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[21]	
32-23	7589-7590	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-24	7590-7591	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-25	7592-7593	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-26	7594-7597	119	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-27	7597-7598	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-28	7599-7603	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-29	7604-7607	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-30	7608-7615	ongoing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-31	7616-7621	Youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-32	7622-7628	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-33	7629-7635	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-34	7636-7640	Risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-35	7641-7644	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-36	7645-7655	Resilience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-37	7656-7657	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-38	7657-7661	YouR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-39	7661-7662	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-40	7663-7668	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-41	7668-7669	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-42	7670-7671	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-43	7671-7672	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-44	7672-7673	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-45	7674-7676	38	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-46	7677-7689	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-47	7690-7693	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-48	7694-7697	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-49	7698-7701	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-50	7702-7706	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-51	7707-7712	CHR-P	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-52	7713-7721	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-53	7722-7723	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-54	7723-7728	CHR-N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-55	7728-7729	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-56	7730-7733	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-57	7734-7738	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-58	7739-7752	characterized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-59	7753-7755	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-60	7756-7768	nonpsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-61	7769-7778	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-62	7778-7779	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-63	7780-7784	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-64	7785-7787	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-65	7788-7797	affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[22]	
32-66	7798-7807	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder[22]	
32-67	7808-7809	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-68	7809-7810	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-69	7811-7812	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-70	7813-7815	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-71	7815-7816	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-72	7816-7817	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-73	7818-7825	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[23]	
32-74	7826-7835	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder[23]	
32-75	7836-7837	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-76	7837-7838	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-77	7839-7840	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-78	7841-7843	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-79	7843-7844	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-80	7844-7845	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-81	7846-7852	eating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-82	7853-7862	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-83	7863-7864	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-84	7864-7865	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-85	7866-7867	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-86	7868-7869	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-87	7869-7870	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-88	7870-7871	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-89	7872-7875	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-90	7875-7876	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-91	7876-7878	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-92	7879-7888	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[24]	
32-93	7889-7894	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[24]	
32-94	7895-7896	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-95	7896-7897	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-96	7898-7899	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-97	7900-7902	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-98	7902-7903	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-99	7903-7904	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-100	7905-7906	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-101	7906-7907	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-102	7907-7908	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-103	7909-7911	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-104	7912-7920	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[25]	
32-105	7921-7925	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[25]	
32-106	7926-7929	FEP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[25]	
32-107	7930-7931	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-108	7931-7933	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-109	7934-7953	antipsychotic-naive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-110	7953-7954	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-111	7954-7955	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-112	7956-7959	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-113	7960-7961	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-114	7961-7962	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-115	7962-7963	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-116	7964-7966	49	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-117	7967-7974	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
32-118	7975-7982	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
32-119	7983-7994	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
32-120	7995-7996	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
32-121	7996-7998	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
32-122	7998-7999	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
32-123	8000-8007	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-124	8008-8010	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-125	8011-8015	axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-126	8016-8017	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-127	8018-8027	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-128	8028-8030	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-129	8031-8037	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-130	8038-8045	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-131	8046-8048	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-132	8049-8058	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-133	8059-8068	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
32-134	8068-8069	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=Data from 10 patients with FEP and 10 HC have been published previously.
33-1	8070-8074	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-2	8075-8079	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-3	8080-8082	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-4	8083-8091	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-5	8092-8096	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-6	8097-8100	FEP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[28]	
33-7	8101-8104	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-8	8105-8107	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-9	8108-8110	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
33-10	8111-8115	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-11	8116-8120	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-12	8121-8130	published	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-13	8131-8141	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-14	8141-8142	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=The CHR-P status was confirmed by ultrahigh-risk criteria according to the Comprehensive Assessment of At Risk Mental States (CAARMS) interview and the Cognitive Disturbances and Cognitive-Perceptive Basic Symptoms criteria according to the Schizophrenia Proneness Instrument, Adult version (SPI-A) (see Uhlhaas et al).
34-1	8143-8146	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-2	8147-8152	CHR-P	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-3	8153-8159	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-4	8160-8163	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-5	8164-8173	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-6	8174-8176	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-7	8177-8191	ultrahigh-risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-8	8192-8200	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-9	8201-8210	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-10	8211-8213	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-11	8214-8217	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-12	8218-8231	Comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-13	8232-8242	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-14	8243-8245	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-15	8246-8248	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-16	8249-8253	Risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-17	8254-8260	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-18	8261-8267	States	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-19	8268-8269	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-20	8269-8275	CAARMS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-21	8275-8276	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-22	8277-8286	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[30]	
34-23	8287-8290	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-24	8291-8294	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-25	8295-8304	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-26	8305-8317	Disturbances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-27	8318-8321	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-28	8322-8342	Cognitive-Perceptive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-29	8343-8348	Basic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-30	8349-8357	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-31	8358-8366	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-32	8367-8376	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-33	8377-8379	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-34	8380-8383	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-35	8384-8397	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-36	8398-8407	Proneness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-37	8408-8418	Instrument	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-38	8418-8419	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-39	8420-8425	Adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-40	8426-8433	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale[31]	
34-41	8434-8435	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-42	8435-8440	SPI-A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-43	8440-8441	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-44	8442-8443	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-45	8443-8446	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-46	8447-8454	Uhlhaas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-47	8455-8457	et	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-48	8458-8460	al	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-49	8460-8461	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
34-50	8461-8462	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=Patients with FEP were assessed with the Structured Clinical Interview for DSM-IV (Table) and with the Positive and Negative Symptom Scale.
35-1	8463-8471	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[32]	
35-2	8472-8476	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[32]	
35-3	8477-8480	FEP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[32]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[33]	
35-4	8481-8485	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-5	8486-8494	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-6	8495-8499	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-7	8500-8503	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-8	8504-8514	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[34]	
35-9	8515-8523	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[34]	
35-10	8524-8533	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[34]	
35-11	8534-8537	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[34]	
35-12	8538-8544	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[34]	
35-13	8545-8546	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-14	8546-8551	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-15	8551-8552	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-16	8553-8556	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-17	8557-8561	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-18	8562-8565	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
35-19	8566-8574	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[35]	
35-20	8575-8578	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[35]	
35-21	8579-8587	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[35]	
35-22	8588-8595	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[35]	
35-23	8596-8601	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[35]	
35-24	8601-8602	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=For all groups except patients with FEP, neurocognition was assessed with the Brief Assessment of Cognition in Schizophrenia (BACS).
36-1	8603-8606	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-2	8607-8610	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-3	8611-8617	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-4	8618-8624	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-5	8625-8633	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[36]	
36-6	8634-8638	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[36]	
36-7	8639-8642	FEP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[36]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[37]	
36-8	8642-8643	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-9	8644-8658	neurocognition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-10	8659-8662	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-11	8663-8671	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-12	8672-8676	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-13	8677-8680	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-14	8681-8686	Brief	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-15	8687-8697	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-16	8698-8700	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-17	8701-8710	Cognition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-18	8711-8713	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-19	8714-8727	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-20	8728-8729	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-21	8729-8733	BACS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[38]	
36-22	8733-8734	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
36-23	8734-8735	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=The study was approved by the ethical committees of University of Glasgow and the National Health Services Research Ethical Committee Glasgow and Greater Clyde.
37-1	8736-8739	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-2	8740-8745	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-3	8746-8749	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-4	8750-8758	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-5	8759-8761	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-6	8762-8765	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-7	8766-8773	ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-8	8774-8784	committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-9	8785-8787	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-10	8788-8798	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-11	8799-8801	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-12	8802-8809	Glasgow	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-13	8810-8813	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-14	8814-8817	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-15	8818-8826	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-16	8827-8833	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-17	8834-8842	Services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-18	8843-8851	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-19	8852-8859	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-20	8860-8869	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-21	8870-8877	Glasgow	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-22	8878-8881	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-23	8882-8889	Greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-24	8890-8895	Clyde	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
37-25	8895-8896	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	

#Text=All participants provided written informed consent.
38-1	8897-8900	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
38-2	8901-8913	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
38-3	8914-8922	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
38-4	8923-8930	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
38-5	8931-8939	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
38-6	8940-8947	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
38-7	8947-8948	.	_	

#Text=Demographics, Clinical Data, and Task Performance
#Text=Demographic\tHC\tCHR-N\tCHR-P\tFEP\tGroup effecta\tPairwise comparisons\t \tNo. of participants\t49\t38\t119\t26\tNA\tNA\t \tAge, (SD), y\t23 (3.6)\t23 (4.7)\t22 (4.4)\t24 (4.2)\tNA\tNA\t \tMale/female sex, No. (% male)\t16/33 (32.7)\t11/27 (28.9)\t32/87 (26.9)\t16/10 (61.5)\tχ23 = 11.9; P = .008\tFEP to HC: P = .016; FEP to CHR-N: P = .001; FEP to CHR-P: P = .01\t \tEducation, mean (SD), y\t17 (3.0)\t16 (3.5)\t15 (3.1)\t15 (3.0)\tF3,76 = 3.5; P = .02\tCHR-P to HC: P = .03\t \tBACS,b mean (SD)\t\t\t\t\t\t\t \t Verbal memory\t52 (8.7)\t0.01 (1.1)\t−0.36 (1.3)\tNA\tNA\tNA\t \t Digit sequencing\t21 (2.1)\t0.14 (1.2)\t−0.15 (1.5)\tNA\tNA\tNA\t \t Token motor\t81 (11.6)\t−0.66 (1.1)\t−0.98 (1.3)\t-\tF2,93 = 13.8; P < .001\tCHR-N to HC: P = .01; CHR-P - HC: P < .001\t \t Verbal fluency\t59 (13.9)\t−0.22 (1.0)\t0.05 (1.3)\tNA\tNA\tNA\t \t Symbol coding\t74 (11.8)\t0.00 (1.3)\t−0.58 (1.1)\tNA\tF2,84 = 6.8; P = .002\tCHR-P - HC: P = .004; CHR-P – CHR-N: P = .04\t \t Tower of London\t19 (1.7)\t0.15 (1.3)\t−0.21 (1.5)\tNA\tNA\tNA\t \t Composite score\t304 (24.2)\t−0.15 (1.2)\t−0.63 (1.4)\tNA\tF2,93 = 5.8; P = .004\tCHR-P - HC: P = .004\t \tCAARMS, mean (SD)\t\t\t\t\t\t\t \t Unusual thought content\tNA\t1 (1.2)\t2 (1.9)\tNA\tNA\tNA\t \t Nonbizarre ideas\tNA\t1 (1.1)\t3 (1.8)\tNA\tNA\tNA\t \t Perceptual abnormalities\tNA\t1 (1.3)\t3 (1.6)\tNA\tNA\tNA\t \t Disorganized speech\tNA\t1 (0.9)\t1 (1.4)\tNA\tNA\tNA\t \t Total severity score\tNA\t6 (6.1)\t29 (17.8)\tNA\tNA\tNA\t \tGAF, mean (SD)\t88 (6.4)\t70 (12.8)\t57 (13.4)\t41 (16.9)\tF3,75 = 167; P < .001\tAll contrasts P < .001\t \tGF-role, mean (SD)\t8.6 (0.8)\t8.1 (0.8)\t7.4 (1.2)\tNA\tF2,99 = 29.6; P < .001\tCHR-N - HC: P = .037; CHR-P to HC: P < .001; CHR-P to CHR-N: P < .001\t \tGF-social, mean (SD)\t8.8 (0.4)\t8.2 (0.8)\t7.5 (1.2)\tNA\tF2,94 = 59.5, P < .001\tCHR-N - HC: P < .001; CHR-P to HC: P < .001; CHR-P to CHR-N: P < .001\t \tPANSS, mean (SD)\t\t\t\t\t\t\t \t Positive\tNA\tNA\tNA\t18 (7.2)\tNA\tNA\t \t Negative\tNA\tNA\tNA\t15 (9.3)\tNA\tNA\t \t Cognitive\tNA\tNA\tNA\t20 (9.2)\tNA\tNA\t \t Excitement\tNA\tNA\tNA\t9 (4.3)\tNA\tNA\t \t Depression\tNA\tNA\tNA\t12 (5.9)\tNA\tNA\t \t Total score\tNA\tNA\tNA\t74 (28.4)\tNA\tNA\t \tMedication, No. (%)c\t\t\t\t\t\t\t \t None\t48\t27\t61\t6\tNA\tNA\t \t Antidepressants\t0\t11\t47\t13\tNA\tNA\t \t Mood stabilizers\t0\t0\t5\t0\tNA\tNA\t \t Antipsychotics\t0\t0\t3\t13\tNA\tNA\t \t Other (unknown)\t1 (0)\t2 (0)\t21 (0)\t5 (0)\tNA\tNA\t \tCHR-P categories\t\t\t\t\t\t\t \t SPI-A (COGDIS/COPER/both items)\tNA\tNA\t30 (4/15/11)\tNA\tNA\tNA\t \t CAARMS (APS/vulnerability criteria)\tNA\tNA\t89 (87/2)\tNA\tNA\tNA\t \t CAARMS plus SPI-A (COGDIS/COPER/both items)\tNA\tNA\t55 (9/22/24)\tNA\tNA\tNA\t \tMINI categories\t\t\t\t\t\t\t \t Depressive/mood disorders\tNA\t11\t75\tNA\tNA\tNA\t \t Anxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorder\tNA\t16\t87\tNA\tNA\tNA\t \t Drug/alcohol abuse/dependence\tNA\t10\t42\tNA\tNA\tNA\t \t Eating disorders\tNA\t1\t10\tNA\tNA\tNA\t \tDSM-IV/Structured Clinical Interview\t\t\t\t\t\t\t \t Schizophrenia\tNA\tNA\tNA\t9\tNA\tNA\t \t Schizophreniform disorder\tNA\tNA\tNA\t3\tNA\tNA\t \t Schizoaffective disorder\tNA\tNA\tNA\t1\tNA\tNA\t \t Psychotic disorder NOS\tNA\tNA\tNA\t8\tNA\tNA\t \t Brief psychotic disorder\tNA\tNA\tNA\t1\tNA\tNA\t \t Mood disorders with psychotic features\tNA\tNA\tNA\t4\tNA\tNA\t \tTrial No., total included (SD)\t197 (16.3)\t194 (16.2)\t185 (26.5)\t181 (29.2)\tF3,80 = 5.9; P = .001\tCHR-P to HC: P = .002\t \tTask performance\t\t\t\t\t\t\t \t Accuracy, % correct (SD)\t92.2 (6.9)\t92.0 (5.6)\t88.0 (9.8)\t85.9 (12.8)\tF3,79 = 5.5, P = .002\tCHR-P to HC: P = .01; CHR-P vs CHR-N: P = .01\t \t Reaction time, mean (SD), ms\t528 (68.4)\t524 (80.1)\t545 (84.9)\t577 (100.1)\tNA\tNA\t \t Response variance,d mean (SD), ms\t151.7 (37.5)\t154.3 (34.9)\t164.3 (42.2)\t179.1 (40.8)\tF3,79 = 3.3; P = .02\tFEP to HC: P = .03\t \t
#Text=Abbreviations: APS, attenuated psychotic symptoms; BACS, Brief Assessment of Cognition in Schizophrenia; CAARMS, Comprehensive Assessment of At Risk Mental States; CHR-N, clinical high risk negative; CHR-P, clinical high risk positive; COGDIS/COPER, Cognitive Disturbances and Cognitive-Perceptive Basic Symptoms criteria; FEP, first-episode psychosis; GAF, global assessment of functioning; GF, global functioning; HC, healthy control individual; MINI, Mini-International Neuropsychiatric Interview; PANSS, Positive and Negative Symptom Scale; SPI-A, Schizophrenia Proneness Instrument, Adult version.
39-1	8949-8961	Demographics	_	
39-2	8961-8962	,	_	
39-3	8963-8971	Clinical	_	
39-4	8972-8976	Data	_	
39-5	8976-8977	,	_	
39-6	8978-8981	and	_	
39-7	8982-8986	Task	_	
39-8	8987-8998	Performance	_	
39-9	8999-9010	Demographic	_	
39-10	9011-9013	HC	_	
39-11	9014-9019	CHR-N	_	
39-12	9020-9025	CHR-P	_	
39-13	9026-9029	FEP	_	
39-14	9030-9035	Group	_	
39-15	9036-9043	effecta	_	
39-16	9044-9052	Pairwise	_	
39-17	9053-9064	comparisons	_	
39-18	9067-9069	No	_	
39-19	9069-9070	.	_	
39-20	9071-9073	of	_	
39-21	9074-9086	participants	_	
39-22	9087-9089	49	_	
39-23	9090-9092	38	_	
39-24	9093-9096	119	_	
39-25	9097-9099	26	_	
39-26	9100-9102	NA	_	
39-27	9103-9105	NA	_	
39-28	9108-9111	Age	_	
39-29	9111-9112	,	_	
39-30	9113-9114	(	_	
39-31	9114-9116	SD	_	
39-32	9116-9117	)	_	
39-33	9117-9118	,	_	
39-34	9119-9120	y	_	
39-35	9121-9123	23	_	
39-36	9124-9125	(	_	
39-37	9125-9128	3.6	_	
39-38	9128-9129	)	_	
39-39	9130-9132	23	_	
39-40	9133-9134	(	_	
39-41	9134-9137	4.7	_	
39-42	9137-9138	)	_	
39-43	9139-9141	22	_	
39-44	9142-9143	(	_	
39-45	9143-9146	4.4	_	
39-46	9146-9147	)	_	
39-47	9148-9150	24	_	
39-48	9151-9152	(	_	
39-49	9152-9155	4.2	_	
39-50	9155-9156	)	_	
39-51	9157-9159	NA	_	
39-52	9160-9162	NA	_	
39-53	9165-9169	Male	_	
39-54	9169-9170	/	_	
39-55	9170-9176	female	_	
39-56	9177-9180	sex	_	
39-57	9180-9181	,	_	
39-58	9182-9184	No	_	
39-59	9184-9185	.	_	
39-60	9186-9187	(	_	
39-61	9187-9188	%	_	
39-62	9189-9193	male	_	
39-63	9193-9194	)	_	
39-64	9195-9197	16	_	
39-65	9197-9198	/	_	
39-66	9198-9200	33	_	
39-67	9201-9202	(	_	
39-68	9202-9206	32.7	_	
39-69	9206-9207	)	_	
39-70	9208-9210	11	_	
39-71	9210-9211	/	_	
39-72	9211-9213	27	_	
39-73	9214-9215	(	_	
39-74	9215-9219	28.9	_	
39-75	9219-9220	)	_	
39-76	9221-9223	32	_	
39-77	9223-9224	/	_	
39-78	9224-9226	87	_	
39-79	9227-9228	(	_	
39-80	9228-9232	26.9	_	
39-81	9232-9233	)	_	
39-82	9234-9236	16	_	
39-83	9236-9237	/	_	
39-84	9237-9239	10	_	
39-85	9240-9241	(	_	
39-86	9241-9245	61.5	_	
39-87	9245-9246	)	_	
39-88	9247-9250	χ23	_	
39-89	9251-9252	=	_	
39-90	9253-9257	11.9	_	
39-91	9257-9258	;	_	
39-92	9259-9260	P	_	
39-93	9261-9262	=	_	
39-94	9263-9267	.008	_	
39-95	9268-9271	FEP	_	
39-96	9272-9274	to	_	
39-97	9275-9277	HC	_	
39-98	9277-9278	:	_	
39-99	9279-9280	P	_	
39-100	9281-9282	=	_	
39-101	9283-9287	.016	_	
39-102	9287-9288	;	_	
39-103	9289-9292	FEP	_	
39-104	9293-9295	to	_	
39-105	9296-9301	CHR-N	_	
39-106	9301-9302	:	_	
39-107	9303-9304	P	_	
39-108	9305-9306	=	_	
39-109	9307-9311	.001	_	
39-110	9311-9312	;	_	
39-111	9313-9316	FEP	_	
39-112	9317-9319	to	_	
39-113	9320-9325	CHR-P	_	
39-114	9325-9326	:	_	
39-115	9327-9328	P	_	
39-116	9329-9330	=	_	
39-117	9331-9334	.01	_	
39-118	9337-9346	Education	_	
39-119	9346-9347	,	_	
39-120	9348-9352	mean	_	
39-121	9353-9354	(	_	
39-122	9354-9356	SD	_	
39-123	9356-9357	)	_	
39-124	9357-9358	,	_	
39-125	9359-9360	y	_	
39-126	9361-9363	17	_	
39-127	9364-9365	(	_	
39-128	9365-9368	3.0	_	
39-129	9368-9369	)	_	
39-130	9370-9372	16	_	
39-131	9373-9374	(	_	
39-132	9374-9377	3.5	_	
39-133	9377-9378	)	_	
39-134	9379-9381	15	_	
39-135	9382-9383	(	_	
39-136	9383-9386	3.1	_	
39-137	9386-9387	)	_	
39-138	9388-9390	15	_	
39-139	9391-9392	(	_	
39-140	9392-9395	3.0	_	
39-141	9395-9396	)	_	
39-142	9397-9402	F3,76	_	
39-143	9403-9404	=	_	
39-144	9405-9408	3.5	_	
39-145	9408-9409	;	_	
39-146	9410-9411	P	_	
39-147	9412-9413	=	_	
39-148	9414-9417	.02	_	
39-149	9418-9423	CHR-P	_	
39-150	9424-9426	to	_	
39-151	9427-9429	HC	_	
39-152	9429-9430	:	_	
39-153	9431-9432	P	_	
39-154	9433-9434	=	_	
39-155	9435-9438	.03	_	
39-156	9441-9445	BACS	_	
39-157	9445-9446	,	_	
39-158	9446-9447	b	_	
39-159	9448-9452	mean	_	
39-160	9453-9454	(	_	
39-161	9454-9456	SD	_	
39-162	9456-9457	)	_	
39-163	9467-9473	Verbal	_	
39-164	9474-9480	memory	_	
39-165	9481-9483	52	_	
39-166	9484-9485	(	_	
39-167	9485-9488	8.7	_	
39-168	9488-9489	)	_	
39-169	9490-9494	0.01	_	
39-170	9495-9496	(	_	
39-171	9496-9499	1.1	_	
39-172	9499-9500	)	_	
39-173	9501-9502	−	_	
39-174	9502-9506	0.36	_	
39-175	9507-9508	(	_	
39-176	9508-9511	1.3	_	
39-177	9511-9512	)	_	
39-178	9513-9515	NA	_	
39-179	9516-9518	NA	_	
39-180	9519-9521	NA	_	
39-181	9525-9530	Digit	_	
39-182	9531-9541	sequencing	_	
39-183	9542-9544	21	_	
39-184	9545-9546	(	_	
39-185	9546-9549	2.1	_	
39-186	9549-9550	)	_	
39-187	9551-9555	0.14	_	
39-188	9556-9557	(	_	
39-189	9557-9560	1.2	_	
39-190	9560-9561	)	_	
39-191	9562-9563	−	_	
39-192	9563-9567	0.15	_	
39-193	9568-9569	(	_	
39-194	9569-9572	1.5	_	
39-195	9572-9573	)	_	
39-196	9574-9576	NA	_	
39-197	9577-9579	NA	_	
39-198	9580-9582	NA	_	
39-199	9586-9591	Token	_	
39-200	9592-9597	motor	_	
39-201	9598-9600	81	_	
39-202	9601-9602	(	_	
39-203	9602-9606	11.6	_	
39-204	9606-9607	)	_	
39-205	9608-9609	−	_	
39-206	9609-9613	0.66	_	
39-207	9614-9615	(	_	
39-208	9615-9618	1.1	_	
39-209	9618-9619	)	_	
39-210	9620-9621	−	_	
39-211	9621-9625	0.98	_	
39-212	9626-9627	(	_	
39-213	9627-9630	1.3	_	
39-214	9630-9631	)	_	
39-215	9632-9633	-	_	
39-216	9634-9639	F2,93	_	
39-217	9640-9641	=	_	
39-218	9642-9646	13.8	_	
39-219	9646-9647	;	_	
39-220	9648-9649	P	_	
39-221	9650-9651	<	_	
39-222	9652-9656	.001	_	
39-223	9657-9662	CHR-N	_	
39-224	9663-9665	to	_	
39-225	9666-9668	HC	_	
39-226	9668-9669	:	_	
39-227	9670-9671	P	_	
39-228	9672-9673	=	_	
39-229	9674-9677	.01	_	
39-230	9677-9678	;	_	
39-231	9679-9684	CHR-P	_	
39-232	9685-9686	-	_	
39-233	9687-9689	HC	_	
39-234	9689-9690	:	_	
39-235	9691-9692	P	_	
39-236	9693-9694	<	_	
39-237	9695-9699	.001	_	
39-238	9703-9709	Verbal	_	
39-239	9710-9717	fluency	_	
39-240	9718-9720	59	_	
39-241	9721-9722	(	_	
39-242	9722-9726	13.9	_	
39-243	9726-9727	)	_	
39-244	9728-9729	−	_	
39-245	9729-9733	0.22	_	
39-246	9734-9735	(	_	
39-247	9735-9738	1.0	_	
39-248	9738-9739	)	_	
39-249	9740-9744	0.05	_	
39-250	9745-9746	(	_	
39-251	9746-9749	1.3	_	
39-252	9749-9750	)	_	
39-253	9751-9753	NA	_	
39-254	9754-9756	NA	_	
39-255	9757-9759	NA	_	
39-256	9763-9769	Symbol	_	
39-257	9770-9776	coding	_	
39-258	9777-9779	74	_	
39-259	9780-9781	(	_	
39-260	9781-9785	11.8	_	
39-261	9785-9786	)	_	
39-262	9787-9791	0.00	_	
39-263	9792-9793	(	_	
39-264	9793-9796	1.3	_	
39-265	9796-9797	)	_	
39-266	9798-9799	−	_	
39-267	9799-9803	0.58	_	
39-268	9804-9805	(	_	
39-269	9805-9808	1.1	_	
39-270	9808-9809	)	_	
39-271	9810-9812	NA	_	
39-272	9813-9818	F2,84	_	
39-273	9819-9820	=	_	
39-274	9821-9824	6.8	_	
39-275	9824-9825	;	_	
39-276	9826-9827	P	_	
39-277	9828-9829	=	_	
39-278	9830-9834	.002	_	
39-279	9835-9840	CHR-P	_	
39-280	9841-9842	-	_	
39-281	9843-9845	HC	_	
39-282	9845-9846	:	_	
39-283	9847-9848	P	_	
39-284	9849-9850	=	_	
39-285	9851-9855	.004	_	
39-286	9855-9856	;	_	
39-287	9857-9862	CHR-P	_	
39-288	9863-9864	–	_	
39-289	9865-9870	CHR-N	_	
39-290	9870-9871	:	_	
39-291	9872-9873	P	_	
39-292	9874-9875	=	_	
39-293	9876-9879	.04	_	
39-294	9883-9888	Tower	_	
39-295	9889-9891	of	_	
39-296	9892-9898	London	_	
39-297	9899-9901	19	_	
39-298	9902-9903	(	_	
39-299	9903-9906	1.7	_	
39-300	9906-9907	)	_	
39-301	9908-9912	0.15	_	
39-302	9913-9914	(	_	
39-303	9914-9917	1.3	_	
39-304	9917-9918	)	_	
39-305	9919-9920	−	_	
39-306	9920-9924	0.21	_	
39-307	9925-9926	(	_	
39-308	9926-9929	1.5	_	
39-309	9929-9930	)	_	
39-310	9931-9933	NA	_	
39-311	9934-9936	NA	_	
39-312	9937-9939	NA	_	
39-313	9943-9952	Composite	_	
39-314	9953-9958	score	_	
39-315	9959-9962	304	_	
39-316	9963-9964	(	_	
39-317	9964-9968	24.2	_	
39-318	9968-9969	)	_	
39-319	9970-9971	−	_	
39-320	9971-9975	0.15	_	
39-321	9976-9977	(	_	
39-322	9977-9980	1.2	_	
39-323	9980-9981	)	_	
39-324	9982-9983	−	_	
39-325	9983-9987	0.63	_	
39-326	9988-9989	(	_	
39-327	9989-9992	1.4	_	
39-328	9992-9993	)	_	
39-329	9994-9996	NA	_	
39-330	9997-10002	F2,93	_	
39-331	10003-10004	=	_	
39-332	10005-10008	5.8	_	
39-333	10008-10009	;	_	
39-334	10010-10011	P	_	
39-335	10012-10013	=	_	
39-336	10014-10018	.004	_	
39-337	10019-10024	CHR-P	_	
39-338	10025-10026	-	_	
39-339	10027-10029	HC	_	
39-340	10029-10030	:	_	
39-341	10031-10032	P	_	
39-342	10033-10034	=	_	
39-343	10035-10039	.004	_	
39-344	10042-10048	CAARMS	_	
39-345	10048-10049	,	_	
39-346	10050-10054	mean	_	
39-347	10055-10056	(	_	
39-348	10056-10058	SD	_	
39-349	10058-10059	)	_	
39-350	10069-10076	Unusual	_	
39-351	10077-10084	thought	_	
39-352	10085-10092	content	_	
39-353	10093-10095	NA	_	
39-354	10096-10097	1	_	
39-355	10098-10099	(	_	
39-356	10099-10102	1.2	_	
39-357	10102-10103	)	_	
39-358	10104-10105	2	_	
39-359	10106-10107	(	_	
39-360	10107-10110	1.9	_	
39-361	10110-10111	)	_	
39-362	10112-10114	NA	_	
39-363	10115-10117	NA	_	
39-364	10118-10120	NA	_	
39-365	10124-10134	Nonbizarre	_	
39-366	10135-10140	ideas	_	
39-367	10141-10143	NA	_	
39-368	10144-10145	1	_	
39-369	10146-10147	(	_	
39-370	10147-10150	1.1	_	
39-371	10150-10151	)	_	
39-372	10152-10153	3	_	
39-373	10154-10155	(	_	
39-374	10155-10158	1.8	_	
39-375	10158-10159	)	_	
39-376	10160-10162	NA	_	
39-377	10163-10165	NA	_	
39-378	10166-10168	NA	_	
39-379	10172-10182	Perceptual	_	
39-380	10183-10196	abnormalities	_	
39-381	10197-10199	NA	_	
39-382	10200-10201	1	_	
39-383	10202-10203	(	_	
39-384	10203-10206	1.3	_	
39-385	10206-10207	)	_	
39-386	10208-10209	3	_	
39-387	10210-10211	(	_	
39-388	10211-10214	1.6	_	
39-389	10214-10215	)	_	
39-390	10216-10218	NA	_	
39-391	10219-10221	NA	_	
39-392	10222-10224	NA	_	
39-393	10228-10240	Disorganized	_	
39-394	10241-10247	speech	_	
39-395	10248-10250	NA	_	
39-396	10251-10252	1	_	
39-397	10253-10254	(	_	
39-398	10254-10257	0.9	_	
39-399	10257-10258	)	_	
39-400	10259-10260	1	_	
39-401	10261-10262	(	_	
39-402	10262-10265	1.4	_	
39-403	10265-10266	)	_	
39-404	10267-10269	NA	_	
39-405	10270-10272	NA	_	
39-406	10273-10275	NA	_	
39-407	10279-10284	Total	_	
39-408	10285-10293	severity	_	
39-409	10294-10299	score	_	
39-410	10300-10302	NA	_	
39-411	10303-10304	6	_	
39-412	10305-10306	(	_	
39-413	10306-10309	6.1	_	
39-414	10309-10310	)	_	
39-415	10311-10313	29	_	
39-416	10314-10315	(	_	
39-417	10315-10319	17.8	_	
39-418	10319-10320	)	_	
39-419	10321-10323	NA	_	
39-420	10324-10326	NA	_	
39-421	10327-10329	NA	_	
39-422	10332-10335	GAF	_	
39-423	10335-10336	,	_	
39-424	10337-10341	mean	_	
39-425	10342-10343	(	_	
39-426	10343-10345	SD	_	
39-427	10345-10346	)	_	
39-428	10347-10349	88	_	
39-429	10350-10351	(	_	
39-430	10351-10354	6.4	_	
39-431	10354-10355	)	_	
39-432	10356-10358	70	_	
39-433	10359-10360	(	_	
39-434	10360-10364	12.8	_	
39-435	10364-10365	)	_	
39-436	10366-10368	57	_	
39-437	10369-10370	(	_	
39-438	10370-10374	13.4	_	
39-439	10374-10375	)	_	
39-440	10376-10378	41	_	
39-441	10379-10380	(	_	
39-442	10380-10384	16.9	_	
39-443	10384-10385	)	_	
39-444	10386-10391	F3,75	_	
39-445	10392-10393	=	_	
39-446	10394-10397	167	_	
39-447	10397-10398	;	_	
39-448	10399-10400	P	_	
39-449	10401-10402	<	_	
39-450	10403-10407	.001	_	
39-451	10408-10411	All	_	
39-452	10412-10421	contrasts	_	
39-453	10422-10423	P	_	
39-454	10424-10425	<	_	
39-455	10426-10430	.001	_	
39-456	10433-10440	GF-role	_	
39-457	10440-10441	,	_	
39-458	10442-10446	mean	_	
39-459	10447-10448	(	_	
39-460	10448-10450	SD	_	
39-461	10450-10451	)	_	
39-462	10452-10455	8.6	_	
39-463	10456-10457	(	_	
39-464	10457-10460	0.8	_	
39-465	10460-10461	)	_	
39-466	10462-10465	8.1	_	
39-467	10466-10467	(	_	
39-468	10467-10470	0.8	_	
39-469	10470-10471	)	_	
39-470	10472-10475	7.4	_	
39-471	10476-10477	(	_	
39-472	10477-10480	1.2	_	
39-473	10480-10481	)	_	
39-474	10482-10484	NA	_	
39-475	10485-10490	F2,99	_	
39-476	10491-10492	=	_	
39-477	10493-10497	29.6	_	
39-478	10497-10498	;	_	
39-479	10499-10500	P	_	
39-480	10501-10502	<	_	
39-481	10503-10507	.001	_	
39-482	10508-10513	CHR-N	_	
39-483	10514-10515	-	_	
39-484	10516-10518	HC	_	
39-485	10518-10519	:	_	
39-486	10520-10521	P	_	
39-487	10522-10523	=	_	
39-488	10524-10528	.037	_	
39-489	10528-10529	;	_	
39-490	10530-10535	CHR-P	_	
39-491	10536-10538	to	_	
39-492	10539-10541	HC	_	
39-493	10541-10542	:	_	
39-494	10543-10544	P	_	
39-495	10545-10546	<	_	
39-496	10547-10551	.001	_	
39-497	10551-10552	;	_	
39-498	10553-10558	CHR-P	_	
39-499	10559-10561	to	_	
39-500	10562-10567	CHR-N	_	
39-501	10567-10568	:	_	
39-502	10569-10570	P	_	
39-503	10571-10572	<	_	
39-504	10573-10577	.001	_	
39-505	10580-10589	GF-social	_	
39-506	10589-10590	,	_	
39-507	10591-10595	mean	_	
39-508	10596-10597	(	_	
39-509	10597-10599	SD	_	
39-510	10599-10600	)	_	
39-511	10601-10604	8.8	_	
39-512	10605-10606	(	_	
39-513	10606-10609	0.4	_	
39-514	10609-10610	)	_	
39-515	10611-10614	8.2	_	
39-516	10615-10616	(	_	
39-517	10616-10619	0.8	_	
39-518	10619-10620	)	_	
39-519	10621-10624	7.5	_	
39-520	10625-10626	(	_	
39-521	10626-10629	1.2	_	
39-522	10629-10630	)	_	
39-523	10631-10633	NA	_	
39-524	10634-10639	F2,94	_	
39-525	10640-10641	=	_	
39-526	10642-10646	59.5	_	
39-527	10646-10647	,	_	
39-528	10648-10649	P	_	
39-529	10650-10651	<	_	
39-530	10652-10656	.001	_	
39-531	10657-10662	CHR-N	_	
39-532	10663-10664	-	_	
39-533	10665-10667	HC	_	
39-534	10667-10668	:	_	
39-535	10669-10670	P	_	
39-536	10671-10672	<	_	
39-537	10673-10677	.001	_	
39-538	10677-10678	;	_	
39-539	10679-10684	CHR-P	_	
39-540	10685-10687	to	_	
39-541	10688-10690	HC	_	
39-542	10690-10691	:	_	
39-543	10692-10693	P	_	
39-544	10694-10695	<	_	
39-545	10696-10700	.001	_	
39-546	10700-10701	;	_	
39-547	10702-10707	CHR-P	_	
39-548	10708-10710	to	_	
39-549	10711-10716	CHR-N	_	
39-550	10716-10717	:	_	
39-551	10718-10719	P	_	
39-552	10720-10721	<	_	
39-553	10722-10726	.001	_	
39-554	10729-10734	PANSS	_	
39-555	10734-10735	,	_	
39-556	10736-10740	mean	_	
39-557	10741-10742	(	_	
39-558	10742-10744	SD	_	
39-559	10744-10745	)	_	
39-560	10755-10763	Positive	_	
39-561	10764-10766	NA	_	
39-562	10767-10769	NA	_	
39-563	10770-10772	NA	_	
39-564	10773-10775	18	_	
39-565	10776-10777	(	_	
39-566	10777-10780	7.2	_	
39-567	10780-10781	)	_	
39-568	10782-10784	NA	_	
39-569	10785-10787	NA	_	
39-570	10791-10799	Negative	_	
39-571	10800-10802	NA	_	
39-572	10803-10805	NA	_	
39-573	10806-10808	NA	_	
39-574	10809-10811	15	_	
39-575	10812-10813	(	_	
39-576	10813-10816	9.3	_	
39-577	10816-10817	)	_	
39-578	10818-10820	NA	_	
39-579	10821-10823	NA	_	
39-580	10827-10836	Cognitive	_	
39-581	10837-10839	NA	_	
39-582	10840-10842	NA	_	
39-583	10843-10845	NA	_	
39-584	10846-10848	20	_	
39-585	10849-10850	(	_	
39-586	10850-10853	9.2	_	
39-587	10853-10854	)	_	
39-588	10855-10857	NA	_	
39-589	10858-10860	NA	_	
39-590	10864-10874	Excitement	_	
39-591	10875-10877	NA	_	
39-592	10878-10880	NA	_	
39-593	10881-10883	NA	_	
39-594	10884-10885	9	_	
39-595	10886-10887	(	_	
39-596	10887-10890	4.3	_	
39-597	10890-10891	)	_	
39-598	10892-10894	NA	_	
39-599	10895-10897	NA	_	
39-600	10901-10911	Depression	_	
39-601	10912-10914	NA	_	
39-602	10915-10917	NA	_	
39-603	10918-10920	NA	_	
39-604	10921-10923	12	_	
39-605	10924-10925	(	_	
39-606	10925-10928	5.9	_	
39-607	10928-10929	)	_	
39-608	10930-10932	NA	_	
39-609	10933-10935	NA	_	
39-610	10939-10944	Total	_	
39-611	10945-10950	score	_	
39-612	10951-10953	NA	_	
39-613	10954-10956	NA	_	
39-614	10957-10959	NA	_	
39-615	10960-10962	74	_	
39-616	10963-10964	(	_	
39-617	10964-10968	28.4	_	
39-618	10968-10969	)	_	
39-619	10970-10972	NA	_	
39-620	10973-10975	NA	_	
39-621	10978-10988	Medication	_	
39-622	10988-10989	,	_	
39-623	10990-10992	No	_	
39-624	10992-10993	.	_	
39-625	10994-10995	(	_	
39-626	10995-10996	%	_	
39-627	10996-10997	)	_	
39-628	10997-10998	c	_	
39-629	11008-11012	None	_	
39-630	11013-11015	48	_	
39-631	11016-11018	27	_	
39-632	11019-11021	61	_	
39-633	11022-11023	6	_	
39-634	11024-11026	NA	_	
39-635	11027-11029	NA	_	
39-636	11033-11048	Antidepressants	_	
39-637	11049-11050	0	_	
39-638	11051-11053	11	_	
39-639	11054-11056	47	_	
39-640	11057-11059	13	_	
39-641	11060-11062	NA	_	
39-642	11063-11065	NA	_	
39-643	11069-11073	Mood	_	
39-644	11074-11085	stabilizers	_	
39-645	11086-11087	0	_	
39-646	11088-11089	0	_	
39-647	11090-11091	5	_	
39-648	11092-11093	0	_	
39-649	11094-11096	NA	_	
39-650	11097-11099	NA	_	
39-651	11103-11117	Antipsychotics	_	
39-652	11118-11119	0	_	
39-653	11120-11121	0	_	
39-654	11122-11123	3	_	
39-655	11124-11126	13	_	
39-656	11127-11129	NA	_	
39-657	11130-11132	NA	_	
39-658	11136-11141	Other	_	
39-659	11142-11143	(	_	
39-660	11143-11150	unknown	_	
39-661	11150-11151	)	_	
39-662	11152-11153	1	_	
39-663	11154-11155	(	_	
39-664	11155-11156	0	_	
39-665	11156-11157	)	_	
39-666	11158-11159	2	_	
39-667	11160-11161	(	_	
39-668	11161-11162	0	_	
39-669	11162-11163	)	_	
39-670	11164-11166	21	_	
39-671	11167-11168	(	_	
39-672	11168-11169	0	_	
39-673	11169-11170	)	_	
39-674	11171-11172	5	_	
39-675	11173-11174	(	_	
39-676	11174-11175	0	_	
39-677	11175-11176	)	_	
39-678	11177-11179	NA	_	
39-679	11180-11182	NA	_	
39-680	11185-11190	CHR-P	_	
39-681	11191-11201	categories	_	
39-682	11211-11216	SPI-A	_	
39-683	11217-11218	(	_	
39-684	11218-11224	COGDIS	_	
39-685	11224-11225	/	_	
39-686	11225-11230	COPER	_	
39-687	11230-11231	/	_	
39-688	11231-11235	both	_	
39-689	11236-11241	items	_	
39-690	11241-11242	)	_	
39-691	11243-11245	NA	_	
39-692	11246-11248	NA	_	
39-693	11249-11251	30	_	
39-694	11252-11253	(	_	
39-695	11253-11254	4	_	
39-696	11254-11255	/	_	
39-697	11255-11257	15	_	
39-698	11257-11258	/	_	
39-699	11258-11260	11	_	
39-700	11260-11261	)	_	
39-701	11262-11264	NA	_	
39-702	11265-11267	NA	_	
39-703	11268-11270	NA	_	
39-704	11274-11280	CAARMS	_	
39-705	11281-11282	(	_	
39-706	11282-11285	APS	_	
39-707	11285-11286	/	_	
39-708	11286-11299	vulnerability	_	
39-709	11300-11308	criteria	_	
39-710	11308-11309	)	_	
39-711	11310-11312	NA	_	
39-712	11313-11315	NA	_	
39-713	11316-11318	89	_	
39-714	11319-11320	(	_	
39-715	11320-11322	87	_	
39-716	11322-11323	/	_	
39-717	11323-11324	2	_	
39-718	11324-11325	)	_	
39-719	11326-11328	NA	_	
39-720	11329-11331	NA	_	
39-721	11332-11334	NA	_	
39-722	11338-11344	CAARMS	_	
39-723	11345-11349	plus	_	
39-724	11350-11355	SPI-A	_	
39-725	11356-11357	(	_	
39-726	11357-11363	COGDIS	_	
39-727	11363-11364	/	_	
39-728	11364-11369	COPER	_	
39-729	11369-11370	/	_	
39-730	11370-11374	both	_	
39-731	11375-11380	items	_	
39-732	11380-11381	)	_	
39-733	11382-11384	NA	_	
39-734	11385-11387	NA	_	
39-735	11388-11390	55	_	
39-736	11391-11392	(	_	
39-737	11392-11393	9	_	
39-738	11393-11394	/	_	
39-739	11394-11396	22	_	
39-740	11396-11397	/	_	
39-741	11397-11399	24	_	
39-742	11399-11400	)	_	
39-743	11401-11403	NA	_	
39-744	11404-11406	NA	_	
39-745	11407-11409	NA	_	
39-746	11412-11416	MINI	_	
39-747	11417-11427	categories	_	
39-748	11437-11447	Depressive	_	
39-749	11447-11448	/	_	
39-750	11448-11452	mood	_	
39-751	11453-11462	disorders	_	
39-752	11463-11465	NA	_	
39-753	11466-11468	11	_	
39-754	11469-11471	75	_	
39-755	11472-11474	NA	_	
39-756	11475-11477	NA	_	
39-757	11478-11480	NA	_	
39-758	11484-11491	Anxiety	_	
39-759	11492-11501	disorders	_	
39-760	11501-11502	/	_	
39-761	11502-11515	posttraumatic	_	
39-762	11516-11522	stress	_	
39-763	11523-11531	disorder	_	
39-764	11531-11532	/	_	
39-765	11532-11552	obsessive-compulsive	_	
39-766	11553-11561	disorder	_	
39-767	11562-11564	NA	_	
39-768	11565-11567	16	_	
39-769	11568-11570	87	_	
39-770	11571-11573	NA	_	
39-771	11574-11576	NA	_	
39-772	11577-11579	NA	_	
39-773	11583-11587	Drug	_	
39-774	11587-11588	/	_	
39-775	11588-11595	alcohol	_	
39-776	11596-11601	abuse	_	
39-777	11601-11602	/	_	
39-778	11602-11612	dependence	_	
39-779	11613-11615	NA	_	
39-780	11616-11618	10	_	
39-781	11619-11621	42	_	
39-782	11622-11624	NA	_	
39-783	11625-11627	NA	_	
39-784	11628-11630	NA	_	
39-785	11634-11640	Eating	_	
39-786	11641-11650	disorders	_	
39-787	11651-11653	NA	_	
39-788	11654-11655	1	_	
39-789	11656-11658	10	_	
39-790	11659-11661	NA	_	
39-791	11662-11664	NA	_	
39-792	11665-11667	NA	_	
39-793	11670-11676	DSM-IV	_	
39-794	11676-11677	/	_	
39-795	11677-11687	Structured	_	
39-796	11688-11696	Clinical	_	
39-797	11697-11706	Interview	_	
39-798	11716-11729	Schizophrenia	_	
39-799	11730-11732	NA	_	
39-800	11733-11735	NA	_	
39-801	11736-11738	NA	_	
39-802	11739-11740	9	_	
39-803	11741-11743	NA	_	
39-804	11744-11746	NA	_	
39-805	11750-11766	Schizophreniform	_	
39-806	11767-11775	disorder	_	
39-807	11776-11778	NA	_	
39-808	11779-11781	NA	_	
39-809	11782-11784	NA	_	
39-810	11785-11786	3	_	
39-811	11787-11789	NA	_	
39-812	11790-11792	NA	_	
39-813	11796-11811	Schizoaffective	_	
39-814	11812-11820	disorder	_	
39-815	11821-11823	NA	_	
39-816	11824-11826	NA	_	
39-817	11827-11829	NA	_	
39-818	11830-11831	1	_	
39-819	11832-11834	NA	_	
39-820	11835-11837	NA	_	
39-821	11841-11850	Psychotic	_	
39-822	11851-11859	disorder	_	
39-823	11860-11863	NOS	_	
39-824	11864-11866	NA	_	
39-825	11867-11869	NA	_	
39-826	11870-11872	NA	_	
39-827	11873-11874	8	_	
39-828	11875-11877	NA	_	
39-829	11878-11880	NA	_	
39-830	11884-11889	Brief	_	
39-831	11890-11899	psychotic	_	
39-832	11900-11908	disorder	_	
39-833	11909-11911	NA	_	
39-834	11912-11914	NA	_	
39-835	11915-11917	NA	_	
39-836	11918-11919	1	_	
39-837	11920-11922	NA	_	
39-838	11923-11925	NA	_	
39-839	11929-11933	Mood	_	
39-840	11934-11943	disorders	_	
39-841	11944-11948	with	_	
39-842	11949-11958	psychotic	_	
39-843	11959-11967	features	_	
39-844	11968-11970	NA	_	
39-845	11971-11973	NA	_	
39-846	11974-11976	NA	_	
39-847	11977-11978	4	_	
39-848	11979-11981	NA	_	
39-849	11982-11984	NA	_	
39-850	11987-11992	Trial	_	
39-851	11993-11995	No	_	
39-852	11995-11996	.	_	
39-853	11996-11997	,	_	
39-854	11998-12003	total	_	
39-855	12004-12012	included	_	
39-856	12013-12014	(	_	
39-857	12014-12016	SD	_	
39-858	12016-12017	)	_	
39-859	12018-12021	197	_	
39-860	12022-12023	(	_	
39-861	12023-12027	16.3	_	
39-862	12027-12028	)	_	
39-863	12029-12032	194	_	
39-864	12033-12034	(	_	
39-865	12034-12038	16.2	_	
39-866	12038-12039	)	_	
39-867	12040-12043	185	_	
39-868	12044-12045	(	_	
39-869	12045-12049	26.5	_	
39-870	12049-12050	)	_	
39-871	12051-12054	181	_	
39-872	12055-12056	(	_	
39-873	12056-12060	29.2	_	
39-874	12060-12061	)	_	
39-875	12062-12067	F3,80	_	
39-876	12068-12069	=	_	
39-877	12070-12073	5.9	_	
39-878	12073-12074	;	_	
39-879	12075-12076	P	_	
39-880	12077-12078	=	_	
39-881	12079-12083	.001	_	
39-882	12084-12089	CHR-P	_	
39-883	12090-12092	to	_	
39-884	12093-12095	HC	_	
39-885	12095-12096	:	_	
39-886	12097-12098	P	_	
39-887	12099-12100	=	_	
39-888	12101-12105	.002	_	
39-889	12108-12112	Task	_	
39-890	12113-12124	performance	_	
39-891	12134-12142	Accuracy	_	
39-892	12142-12143	,	_	
39-893	12144-12145	%	_	
39-894	12146-12153	correct	_	
39-895	12154-12155	(	_	
39-896	12155-12157	SD	_	
39-897	12157-12158	)	_	
39-898	12159-12163	92.2	_	
39-899	12164-12165	(	_	
39-900	12165-12168	6.9	_	
39-901	12168-12169	)	_	
39-902	12170-12174	92.0	_	
39-903	12175-12176	(	_	
39-904	12176-12179	5.6	_	
39-905	12179-12180	)	_	
39-906	12181-12185	88.0	_	
39-907	12186-12187	(	_	
39-908	12187-12190	9.8	_	
39-909	12190-12191	)	_	
39-910	12192-12196	85.9	_	
39-911	12197-12198	(	_	
39-912	12198-12202	12.8	_	
39-913	12202-12203	)	_	
39-914	12204-12209	F3,79	_	
39-915	12210-12211	=	_	
39-916	12212-12215	5.5	_	
39-917	12215-12216	,	_	
39-918	12217-12218	P	_	
39-919	12219-12220	=	_	
39-920	12221-12225	.002	_	
39-921	12226-12231	CHR-P	_	
39-922	12232-12234	to	_	
39-923	12235-12237	HC	_	
39-924	12237-12238	:	_	
39-925	12239-12240	P	_	
39-926	12241-12242	=	_	
39-927	12243-12246	.01	_	
39-928	12246-12247	;	_	
39-929	12248-12253	CHR-P	_	
39-930	12254-12256	vs	_	
39-931	12257-12262	CHR-N	_	
39-932	12262-12263	:	_	
39-933	12264-12265	P	_	
39-934	12266-12267	=	_	
39-935	12268-12271	.01	_	
39-936	12275-12283	Reaction	_	
39-937	12284-12288	time	_	
39-938	12288-12289	,	_	
39-939	12290-12294	mean	_	
39-940	12295-12296	(	_	
39-941	12296-12298	SD	_	
39-942	12298-12299	)	_	
39-943	12299-12300	,	_	
39-944	12301-12303	ms	_	
39-945	12304-12307	528	_	
39-946	12308-12309	(	_	
39-947	12309-12313	68.4	_	
39-948	12313-12314	)	_	
39-949	12315-12318	524	_	
39-950	12319-12320	(	_	
39-951	12320-12324	80.1	_	
39-952	12324-12325	)	_	
39-953	12326-12329	545	_	
39-954	12330-12331	(	_	
39-955	12331-12335	84.9	_	
39-956	12335-12336	)	_	
39-957	12337-12340	577	_	
39-958	12341-12342	(	_	
39-959	12342-12347	100.1	_	
39-960	12347-12348	)	_	
39-961	12349-12351	NA	_	
39-962	12352-12354	NA	_	
39-963	12358-12366	Response	_	
39-964	12367-12375	variance	_	
39-965	12375-12376	,	_	
39-966	12376-12377	d	_	
39-967	12378-12382	mean	_	
39-968	12383-12384	(	_	
39-969	12384-12386	SD	_	
39-970	12386-12387	)	_	
39-971	12387-12388	,	_	
39-972	12389-12391	ms	_	
39-973	12392-12397	151.7	_	
39-974	12398-12399	(	_	
39-975	12399-12403	37.5	_	
39-976	12403-12404	)	_	
39-977	12405-12410	154.3	_	
39-978	12411-12412	(	_	
39-979	12412-12416	34.9	_	
39-980	12416-12417	)	_	
39-981	12418-12423	164.3	_	
39-982	12424-12425	(	_	
39-983	12425-12429	42.2	_	
39-984	12429-12430	)	_	
39-985	12431-12436	179.1	_	
39-986	12437-12438	(	_	
39-987	12438-12442	40.8	_	
39-988	12442-12443	)	_	
39-989	12444-12449	F3,79	_	
39-990	12450-12451	=	_	
39-991	12452-12455	3.3	_	
39-992	12455-12456	;	_	
39-993	12457-12458	P	_	
39-994	12459-12460	=	_	
39-995	12461-12464	.02	_	
39-996	12465-12468	FEP	_	
39-997	12469-12471	to	_	
39-998	12472-12474	HC	_	
39-999	12474-12475	:	_	
39-1000	12476-12477	P	_	
39-1001	12478-12479	=	_	
39-1002	12480-12483	.03	_	
39-1003	12487-12500	Abbreviations	_	
39-1004	12500-12501	:	_	
39-1005	12502-12505	APS	_	
39-1006	12505-12506	,	_	
39-1007	12507-12517	attenuated	_	
39-1008	12518-12527	psychotic	_	
39-1009	12528-12536	symptoms	_	
39-1010	12536-12537	;	_	
39-1011	12538-12542	BACS	_	
39-1012	12542-12543	,	_	
39-1013	12544-12549	Brief	_	
39-1014	12550-12560	Assessment	_	
39-1015	12561-12563	of	_	
39-1016	12564-12573	Cognition	_	
39-1017	12574-12576	in	_	
39-1018	12577-12590	Schizophrenia	_	
39-1019	12590-12591	;	_	
39-1020	12592-12598	CAARMS	_	
39-1021	12598-12599	,	_	
39-1022	12600-12613	Comprehensive	_	
39-1023	12614-12624	Assessment	_	
39-1024	12625-12627	of	_	
39-1025	12628-12630	At	_	
39-1026	12631-12635	Risk	_	
39-1027	12636-12642	Mental	_	
39-1028	12643-12649	States	_	
39-1029	12649-12650	;	_	
39-1030	12651-12656	CHR-N	_	
39-1031	12656-12657	,	_	
39-1032	12658-12666	clinical	_	
39-1033	12667-12671	high	_	
39-1034	12672-12676	risk	_	
39-1035	12677-12685	negative	_	
39-1036	12685-12686	;	_	
39-1037	12687-12692	CHR-P	_	
39-1038	12692-12693	,	_	
39-1039	12694-12702	clinical	_	
39-1040	12703-12707	high	_	
39-1041	12708-12712	risk	_	
39-1042	12713-12721	positive	_	
39-1043	12721-12722	;	_	
39-1044	12723-12729	COGDIS	_	
39-1045	12729-12730	/	_	
39-1046	12730-12735	COPER	_	
39-1047	12735-12736	,	_	
39-1048	12737-12746	Cognitive	_	
39-1049	12747-12759	Disturbances	_	
39-1050	12760-12763	and	_	
39-1051	12764-12784	Cognitive-Perceptive	_	
39-1052	12785-12790	Basic	_	
39-1053	12791-12799	Symptoms	_	
39-1054	12800-12808	criteria	_	
39-1055	12808-12809	;	_	
39-1056	12810-12813	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis	
39-1057	12813-12814	,	_	
39-1058	12815-12828	first-episode	_	
39-1059	12829-12838	psychosis	_	
39-1060	12838-12839	;	_	
39-1061	12840-12843	GAF	_	
39-1062	12843-12844	,	_	
39-1063	12845-12851	global	_	
39-1064	12852-12862	assessment	_	
39-1065	12863-12865	of	_	
39-1066	12866-12877	functioning	_	
39-1067	12877-12878	;	_	
39-1068	12879-12881	GF	_	
39-1069	12881-12882	,	_	
39-1070	12883-12889	global	_	
39-1071	12890-12901	functioning	_	
39-1072	12901-12902	;	_	
39-1073	12903-12905	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
39-1074	12905-12906	,	_	
39-1075	12907-12914	healthy	_	
39-1076	12915-12922	control	_	
39-1077	12923-12933	individual	_	
39-1078	12933-12934	;	_	
39-1079	12935-12939	MINI	_	
39-1080	12939-12940	,	_	
39-1081	12941-12959	Mini-International	_	
39-1082	12960-12976	Neuropsychiatric	_	
39-1083	12977-12986	Interview	_	
39-1084	12986-12987	;	_	
39-1085	12988-12993	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
39-1086	12993-12994	,	_	
39-1087	12995-13003	Positive	_	
39-1088	13004-13007	and	_	
39-1089	13008-13016	Negative	_	
39-1090	13017-13024	Symptom	_	
39-1091	13025-13030	Scale	_	
39-1092	13030-13031	;	_	
39-1093	13032-13037	SPI-A	_	
39-1094	13037-13038	,	_	
39-1095	13039-13052	Schizophrenia	_	
39-1096	13053-13062	Proneness	_	
39-1097	13063-13073	Instrument	_	
39-1098	13073-13074	,	_	
39-1099	13075-13080	Adult	_	
39-1100	13081-13088	version	_	
39-1101	13088-13089	.	_	

#Text=All F tests are Welch based; α = .05, 2-sided, 1000 samples bootstrapping, post hoc Games-Howell correction for type I errors.
40-1	13090-13093	All	_	
40-2	13094-13095	F	_	
40-3	13096-13101	tests	_	
40-4	13102-13105	are	_	
40-5	13106-13111	Welch	_	
40-6	13112-13117	based	_	
40-7	13117-13118	;	_	
40-8	13119-13120	α	_	
40-9	13121-13122	=	_	
40-10	13123-13126	.05	_	
40-11	13126-13127	,	_	
40-12	13128-13129	2	_	
40-13	13129-13130	-	_	
40-14	13130-13135	sided	_	
40-15	13135-13136	,	_	
40-16	13137-13141	1000	_	
40-17	13142-13149	samples	_	
40-18	13150-13163	bootstrapping	_	
40-19	13163-13164	,	_	
40-20	13165-13169	post	_	
40-21	13170-13173	hoc	_	
40-22	13174-13186	Games-Howell	_	
40-23	13187-13197	correction	_	
40-24	13198-13201	for	_	
40-25	13202-13206	type	_	
40-26	13207-13208	I	_	
40-27	13209-13215	errors	_	
40-28	13215-13216	.	_	

#Text=BACS scores for clinical groups were standardized to control group data, controlled for sex category.
41-1	13217-13221	BACS	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[40]	
41-2	13222-13228	scores	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[40]	
41-3	13229-13232	for	_	
41-4	13233-13241	clinical	_	
41-5	13242-13248	groups	_	
41-6	13249-13253	were	_	
41-7	13254-13266	standardized	_	
41-8	13267-13269	to	_	
41-9	13270-13277	control	_	
41-10	13278-13283	group	_	
41-11	13284-13288	data	_	
41-12	13288-13289	,	_	
41-13	13290-13300	controlled	_	
41-14	13301-13304	for	_	
41-15	13305-13308	sex	_	
41-16	13309-13317	category	_	
41-17	13317-13318	.	_	

#Text=If multiple medications were reported, they were scored separately in the different categories listed.
42-1	13319-13321	If	_	
42-2	13322-13330	multiple	_	
42-3	13331-13342	medications	_	
42-4	13343-13347	were	_	
42-5	13348-13356	reported	_	
42-6	13356-13357	,	_	
42-7	13358-13362	they	_	
42-8	13363-13367	were	_	
42-9	13368-13374	scored	_	
42-10	13375-13385	separately	_	
42-11	13386-13388	in	_	
42-12	13389-13392	the	_	
42-13	13393-13402	different	_	
42-14	13403-13413	categories	_	
42-15	13414-13420	listed	_	
42-16	13420-13421	.	_	

#Text=Response variance equals standard deviation of response times across trials.
43-1	13422-13430	Response	_	
43-2	13431-13439	variance	_	
43-3	13440-13446	equals	_	
43-4	13447-13455	standard	_	
43-5	13456-13465	deviation	_	
43-6	13466-13468	of	_	
43-7	13469-13477	response	_	
43-8	13478-13483	times	_	
43-9	13484-13490	across	_	
43-10	13491-13497	trials	_	
43-11	13497-13498	.	_	

#Text=Clinical Follow-up
#Text=Participants meeting CHR-P and CHR-N criteria were reassessed at 3-, 6-, 9-, 12-, 18-, 24-, 30-, and 36-month intervals to examine persistence of CHR-P criteria and transition to psychosis (eMethods in the Supplement).
44-1	13499-13507	Clinical	_	
44-2	13508-13517	Follow-up	_	
44-3	13518-13530	Participants	_	
44-4	13531-13538	meeting	_	
44-5	13539-13544	CHR-P	_	
44-6	13545-13548	and	_	
44-7	13549-13554	CHR-N	_	
44-8	13555-13563	criteria	_	
44-9	13564-13568	were	_	
44-10	13569-13579	reassessed	_	
44-11	13580-13582	at	_	
44-12	13583-13584	3	_	
44-13	13584-13585	-	_	
44-14	13585-13586	,	_	
44-15	13587-13588	6	_	
44-16	13588-13589	-	_	
44-17	13589-13590	,	_	
44-18	13591-13592	9	_	
44-19	13592-13593	-	_	
44-20	13593-13594	,	_	
44-21	13595-13597	12	_	
44-22	13597-13598	-	_	
44-23	13598-13599	,	_	
44-24	13600-13602	18	_	
44-25	13602-13603	-	_	
44-26	13603-13604	,	_	
44-27	13605-13607	24	_	
44-28	13607-13608	-	_	
44-29	13608-13609	,	_	
44-30	13610-13612	30	_	
44-31	13612-13613	-	_	
44-32	13613-13614	,	_	
44-33	13615-13618	and	_	
44-34	13619-13621	36	_	
44-35	13621-13622	-	_	
44-36	13622-13627	month	_	
44-37	13628-13637	intervals	_	
44-38	13638-13640	to	_	
44-39	13641-13648	examine	_	
44-40	13649-13660	persistence	_	
44-41	13661-13663	of	_	
44-42	13664-13669	CHR-P	_	
44-43	13670-13678	criteria	_	
44-44	13679-13682	and	_	
44-45	13683-13693	transition	_	
44-46	13694-13696	to	_	
44-47	13697-13706	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis	
44-48	13707-13708	(	_	
44-49	13708-13716	eMethods	_	
44-50	13717-13719	in	_	
44-51	13720-13723	the	_	
44-52	13724-13734	Supplement	_	
44-53	13734-13735	)	_	
44-54	13735-13736	.	_	

#Text=Stimuli and Task
#Text=Participants were presented with 3 blocks of 80 trials, with each trial consisting of a circular sinewave grating that contracted toward central fixation.
45-1	13737-13744	Stimuli	_	
45-2	13745-13748	and	_	
45-3	13749-13753	Task	_	
45-4	13754-13766	Participants	_	
45-5	13767-13771	were	_	
45-6	13772-13781	presented	_	
45-7	13782-13786	with	_	
45-8	13787-13788	3	_	
45-9	13789-13795	blocks	_	
45-10	13796-13798	of	_	
45-11	13799-13801	80	_	
45-12	13802-13808	trials	_	
45-13	13808-13809	,	_	
45-14	13810-13814	with	_	
45-15	13815-13819	each	_	
45-16	13820-13825	trial	_	
45-17	13826-13836	consisting	_	
45-18	13837-13839	of	_	
45-19	13840-13841	a	_	
45-20	13842-13850	circular	_	
45-21	13851-13859	sinewave	_	
45-22	13860-13867	grating	_	
45-23	13868-13872	that	_	
45-24	13873-13883	contracted	_	
45-25	13884-13890	toward	_	
45-26	13891-13898	central	_	
45-27	13899-13907	fixation	_	
45-28	13907-13908	.	_	

#Text=The task of the participants was to detect and respond by button press to a velocity increase of the stimulus, randomly occurring between 750 and 3000 milliseconds (Figure 1).
46-1	13909-13912	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-2	13913-13917	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-3	13918-13920	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-4	13921-13924	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-5	13925-13937	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-6	13938-13941	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-7	13942-13944	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-8	13945-13951	detect	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-9	13952-13955	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-10	13956-13963	respond	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-11	13964-13966	by	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-12	13967-13973	button	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-13	13974-13979	press	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-14	13980-13982	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-15	13983-13984	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-16	13985-13993	velocity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-17	13994-14002	increase	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-18	14003-14005	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-19	14006-14009	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-20	14010-14018	stimulus	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-21	14018-14019	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-22	14020-14028	randomly	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-23	14029-14038	occurring	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-24	14039-14046	between	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-25	14047-14050	750	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-26	14051-14054	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-27	14055-14059	3000	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-28	14060-14072	milliseconds	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]	
46-29	14073-14074	(	_	
46-30	14074-14080	Figure	_	
46-31	14081-14082	1	_	
46-32	14082-14083	)	_	
46-33	14083-14084	.	_	

#Text=Paradigm and Task Performance
#Text=A, Inward moving grating task: participants report, by button press, the onset of a change in velocity of inward motion of the visual stimulus (correct response window, 200-1200 milliseconds).
47-1	14085-14093	Paradigm	_	
47-2	14094-14097	and	_	
47-3	14098-14102	Task	_	
47-4	14103-14114	Performance	_	
47-5	14115-14116	A	_	
47-6	14116-14117	,	_	
47-7	14118-14124	Inward	_	
47-8	14125-14131	moving	_	
47-9	14132-14139	grating	_	
47-10	14140-14144	task	_	
47-11	14144-14145	:	_	
47-12	14146-14158	participants	_	
47-13	14159-14165	report	_	
47-14	14165-14166	,	_	
47-15	14167-14169	by	_	
47-16	14170-14176	button	_	
47-17	14177-14182	press	_	
47-18	14182-14183	,	_	
47-19	14184-14187	the	_	
47-20	14188-14193	onset	_	
47-21	14194-14196	of	_	
47-22	14197-14198	a	_	
47-23	14199-14205	change	_	
47-24	14206-14208	in	_	
47-25	14209-14217	velocity	_	
47-26	14218-14220	of	_	
47-27	14221-14227	inward	_	
47-28	14228-14234	motion	_	
47-29	14235-14237	of	_	
47-30	14238-14241	the	_	
47-31	14242-14248	visual	_	
47-32	14249-14257	stimulus	_	
47-33	14258-14259	(	_	
47-34	14259-14266	correct	_	
47-35	14267-14275	response	_	
47-36	14276-14282	window	_	
47-37	14282-14283	,	_	
47-38	14284-14287	200	_	
47-39	14287-14288	-	_	
47-40	14288-14292	1200	_	
47-41	14293-14305	milliseconds	_	
47-42	14305-14306	)	_	
47-43	14306-14307	.	_	

#Text=Feedback on performance was provided on every trial, shortly after the response onset terminated stimulus presentation.
48-1	14308-14316	Feedback	_	
48-2	14317-14319	on	_	
48-3	14320-14331	performance	_	
48-4	14332-14335	was	_	
48-5	14336-14344	provided	_	
48-6	14345-14347	on	_	
48-7	14348-14353	every	_	
48-8	14354-14359	trial	_	
48-9	14359-14360	,	_	
48-10	14361-14368	shortly	_	
48-11	14369-14374	after	_	
48-12	14375-14378	the	_	
48-13	14379-14387	response	_	
48-14	14388-14393	onset	_	
48-15	14394-14404	terminated	_	
48-16	14405-14413	stimulus	_	
48-17	14414-14426	presentation	_	
48-18	14426-14427	.	_	

#Text=B, Histograms of group means and standard errors for accuracy (% correct), mean reaction times (RTs), and behavioral variability (intraindividual standard deviation of RTs).
49-1	14428-14429	B	_	
49-2	14429-14430	,	_	
49-3	14431-14441	Histograms	_	
49-4	14442-14444	of	_	
49-5	14445-14450	group	_	
49-6	14451-14456	means	_	
49-7	14457-14460	and	_	
49-8	14461-14469	standard	_	
49-9	14470-14476	errors	_	
49-10	14477-14480	for	_	
49-11	14481-14489	accuracy	_	
49-12	14490-14491	(	_	
49-13	14491-14492	%	_	
49-14	14493-14500	correct	_	
49-15	14500-14501	)	_	
49-16	14501-14502	,	_	
49-17	14503-14507	mean	_	
49-18	14508-14516	reaction	_	
49-19	14517-14522	times	_	
49-20	14523-14524	(	_	
49-21	14524-14527	RTs	_	
49-22	14527-14528	)	_	
49-23	14528-14529	,	_	
49-24	14530-14533	and	_	
49-25	14534-14544	behavioral	_	
49-26	14545-14556	variability	_	
49-27	14557-14558	(	_	
49-28	14558-14573	intraindividual	_	
49-29	14574-14582	standard	_	
49-30	14583-14592	deviation	_	
49-31	14593-14595	of	_	
49-32	14596-14599	RTs	_	
49-33	14599-14600	)	_	
49-34	14600-14601	.	_	

#Text=CHR-N indicates clinical high risk negative; CHR-P, clinical high risk positive; FEP, first-episode psychosis; HC, healthy control individuals.
#Text=aIndicates significant group differences (Welch F tests, α = .05, 2-sided, 1000 samples bootstrapping, Games-Howell corrected for multiple comparisons).
50-1	14602-14607	CHR-N	_	
50-2	14608-14617	indicates	_	
50-3	14618-14626	clinical	_	
50-4	14627-14631	high	_	
50-5	14632-14636	risk	_	
50-6	14637-14645	negative	_	
50-7	14645-14646	;	_	
50-8	14647-14652	CHR-P	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[42]	
50-9	14652-14653	,	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[42]	
50-10	14654-14662	clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[42]	
50-11	14663-14667	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[42]	
50-12	14668-14672	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[42]	
50-13	14673-14681	positive	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[42]	
50-14	14681-14682	;	_	
50-15	14683-14686	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[43]	
50-16	14686-14687	,	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[43]	
50-17	14688-14701	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[43]	
50-18	14702-14711	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[43]	
50-19	14711-14712	;	_	
50-20	14713-14715	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]	
50-21	14715-14716	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]	
50-22	14717-14724	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]	
50-23	14725-14732	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]	
50-24	14733-14744	individuals	_	
50-25	14744-14745	.	_	
50-26	14746-14756	aIndicates	_	
50-27	14757-14768	significant	_	
50-28	14769-14774	group	_	
50-29	14775-14786	differences	_	
50-30	14787-14788	(	_	
50-31	14788-14793	Welch	_	
50-32	14794-14795	F	_	
50-33	14796-14801	tests	_	
50-34	14801-14802	,	_	
50-35	14803-14804	α	_	
50-36	14805-14806	=	_	
50-37	14807-14810	.05	_	
50-38	14810-14811	,	_	
50-39	14812-14813	2	_	
50-40	14813-14814	-	_	
50-41	14814-14819	sided	_	
50-42	14819-14820	,	_	
50-43	14821-14825	1000	_	
50-44	14826-14833	samples	_	
50-45	14834-14847	bootstrapping	_	
50-46	14847-14848	,	_	
50-47	14849-14861	Games-Howell	_	
50-48	14862-14871	corrected	_	
50-49	14872-14875	for	_	
50-50	14876-14884	multiple	_	
50-51	14885-14896	comparisons	_	
50-52	14896-14897	)	_	
50-53	14897-14898	.	_	

#Text=Neuroimaging
#Text=Magnetoencephalography data were acquired using a 248-channel 4D-BTI magnetometer system (MAGNES 3600 WH, 4-dimensional neuroimaging; Bio-Medicine), recorded with 1017.25-Hz sampling rate and DC-400 Hz online filtered.
51-1	14899-14911	Neuroimaging	_	
51-2	14912-14934	Magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[45]	
51-3	14935-14939	data	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[45]	
51-4	14940-14944	were	_	
51-5	14945-14953	acquired	_	
51-6	14954-14959	using	_	
51-7	14960-14961	a	_	
51-8	14962-14965	248	_	
51-9	14965-14966	-	_	
51-10	14966-14973	channel	_	
51-11	14974-14980	4D-BTI	_	
51-12	14981-14993	magnetometer	_	
51-13	14994-15000	system	_	
51-14	15001-15002	(	_	
51-15	15002-15008	MAGNES	_	
51-16	15009-15013	3600	_	
51-17	15014-15016	WH	_	
51-18	15016-15017	,	_	
51-19	15018-15019	4	_	
51-20	15019-15020	-	_	
51-21	15020-15031	dimensional	_	
51-22	15032-15044	neuroimaging	_	
51-23	15044-15045	;	_	
51-24	15046-15058	Bio-Medicine	_	
51-25	15058-15059	)	_	
51-26	15059-15060	,	_	
51-27	15061-15069	recorded	_	
51-28	15070-15074	with	_	
51-29	15075-15082	1017.25	_	
51-30	15082-15083	-	_	
51-31	15083-15085	Hz	_	
51-32	15086-15094	sampling	_	
51-33	15095-15099	rate	_	
51-34	15100-15103	and	_	
51-35	15104-15106	DC	_	
51-36	15106-15107	-	_	
51-37	15107-15110	400	_	
51-38	15111-15113	Hz	_	
51-39	15114-15120	online	_	
51-40	15121-15129	filtered	_	
51-41	15129-15130	.	_	

#Text=T1 anatomical scans (3-dimensional magnetization-prepared rapid gradient-echo sequences) were collected for patient-specific source localization of MEG activity (eMethods in the Supplement).
52-1	15131-15133	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[46]	
52-2	15134-15144	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[46]	
52-3	15145-15150	scans	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[46]	
52-4	15151-15152	(	_	
52-5	15152-15153	3	_	
52-6	15153-15154	-	_	
52-7	15154-15165	dimensional	_	
52-8	15166-15188	magnetization-prepared	_	
52-9	15189-15194	rapid	_	
52-10	15195-15208	gradient-echo	_	
52-11	15209-15218	sequences	_	
52-12	15218-15219	)	_	
52-13	15220-15224	were	_	
52-14	15225-15234	collected	_	
52-15	15235-15238	for	_	
52-16	15239-15255	patient-specific	_	
52-17	15256-15262	source	_	
52-18	15263-15275	localization	_	
52-19	15276-15278	of	_	
52-20	15279-15282	MEG	_	
52-21	15283-15291	activity	_	
52-22	15292-15293	(	_	
52-23	15293-15301	eMethods	_	
52-24	15302-15304	in	_	
52-25	15305-15308	the	_	
52-26	15309-15319	Supplement	_	
52-27	15319-15320	)	_	
52-28	15320-15321	.	_	

#Text=Magnetoencephalography Data Analysis
#Text=Magnetoencephalography data were analyzed with MATLAB using the open-source Fieldtrip Toolbox.
53-1	15322-15344	Magnetoencephalography	_	
53-2	15345-15349	Data	_	
53-3	15350-15358	Analysis	_	
53-4	15359-15381	Magnetoencephalography	_	
53-5	15382-15386	data	_	
53-6	15387-15391	were	_	
53-7	15392-15400	analyzed	_	
53-8	15401-15405	with	_	
53-9	15406-15412	MATLAB	_	
53-10	15413-15418	using	_	
53-11	15419-15422	the	_	
53-12	15423-15434	open-source	_	
53-13	15435-15444	Fieldtrip	_	
53-14	15445-15452	Toolbox	_	
53-15	15452-15453	.	_	

#Text=Preprocessing included correct trials only with nonoverlapping 3.8-second segments (1-second baseline), time locked to the onset of the visual grating.
54-1	15454-15467	Preprocessing	_	
54-2	15468-15476	included	_	
54-3	15477-15484	correct	_	
54-4	15485-15491	trials	_	
54-5	15492-15496	only	_	
54-6	15497-15501	with	_	
54-7	15502-15516	nonoverlapping	_	
54-8	15517-15520	3.8	_	
54-9	15520-15521	-	_	
54-10	15521-15527	second	_	
54-11	15528-15536	segments	_	
54-12	15537-15538	(	_	
54-13	15538-15539	1	_	
54-14	15539-15540	-	_	
54-15	15540-15546	second	_	
54-16	15547-15555	baseline	_	
54-17	15555-15556	)	_	
54-18	15556-15557	,	_	
54-19	15558-15562	time	_	
54-20	15563-15569	locked	_	
54-21	15570-15572	to	_	
54-22	15573-15576	the	_	
54-23	15577-15582	onset	_	
54-24	15583-15585	of	_	
54-25	15586-15589	the	_	
54-26	15590-15596	visual	_	
54-27	15597-15604	grating	_	
54-28	15604-15605	.	_	

#Text=Line noise was attenuated with a discrete 50-Hz Fourier transform filter, and faulty sensors with large signal variance or flat signals were removed.
55-1	15606-15610	Line	_	
55-2	15611-15616	noise	_	
55-3	15617-15620	was	_	
55-4	15621-15631	attenuated	_	
55-5	15632-15636	with	_	
55-6	15637-15638	a	_	
55-7	15639-15647	discrete	_	
55-8	15648-15650	50	_	
55-9	15650-15651	-	_	
55-10	15651-15653	Hz	_	
55-11	15654-15661	Fourier	_	
55-12	15662-15671	transform	_	
55-13	15672-15678	filter	_	
55-14	15678-15679	,	_	
55-15	15680-15683	and	_	
55-16	15684-15690	faulty	_	
55-17	15691-15698	sensors	_	
55-18	15699-15703	with	_	
55-19	15704-15709	large	_	
55-20	15710-15716	signal	_	
55-21	15717-15725	variance	_	
55-22	15726-15728	or	_	
55-23	15729-15733	flat	_	
55-24	15734-15741	signals	_	
55-25	15742-15746	were	_	
55-26	15747-15754	removed	_	
55-27	15754-15755	.	_	

#Text=Data were denoised relative to MEG reference channels and downsampled to 300 Hz.
56-1	15756-15760	Data	_	
56-2	15761-15765	were	_	
56-3	15766-15774	denoised	_	
56-4	15775-15783	relative	_	
56-5	15784-15786	to	_	
56-6	15787-15790	MEG	_	
56-7	15791-15800	reference	_	
56-8	15801-15809	channels	_	
56-9	15810-15813	and	_	
56-10	15814-15825	downsampled	_	
56-11	15826-15828	to	_	
56-12	15829-15832	300	_	
56-13	15833-15835	Hz	_	
56-14	15835-15836	.	_	

#Text=Artifact-free data were created by removing trials with excessive transient muscle activity, slow drift, or superconducting quantum interference device jumps using visual inspection, and independent component analysis–based removal of eye blink, eye movement, and electrocardiographic artifacts.
57-1	15837-15850	Artifact-free	_	
57-2	15851-15855	data	_	
57-3	15856-15860	were	_	
57-4	15861-15868	created	_	
57-5	15869-15871	by	_	
57-6	15872-15880	removing	_	
57-7	15881-15887	trials	_	
57-8	15888-15892	with	_	
57-9	15893-15902	excessive	_	
57-10	15903-15912	transient	_	
57-11	15913-15919	muscle	_	
57-12	15920-15928	activity	_	
57-13	15928-15929	,	_	
57-14	15930-15934	slow	_	
57-15	15935-15940	drift	_	
57-16	15940-15941	,	_	
57-17	15942-15944	or	_	
57-18	15945-15960	superconducting	_	
57-19	15961-15968	quantum	_	
57-20	15969-15981	interference	_	
57-21	15982-15988	device	_	
57-22	15989-15994	jumps	_	
57-23	15995-16000	using	_	
57-24	16001-16007	visual	_	
57-25	16008-16018	inspection	_	
57-26	16018-16019	,	_	
57-27	16020-16023	and	_	
57-28	16024-16035	independent	_	
57-29	16036-16045	component	_	
57-30	16046-16060	analysis–based	_	
57-31	16061-16068	removal	_	
57-32	16069-16071	of	_	
57-33	16072-16075	eye	_	
57-34	16076-16081	blink	_	
57-35	16081-16082	,	_	
57-36	16083-16086	eye	_	
57-37	16087-16095	movement	_	
57-38	16095-16096	,	_	
57-39	16097-16100	and	_	
57-40	16101-16121	electrocardiographic	_	
57-41	16122-16131	artifacts	_	
57-42	16131-16132	.	_	

#Text=Data were then submitted to time-frequency (TFR) analyses (1-90 Hz, stepsize 50 milliseconds, 450 milliseconds sliding-window fast-fourier transformed [FFT]; Hanning tapered), computed for planar-orientation transformed MEG data.
58-1	16133-16137	Data	_	
58-2	16138-16142	were	_	
58-3	16143-16147	then	_	
58-4	16148-16157	submitted	_	
58-5	16158-16160	to	_	
58-6	16161-16175	time-frequency	_	
58-7	16176-16177	(	_	
58-8	16177-16180	TFR	_	
58-9	16180-16181	)	_	
58-10	16182-16190	analyses	_	
58-11	16191-16192	(	_	
58-12	16192-16193	1	_	
58-13	16193-16194	-	_	
58-14	16194-16196	90	_	
58-15	16197-16199	Hz	_	
58-16	16199-16200	,	_	
58-17	16201-16209	stepsize	_	
58-18	16210-16212	50	_	
58-19	16213-16225	milliseconds	_	
58-20	16225-16226	,	_	
58-21	16227-16230	450	_	
58-22	16231-16243	milliseconds	_	
58-23	16244-16258	sliding-window	_	
58-24	16259-16271	fast-fourier	_	
58-25	16272-16283	transformed	_	
58-26	16284-16285	[	_	
58-27	16285-16288	FFT	_	
58-28	16288-16289	]	_	
58-29	16289-16290	;	_	
58-30	16291-16298	Hanning	_	
58-31	16299-16306	tapered	_	
58-32	16306-16307	)	_	
58-33	16307-16308	,	_	
58-34	16309-16317	computed	_	
58-35	16318-16321	for	_	
58-36	16322-16340	planar-orientation	_	
58-37	16341-16352	transformed	_	
58-38	16353-16356	MEG	_	
58-39	16357-16361	data	_	
58-40	16361-16362	.	_	

#Text=Whole-brain source estimation of γ-band power (57-67 Hz) between 250 and 750 milliseconds was computed using the Dynamic Imaging of Coherent Sources beamforming approach (eMethods in the Supplement). γ-Band source data were statistically tested across groups to determine the location of main effects (Figure 2).
59-1	16363-16374	Whole-brain	_	
59-2	16375-16381	source	_	
59-3	16382-16392	estimation	_	
59-4	16393-16395	of	_	
59-5	16396-16402	γ-band	_	
59-6	16403-16408	power	_	
59-7	16409-16410	(	_	
59-8	16410-16412	57	_	
59-9	16412-16413	-	_	
59-10	16413-16415	67	_	
59-11	16416-16418	Hz	_	
59-12	16418-16419	)	_	
59-13	16420-16427	between	_	
59-14	16428-16431	250	_	
59-15	16432-16435	and	_	
59-16	16436-16439	750	_	
59-17	16440-16452	milliseconds	_	
59-18	16453-16456	was	_	
59-19	16457-16465	computed	_	
59-20	16466-16471	using	_	
59-21	16472-16475	the	_	
59-22	16476-16483	Dynamic	_	
59-23	16484-16491	Imaging	_	
59-24	16492-16494	of	_	
59-25	16495-16503	Coherent	_	
59-26	16504-16511	Sources	_	
59-27	16512-16523	beamforming	_	
59-28	16524-16532	approach	_	
59-29	16533-16534	(	_	
59-30	16534-16542	eMethods	_	
59-31	16543-16545	in	_	
59-32	16546-16549	the	_	
59-33	16550-16560	Supplement	_	
59-34	16560-16561	)	_	
59-35	16561-16562	.	_	
59-36	16563-16569	γ-Band	_	
59-37	16570-16576	source	_	
59-38	16577-16581	data	_	
59-39	16582-16586	were	_	
59-40	16587-16600	statistically	_	
59-41	16601-16607	tested	_	
59-42	16608-16614	across	_	
59-43	16615-16621	groups	_	
59-44	16622-16624	to	_	
59-45	16625-16634	determine	_	
59-46	16635-16638	the	_	
59-47	16639-16647	location	_	
59-48	16648-16650	of	_	
59-49	16651-16655	main	_	
59-50	16656-16663	effects	_	
59-51	16664-16665	(	_	
59-52	16665-16671	Figure	_	
59-53	16672-16673	2	_	
59-54	16673-16674	)	_	
59-55	16674-16675	.	_	

#Text=These were then used to guide selection of the main regions of interest (ROIs) for more fine-grained virtual channel analyses (Figure 2 and Figure 3C) (eMethods in the Supplement).
60-1	16676-16681	These	_	
60-2	16682-16686	were	_	
60-3	16687-16691	then	_	
60-4	16692-16696	used	_	
60-5	16697-16699	to	_	
60-6	16700-16705	guide	_	
60-7	16706-16715	selection	_	
60-8	16716-16718	of	_	
60-9	16719-16722	the	_	
60-10	16723-16727	main	_	
60-11	16728-16735	regions	_	
60-12	16736-16738	of	_	
60-13	16739-16747	interest	_	
60-14	16748-16749	(	_	
60-15	16749-16753	ROIs	_	
60-16	16753-16754	)	_	
60-17	16755-16758	for	_	
60-18	16759-16763	more	_	
60-19	16764-16776	fine-grained	_	
60-20	16777-16784	virtual	_	
60-21	16785-16792	channel	_	
60-22	16793-16801	analyses	_	
60-23	16802-16803	(	_	
60-24	16803-16809	Figure	_	
60-25	16810-16811	2	_	
60-26	16812-16815	and	_	
60-27	16816-16822	Figure	_	
60-28	16823-16825	3C	_	
60-29	16825-16826	)	_	
60-30	16827-16828	(	_	
60-31	16828-16836	eMethods	_	
60-32	16837-16839	in	_	
60-33	16840-16843	the	_	
60-34	16844-16854	Supplement	_	
60-35	16854-16855	)	_	
60-36	16855-16856	.	_	

#Text=Virtual channel time series were used for the analysis of event-related fields (ERF), TFR, inter-trial phase coherence (ITPC), baseline FFT, and Granger causality (GC).
61-1	16857-16864	Virtual	_	
61-2	16865-16872	channel	_	
61-3	16873-16877	time	_	
61-4	16878-16884	series	_	
61-5	16885-16889	were	_	
61-6	16890-16894	used	_	
61-7	16895-16898	for	_	
61-8	16899-16902	the	_	
61-9	16903-16911	analysis	_	
61-10	16912-16914	of	_	
61-11	16915-16928	event-related	_	
61-12	16929-16935	fields	_	
61-13	16936-16937	(	_	
61-14	16937-16940	ERF	_	
61-15	16940-16941	)	_	
61-16	16941-16942	,	_	
61-17	16943-16946	TFR	_	
61-18	16946-16947	,	_	
61-19	16948-16959	inter-trial	_	
61-20	16960-16965	phase	_	
61-21	16966-16975	coherence	_	
61-22	16976-16977	(	_	
61-23	16977-16981	ITPC	_	
61-24	16981-16982	)	_	
61-25	16982-16983	,	_	
61-26	16984-16992	baseline	_	
61-27	16993-16996	FFT	_	
61-28	16996-16997	,	_	
61-29	16998-17001	and	_	
61-30	17002-17009	Granger	_	
61-31	17010-17019	causality	_	
61-32	17020-17021	(	_	
61-33	17021-17023	GC	_	
61-34	17023-17024	)	_	
61-35	17024-17025	.	_	

#Text=Sensor and Source-Power Magnetoencephalography (MEG) Data
#Text=A, Sensor-level MEG data: left topographical distribution plot shows grand average–induced γ power (n = 232) changes from baseline, with white dots marking the sensors for which the time frequency response (TFR) plot in the middle is plotted.
62-1	17026-17032	Sensor	_	
62-2	17033-17036	and	_	
62-3	17037-17049	Source-Power	_	
62-4	17050-17072	Magnetoencephalography	_	
62-5	17073-17074	(	_	
62-6	17074-17077	MEG	_	
62-7	17077-17078	)	_	
62-8	17079-17083	Data	_	
62-9	17084-17085	A	_	
62-10	17085-17086	,	_	
62-11	17087-17099	Sensor-level	_	
62-12	17100-17103	MEG	_	
62-13	17104-17108	data	_	
62-14	17108-17109	:	_	
62-15	17110-17114	left	_	
62-16	17115-17128	topographical	_	
62-17	17129-17141	distribution	_	
62-18	17142-17146	plot	_	
62-19	17147-17152	shows	_	
62-20	17153-17158	grand	_	
62-21	17159-17174	average–induced	_	
62-22	17175-17176	γ	_	
62-23	17177-17182	power	_	
62-24	17183-17184	(	_	
62-25	17184-17185	n	_	
62-26	17186-17187	=	_	
62-27	17188-17191	232	_	
62-28	17191-17192	)	_	
62-29	17193-17200	changes	_	
62-30	17201-17205	from	_	
62-31	17206-17214	baseline	_	
62-32	17214-17215	,	_	
62-33	17216-17220	with	_	
62-34	17221-17226	white	_	
62-35	17227-17231	dots	_	
62-36	17232-17239	marking	_	
62-37	17240-17243	the	_	
62-38	17244-17251	sensors	_	
62-39	17252-17255	for	_	
62-40	17256-17261	which	_	
62-41	17262-17265	the	_	
62-42	17266-17270	time	_	
62-43	17271-17280	frequency	_	
62-44	17281-17289	response	_	
62-45	17290-17291	(	_	
62-46	17291-17294	TFR	_	
62-47	17294-17295	)	_	
62-48	17296-17300	plot	_	
62-49	17301-17303	in	_	
62-50	17304-17307	the	_	
62-51	17308-17314	middle	_	
62-52	17315-17317	is	_	
62-53	17318-17325	plotted	_	
62-54	17325-17326	.	_	

#Text=In the TFR plot, the outlined (black box) window indicates the window of statistical testing for group differences in γ power.
63-1	17327-17329	In	_	
63-2	17330-17333	the	_	
63-3	17334-17337	TFR	_	
63-4	17338-17342	plot	_	
63-5	17342-17343	,	_	
63-6	17344-17347	the	_	
63-7	17348-17356	outlined	_	
63-8	17357-17358	(	_	
63-9	17358-17363	black	_	
63-10	17364-17367	box	_	
63-11	17367-17368	)	_	
63-12	17369-17375	window	_	
63-13	17376-17385	indicates	_	
63-14	17386-17389	the	_	
63-15	17390-17396	window	_	
63-16	17397-17399	of	_	
63-17	17400-17411	statistical	_	
63-18	17412-17419	testing	_	
63-19	17420-17423	for	_	
63-20	17424-17429	group	_	
63-21	17430-17441	differences	_	
63-22	17442-17444	in	_	
63-23	17445-17446	γ	_	
63-24	17447-17452	power	_	
63-25	17452-17453	.	_	

#Text=The TFR plot shows evoked activity from stimulus onset (time zero) to approximately 250 milliseconds, from which latency-induced activity is shown up to 1500 milliseconds.
64-1	17454-17457	The	_	
64-2	17458-17461	TFR	_	
64-3	17462-17466	plot	_	
64-4	17467-17472	shows	_	
64-5	17473-17479	evoked	_	
64-6	17480-17488	activity	_	
64-7	17489-17493	from	_	
64-8	17494-17502	stimulus	_	
64-9	17503-17508	onset	_	
64-10	17509-17510	(	_	
64-11	17510-17514	time	_	
64-12	17515-17519	zero	_	
64-13	17519-17520	)	_	
64-14	17521-17523	to	_	
64-15	17524-17537	approximately	_	
64-16	17538-17541	250	_	
64-17	17542-17554	milliseconds	_	
64-18	17554-17555	,	_	
64-19	17556-17560	from	_	
64-20	17561-17566	which	_	
64-21	17567-17582	latency-induced	_	
64-22	17583-17591	activity	_	
64-23	17592-17594	is	_	
64-24	17595-17600	shown	_	
64-25	17601-17603	up	_	
64-26	17604-17606	to	_	
64-27	17607-17611	1500	_	
64-28	17612-17624	milliseconds	_	
64-29	17624-17625	.	_	

#Text=Right topographical distribution plot shows F values of significant (marked with white dots) sensors showing a main group effect on γ power.
65-1	17626-17631	Right	_	
65-2	17632-17645	topographical	_	
65-3	17646-17658	distribution	_	
65-4	17659-17663	plot	_	
65-5	17664-17669	shows	_	
65-6	17670-17671	F	_	
65-7	17672-17678	values	_	
65-8	17679-17681	of	_	
65-9	17682-17693	significant	_	
65-10	17694-17695	(	_	
65-11	17695-17701	marked	_	
65-12	17702-17706	with	_	
65-13	17707-17712	white	_	
65-14	17713-17717	dots	_	
65-15	17717-17718	)	_	
65-16	17719-17726	sensors	_	
65-17	17727-17734	showing	_	
65-18	17735-17736	a	_	
65-19	17737-17741	main	_	
65-20	17742-17747	group	_	
65-21	17748-17754	effect	_	
65-22	17755-17757	on	_	
65-23	17758-17759	γ	_	
65-24	17760-17765	power	_	
65-25	17765-17766	.	_	

#Text=B, Beamformer-localized main group effect on γ power.
66-1	17767-17768	B	_	
66-2	17768-17769	,	_	
66-3	17770-17790	Beamformer-localized	_	
66-4	17791-17795	main	_	
66-5	17796-17801	group	_	
66-6	17802-17808	effect	_	
66-7	17809-17811	on	_	
66-8	17812-17813	γ	_	
66-9	17814-17819	power	_	
66-10	17819-17820	.	_	

#Text=Lighter-blue and light-orange values mark areas of significant effects uncorrected for multiple comparisons, whereas the darker colors display false discovery rate–corrected areas (α = .05; 2-sided).
67-1	17821-17833	Lighter-blue	_	
67-2	17834-17837	and	_	
67-3	17838-17850	light-orange	_	
67-4	17851-17857	values	_	
67-5	17858-17862	mark	_	
67-6	17863-17868	areas	_	
67-7	17869-17871	of	_	
67-8	17872-17883	significant	_	
67-9	17884-17891	effects	_	
67-10	17892-17903	uncorrected	_	
67-11	17904-17907	for	_	
67-12	17908-17916	multiple	_	
67-13	17917-17928	comparisons	_	
67-14	17928-17929	,	_	
67-15	17930-17937	whereas	_	
67-16	17938-17941	the	_	
67-17	17942-17948	darker	_	
67-18	17949-17955	colors	_	
67-19	17956-17963	display	_	
67-20	17964-17969	false	_	
67-21	17970-17979	discovery	_	
67-22	17980-17994	rate–corrected	_	
67-23	17995-18000	areas	_	
67-24	18001-18002	(	_	
67-25	18002-18003	α	_	
67-26	18004-18005	=	_	
67-27	18006-18009	.05	_	
67-28	18009-18010	;	_	
67-29	18011-18012	2	_	
67-30	18012-18013	-	_	
67-31	18013-18018	sided	_	
67-32	18018-18019	)	_	
67-33	18019-18020	.	_	

#Text=C, Locations across visual cortical areas of significant γ activity from which virtual channel time-series MEG data were reconstructed.
68-1	18021-18022	C	_	
68-2	18022-18023	,	_	
68-3	18024-18033	Locations	_	
68-4	18034-18040	across	_	
68-5	18041-18047	visual	_	
68-6	18048-18056	cortical	_	
68-7	18057-18062	areas	_	
68-8	18063-18065	of	_	
68-9	18066-18077	significant	_	
68-10	18078-18079	γ	_	
68-11	18080-18088	activity	_	
68-12	18089-18093	from	_	
68-13	18094-18099	which	_	
68-14	18100-18107	virtual	_	
68-15	18108-18115	channel	_	
68-16	18116-18127	time-series	_	
68-17	18128-18131	MEG	_	
68-18	18132-18136	data	_	
68-19	18137-18141	were	_	
68-20	18142-18155	reconstructed	_	
68-21	18155-18156	.	_	

#Text=The 10 occipital regions of interest (ROIs) included 3 subregions covering the primary visual cortex.
69-1	18157-18160	The	_	
69-2	18161-18163	10	_	
69-3	18164-18173	occipital	_	
69-4	18174-18181	regions	_	
69-5	18182-18184	of	_	
69-6	18185-18193	interest	_	
69-7	18194-18195	(	_	
69-8	18195-18199	ROIs	_	
69-9	18199-18200	)	_	
69-10	18201-18209	included	_	
69-11	18210-18211	3	_	
69-12	18212-18222	subregions	_	
69-13	18223-18231	covering	_	
69-14	18232-18235	the	_	
69-15	18236-18243	primary	_	
69-16	18244-18250	visual	_	
69-17	18251-18257	cortex	_	
69-18	18257-18258	.	_	

#Text=CAL indicates calcarine; CUN, cuneus; IOG, inferior occipital gyrus; MOG, middle occipital gyrus; SOG, superior occipital gyrus.
70-1	18259-18262	CAL	_	
70-2	18263-18272	indicates	_	
70-3	18273-18282	calcarine	_	
70-4	18282-18283	;	_	
70-5	18284-18287	CUN	_	
70-6	18287-18288	,	_	
70-7	18289-18295	cuneus	_	
70-8	18295-18296	;	_	
70-9	18297-18300	IOG	_	
70-10	18300-18301	,	_	
70-11	18302-18310	inferior	_	
70-12	18311-18320	occipital	_	
70-13	18321-18326	gyrus	_	
70-14	18326-18327	;	_	
70-15	18328-18331	MOG	_	
70-16	18331-18332	,	_	
70-17	18333-18339	middle	_	
70-18	18340-18349	occipital	_	
70-19	18350-18355	gyrus	_	
70-20	18355-18356	;	_	
70-21	18357-18360	SOG	_	
70-22	18360-18361	,	_	
70-23	18362-18370	superior	_	
70-24	18371-18380	occipital	_	
70-25	18381-18386	gyrus	_	
70-26	18386-18387	.	_	

#Text=Virtual Channel Time Frequency Response (TFR) and Intertrial Phase Coherence (ITPC) Analyses
#Text=A, Top 4 panels show per group the TFR, averaged over all virtual-channel regions of interest (ROIs) shown in Figure 2C.
71-1	18389-18396	Virtual	_	
71-2	18397-18404	Channel	_	
71-3	18405-18409	Time	_	
71-4	18410-18419	Frequency	_	
71-5	18420-18428	Response	_	
71-6	18429-18430	(	_	
71-7	18430-18433	TFR	_	
71-8	18433-18434	)	_	
71-9	18435-18438	and	_	
71-10	18439-18449	Intertrial	_	
71-11	18450-18455	Phase	_	
71-12	18456-18465	Coherence	_	
71-13	18466-18467	(	_	
71-14	18467-18471	ITPC	_	
71-15	18471-18472	)	_	
71-16	18473-18481	Analyses	_	
71-17	18482-18483	A	_	
71-18	18483-18484	,	_	
71-19	18485-18488	Top	_	
71-20	18489-18490	4	_	
71-21	18491-18497	panels	_	
71-22	18498-18502	show	_	
71-23	18503-18506	per	_	
71-24	18507-18512	group	_	
71-25	18513-18516	the	_	
71-26	18517-18520	TFR	_	
71-27	18520-18521	,	_	
71-28	18522-18530	averaged	_	
71-29	18531-18535	over	_	
71-30	18536-18539	all	_	
71-31	18540-18555	virtual-channel	_	
71-32	18556-18563	regions	_	
71-33	18564-18566	of	_	
71-34	18567-18575	interest	_	
71-35	18576-18577	(	_	
71-36	18577-18581	ROIs	_	
71-37	18581-18582	)	_	
71-38	18583-18588	shown	_	
71-39	18589-18591	in	_	
71-40	18592-18598	Figure	_	
71-41	18599-18601	2C	_	
71-42	18601-18602	.	_	

#Text=Bottom right panels: TFR plot with statistical results (nonparametric, Monte Carlo–based permutation independent t tests) of group differences in time-frequency clusters between 0 and 750 milliseconds, with significant clusters outlined and the remaining nonsignificant time-frequency bins masked out (opacity, 0.45).
72-1	18603-18609	Bottom	_	
72-2	18610-18615	right	_	
72-3	18616-18622	panels	_	
72-4	18622-18623	:	_	
72-5	18624-18627	TFR	_	
72-6	18628-18632	plot	_	
72-7	18633-18637	with	_	
72-8	18638-18649	statistical	_	
72-9	18650-18657	results	_	
72-10	18658-18659	(	_	
72-11	18659-18672	nonparametric	_	
72-12	18672-18673	,	_	
72-13	18674-18679	Monte	_	
72-14	18680-18691	Carlo–based	_	
72-15	18692-18703	permutation	_	
72-16	18704-18715	independent	_	
72-17	18716-18717	t	_	
72-18	18718-18723	tests	_	
72-19	18723-18724	)	_	
72-20	18725-18727	of	_	
72-21	18728-18733	group	_	
72-22	18734-18745	differences	_	
72-23	18746-18748	in	_	
72-24	18749-18763	time-frequency	_	
72-25	18764-18772	clusters	_	
72-26	18773-18780	between	_	
72-27	18781-18782	0	_	
72-28	18783-18786	and	_	
72-29	18787-18790	750	_	
72-30	18791-18803	milliseconds	_	
72-31	18803-18804	,	_	
72-32	18805-18809	with	_	
72-33	18810-18821	significant	_	
72-34	18822-18830	clusters	_	
72-35	18831-18839	outlined	_	
72-36	18840-18843	and	_	
72-37	18844-18847	the	_	
72-38	18848-18857	remaining	_	
72-39	18858-18872	nonsignificant	_	
72-40	18873-18887	time-frequency	_	
72-41	18888-18892	bins	_	
72-42	18893-18899	masked	_	
72-43	18900-18903	out	_	
72-44	18904-18905	(	_	
72-45	18905-18912	opacity	_	
72-46	18912-18913	,	_	
72-47	18914-18918	0.45	_	
72-48	18918-18919	)	_	
72-49	18919-18920	.	_	

#Text=The line graph on the left shows the γ (57-67 Hz) response over time per group, with error bars representing standard error of the mean.
73-1	18921-18924	The	_	
73-2	18925-18929	line	_	
73-3	18930-18935	graph	_	
73-4	18936-18938	on	_	
73-5	18939-18942	the	_	
73-6	18943-18947	left	_	
73-7	18948-18953	shows	_	
73-8	18954-18957	the	_	
73-9	18958-18959	γ	_	
73-10	18960-18961	(	_	
73-11	18961-18963	57	_	
73-12	18963-18964	-	_	
73-13	18964-18966	67	_	
73-14	18967-18969	Hz	_	
73-15	18969-18970	)	_	
73-16	18971-18979	response	_	
73-17	18980-18984	over	_	
73-18	18985-18989	time	_	
73-19	18990-18993	per	_	
73-20	18994-18999	group	_	
73-21	18999-19000	,	_	
73-22	19001-19005	with	_	
73-23	19006-19011	error	_	
73-24	19012-19016	bars	_	
73-25	19017-19029	representing	_	
73-26	19030-19038	standard	_	
73-27	19039-19044	error	_	
73-28	19045-19047	of	_	
73-29	19048-19051	the	_	
73-30	19052-19056	mean	_	
73-31	19056-19057	.	_	

#Text=B, Top panels show the ITPC responses per group and bottom panels show the significant group differences (between 0-350 milliseconds), with significant time-frequency bins outlined.
74-1	19058-19059	B	_	
74-2	19059-19060	,	_	
74-3	19061-19064	Top	_	
74-4	19065-19071	panels	_	
74-5	19072-19076	show	_	
74-6	19077-19080	the	_	
74-7	19081-19085	ITPC	_	
74-8	19086-19095	responses	_	
74-9	19096-19099	per	_	
74-10	19100-19105	group	_	
74-11	19106-19109	and	_	
74-12	19110-19116	bottom	_	
74-13	19117-19123	panels	_	
74-14	19124-19128	show	_	
74-15	19129-19132	the	_	
74-16	19133-19144	significant	_	
74-17	19145-19150	group	_	
74-18	19151-19162	differences	_	
74-19	19163-19164	(	_	
74-20	19164-19171	between	_	
74-21	19172-19173	0	_	
74-22	19173-19174	-	_	
74-23	19174-19177	350	_	
74-24	19178-19190	milliseconds	_	
74-25	19190-19191	)	_	
74-26	19191-19192	,	_	
74-27	19193-19197	with	_	
74-28	19198-19209	significant	_	
74-29	19210-19224	time-frequency	_	
74-30	19225-19229	bins	_	
74-31	19230-19238	outlined	_	
74-32	19238-19239	.	_	

#Text=The line graph on the left shows γ (30-50 Hz) range ITPC responses per group, with error bars representing standard error of the mean.
75-1	19240-19243	The	_	
75-2	19244-19248	line	_	
75-3	19249-19254	graph	_	
75-4	19255-19257	on	_	
75-5	19258-19261	the	_	
75-6	19262-19266	left	_	
75-7	19267-19272	shows	_	
75-8	19273-19274	γ	_	
75-9	19275-19276	(	_	
75-10	19276-19278	30	_	
75-11	19278-19279	-	_	
75-12	19279-19281	50	_	
75-13	19282-19284	Hz	_	
75-14	19284-19285	)	_	
75-15	19286-19291	range	_	
75-16	19292-19296	ITPC	_	
75-17	19297-19306	responses	_	
75-18	19307-19310	per	_	
75-19	19311-19316	group	_	
75-20	19316-19317	,	_	
75-21	19318-19322	with	_	
75-22	19323-19328	error	_	
75-23	19329-19333	bars	_	
75-24	19334-19346	representing	_	
75-25	19347-19355	standard	_	
75-26	19356-19361	error	_	
75-27	19362-19364	of	_	
75-28	19365-19368	the	_	
75-29	19369-19373	mean	_	
75-30	19373-19374	.	_	

#Text=CHR-N indicates clinical high risk negative; CHR-P, clinical high risk positive; FEP, first-episode psychosis; HC, healthy control individuals.
76-1	19375-19380	CHR-N	_	
76-2	19381-19390	indicates	_	
76-3	19391-19399	clinical	_	
76-4	19400-19404	high	_	
76-5	19405-19409	risk	_	
76-6	19410-19418	negative	_	
76-7	19418-19419	;	_	
76-8	19420-19425	CHR-P	_	
76-9	19425-19426	,	_	
76-10	19427-19435	clinical	_	
76-11	19436-19440	high	_	
76-12	19441-19445	risk	_	
76-13	19446-19454	positive	_	
76-14	19454-19455	;	_	
76-15	19456-19459	FEP	_	
76-16	19459-19460	,	_	
76-17	19461-19474	first-episode	_	
76-18	19475-19484	psychosis	_	
76-19	19484-19485	;	_	
76-20	19486-19488	HC	_	
76-21	19488-19489	,	_	
76-22	19490-19497	healthy	_	
76-23	19498-19505	control	_	
76-24	19506-19517	individuals	_	
76-25	19517-19518	.	_	

#Text=Granger-causality estimates were computed using a nonparametric approach, including spectral density matrices estimated directly from FFT-data (250-750 milliseconds; DC-149 Hz; Hanning tapered; 5-Hz frequency smoothing; 1-Hz resolution; data zero-padded to 4 seconds), followed by matrix factorization and variance decomposition.
77-1	19519-19536	Granger-causality	_	
77-2	19537-19546	estimates	_	
77-3	19547-19551	were	_	
77-4	19552-19560	computed	_	
77-5	19561-19566	using	_	
77-6	19567-19568	a	_	
77-7	19569-19582	nonparametric	_	
77-8	19583-19591	approach	_	
77-9	19591-19592	,	_	
77-10	19593-19602	including	_	
77-11	19603-19611	spectral	_	
77-12	19612-19619	density	_	
77-13	19620-19628	matrices	_	
77-14	19629-19638	estimated	_	
77-15	19639-19647	directly	_	
77-16	19648-19652	from	_	
77-17	19653-19661	FFT-data	_	
77-18	19662-19663	(	_	
77-19	19663-19666	250	_	
77-20	19666-19667	-	_	
77-21	19667-19670	750	_	
77-22	19671-19683	milliseconds	_	
77-23	19683-19684	;	_	
77-24	19685-19687	DC	_	
77-25	19687-19688	-	_	
77-26	19688-19691	149	_	
77-27	19692-19694	Hz	_	
77-28	19694-19695	;	_	
77-29	19696-19703	Hanning	_	
77-30	19704-19711	tapered	_	
77-31	19711-19712	;	_	
77-32	19713-19714	5	_	
77-33	19714-19715	-	_	
77-34	19715-19717	Hz	_	
77-35	19718-19727	frequency	_	
77-36	19728-19737	smoothing	_	
77-37	19737-19738	;	_	
77-38	19739-19740	1	_	
77-39	19740-19741	-	_	
77-40	19741-19743	Hz	_	
77-41	19744-19754	resolution	_	
77-42	19754-19755	;	_	
77-43	19756-19760	data	_	
77-44	19761-19772	zero-padded	_	
77-45	19773-19775	to	_	
77-46	19776-19777	4	_	
77-47	19778-19785	seconds	_	
77-48	19785-19786	)	_	
77-49	19786-19787	,	_	
77-50	19788-19796	followed	_	
77-51	19797-19799	by	_	
77-52	19800-19806	matrix	_	
77-53	19807-19820	factorization	_	
77-54	19821-19824	and	_	
77-55	19825-19833	variance	_	
77-56	19834-19847	decomposition	_	
77-57	19847-19848	.	_	

#Text=Epochs were split into 2 × 250-millisecond segments to increase trial numbers (see Michalareas et al).
78-1	19849-19855	Epochs	_	
78-2	19856-19860	were	_	
78-3	19861-19866	split	_	
78-4	19867-19871	into	_	
78-5	19872-19873	2	_	
78-6	19874-19875	×	_	
78-7	19876-19879	250	_	
78-8	19879-19880	-	_	
78-9	19880-19891	millisecond	_	
78-10	19892-19900	segments	_	
78-11	19901-19903	to	_	
78-12	19904-19912	increase	_	
78-13	19913-19918	trial	_	
78-14	19919-19926	numbers	_	
78-15	19927-19928	(	_	
78-16	19928-19931	see	_	
78-17	19932-19943	Michalareas	_	
78-18	19944-19946	et	_	
78-19	19947-19949	al	_	
78-20	19949-19950	)	_	
78-21	19950-19951	.	_	

#Text=The middle occipital gyrus and cuneus ROIs were not used in the GC analyses to minimize overlap between primary visual, dorsal, and ventral stream connectivity estimates.
79-1	19952-19955	The	_	
79-2	19956-19962	middle	_	
79-3	19963-19972	occipital	_	
79-4	19973-19978	gyrus	_	
79-5	19979-19982	and	_	
79-6	19983-19989	cuneus	_	
79-7	19990-19994	ROIs	_	
79-8	19995-19999	were	_	
79-9	20000-20003	not	_	
79-10	20004-20008	used	_	
79-11	20009-20011	in	_	
79-12	20012-20015	the	_	
79-13	20016-20018	GC	_	
79-14	20019-20027	analyses	_	
79-15	20028-20030	to	_	
79-16	20031-20039	minimize	_	
79-17	20040-20047	overlap	_	
79-18	20048-20055	between	_	
79-19	20056-20063	primary	_	
79-20	20064-20070	visual	_	
79-21	20070-20071	,	_	
79-22	20072-20078	dorsal	_	
79-23	20078-20079	,	_	
79-24	20080-20083	and	_	
79-25	20084-20091	ventral	_	
79-26	20092-20098	stream	_	
79-27	20099-20111	connectivity	_	
79-28	20112-20121	estimates	_	
79-29	20121-20122	.	_	

#Text=Granger-causality data from each pair were averaged over hemisphere to create 4 main ROI pairs for statistical testing.
80-1	20123-20140	Granger-causality	_	
80-2	20141-20145	data	_	
80-3	20146-20150	from	_	
80-4	20151-20155	each	_	
80-5	20156-20160	pair	_	
80-6	20161-20165	were	_	
80-7	20166-20174	averaged	_	
80-8	20175-20179	over	_	
80-9	20180-20190	hemisphere	_	
80-10	20191-20193	to	_	
80-11	20194-20200	create	_	
80-12	20201-20202	4	_	
80-13	20203-20207	main	_	
80-14	20208-20211	ROI	_	
80-15	20212-20217	pairs	_	
80-16	20218-20221	for	_	
80-17	20222-20233	statistical	_	
80-18	20234-20241	testing	_	
80-19	20241-20242	.	_	

#Text=To determine the alterations in feedforward (FF) vs feedback (FB) GC activity, we also computed the directed asymmetry index (DAI; see Michalareas et al, Bastos et al, and eMethods in the Supplement).
81-1	20243-20245	To	_	
81-2	20246-20255	determine	_	
81-3	20256-20259	the	_	
81-4	20260-20271	alterations	_	
81-5	20272-20274	in	_	
81-6	20275-20286	feedforward	_	
81-7	20287-20288	(	_	
81-8	20288-20290	FF	_	
81-9	20290-20291	)	_	
81-10	20292-20294	vs	_	
81-11	20295-20303	feedback	_	
81-12	20304-20305	(	_	
81-13	20305-20307	FB	_	
81-14	20307-20308	)	_	
81-15	20309-20311	GC	_	
81-16	20312-20320	activity	_	
81-17	20320-20321	,	_	
81-18	20322-20324	we	_	
81-19	20325-20329	also	_	
81-20	20330-20338	computed	_	
81-21	20339-20342	the	_	
81-22	20343-20351	directed	_	
81-23	20352-20361	asymmetry	_	
81-24	20362-20367	index	_	
81-25	20368-20369	(	_	
81-26	20369-20372	DAI	_	
81-27	20372-20373	;	_	
81-28	20374-20377	see	_	
81-29	20378-20389	Michalareas	_	
81-30	20390-20392	et	_	
81-31	20393-20395	al	_	
81-32	20395-20396	,	_	
81-33	20397-20403	Bastos	_	
81-34	20404-20406	et	_	
81-35	20407-20409	al	_	
81-36	20409-20410	,	_	
81-37	20411-20414	and	_	
81-38	20415-20423	eMethods	_	
81-39	20424-20426	in	_	
81-40	20427-20430	the	_	
81-41	20431-20441	Supplement	_	
81-42	20441-20442	)	_	
81-43	20442-20443	.	_	

#Text=Statistical Analysis
#Text=Group differences in trial numbers, γ-band peak frequency, behavioral performance, demographic, and clinical data were assessed with 1-way Welch analysis of variance (ANOVA); 2-sided α level of .05.
82-1	20444-20455	Statistical	_	
82-2	20456-20464	Analysis	_	
82-3	20465-20470	Group	_	
82-4	20471-20482	differences	_	
82-5	20483-20485	in	_	
82-6	20486-20491	trial	_	
82-7	20492-20499	numbers	_	
82-8	20499-20500	,	_	
82-9	20501-20507	γ-band	_	
82-10	20508-20512	peak	_	
82-11	20513-20522	frequency	_	
82-12	20522-20523	,	_	
82-13	20524-20534	behavioral	_	
82-14	20535-20546	performance	_	
82-15	20546-20547	,	_	
82-16	20548-20559	demographic	_	
82-17	20559-20560	,	_	
82-18	20561-20564	and	_	
82-19	20565-20573	clinical	_	
82-20	20574-20578	data	_	
82-21	20579-20583	were	_	
82-22	20584-20592	assessed	_	
82-23	20593-20597	with	_	
82-24	20598-20599	1	_	
82-25	20599-20600	-	_	
82-26	20600-20603	way	_	
82-27	20604-20609	Welch	_	
82-28	20610-20618	analysis	_	
82-29	20619-20621	of	_	
82-30	20622-20630	variance	_	
82-31	20631-20632	(	_	
82-32	20632-20637	ANOVA	_	
82-33	20637-20638	)	_	
82-34	20638-20639	;	_	
82-35	20640-20641	2	_	
82-36	20641-20642	-	_	
82-37	20642-20647	sided	_	
82-38	20648-20649	α	_	
82-39	20650-20655	level	_	
82-40	20656-20658	of	_	
82-41	20659-20662	.05	_	
82-42	20662-20663	.	_	

#Text=Brief Assessment of Cognition in Schizophrenia data were first z-normalized to the HC data.
83-1	20664-20669	Brief	_	
83-2	20670-20680	Assessment	_	
83-3	20681-20683	of	_	
83-4	20684-20693	Cognition	_	
83-5	20694-20696	in	_	
83-6	20697-20710	Schizophrenia	_	
83-7	20711-20715	data	_	
83-8	20716-20720	were	_	
83-9	20721-20726	first	_	
83-10	20727-20739	z-normalized	_	
83-11	20740-20742	to	_	
83-12	20743-20746	the	_	
83-13	20747-20749	HC	_	
83-14	20750-20754	data	_	
83-15	20754-20755	.	_	

#Text=Bootstrapping (n = 1000) and Games-Howell correction were used to control type I errors in post hoc pairwise group comparisons.
84-1	20756-20769	Bootstrapping	_	
84-2	20770-20771	(	_	
84-3	20771-20772	n	_	
84-4	20773-20774	=	_	
84-5	20775-20779	1000	_	
84-6	20779-20780	)	_	
84-7	20781-20784	and	_	
84-8	20785-20797	Games-Howell	_	
84-9	20798-20808	correction	_	
84-10	20809-20813	were	_	
84-11	20814-20818	used	_	
84-12	20819-20821	to	_	
84-13	20822-20829	control	_	
84-14	20830-20834	type	_	
84-15	20835-20836	I	_	
84-16	20837-20843	errors	_	
84-17	20844-20846	in	_	
84-18	20847-20851	post	_	
84-19	20852-20855	hoc	_	
84-20	20856-20864	pairwise	_	
84-21	20865-20870	group	_	
84-22	20871-20882	comparisons	_	
84-23	20882-20883	.	_	

#Text=Statistical testing of group differences in MEG virtual-channel data included nonparametric Monte-Carlo–based permutation (n = 2000) independent F test (main group effect) and post hoc t test statistics for ERFs (0-750 milliseconds); TFRs and ITPC power (1-90 Hz, 0-750 milliseconds for TFR power, 0-350 milliseconds for ITPC, and dB change from a 500-millisecond baseline); baseline FFT spectra (1-90 Hz); and GC data.
85-1	20884-20895	Statistical	_	
85-2	20896-20903	testing	_	
85-3	20904-20906	of	_	
85-4	20907-20912	group	_	
85-5	20913-20924	differences	_	
85-6	20925-20927	in	_	
85-7	20928-20931	MEG	_	
85-8	20932-20947	virtual-channel	_	
85-9	20948-20952	data	_	
85-10	20953-20961	included	_	
85-11	20962-20975	nonparametric	_	
85-12	20976-20993	Monte-Carlo–based	_	
85-13	20994-21005	permutation	_	
85-14	21006-21007	(	_	
85-15	21007-21008	n	_	
85-16	21009-21010	=	_	
85-17	21011-21015	2000	_	
85-18	21015-21016	)	_	
85-19	21017-21028	independent	_	
85-20	21029-21030	F	_	
85-21	21031-21035	test	_	
85-22	21036-21037	(	_	
85-23	21037-21041	main	_	
85-24	21042-21047	group	_	
85-25	21048-21054	effect	_	
85-26	21054-21055	)	_	
85-27	21056-21059	and	_	
85-28	21060-21064	post	_	
85-29	21065-21068	hoc	_	
85-30	21069-21070	t	_	
85-31	21071-21075	test	_	
85-32	21076-21086	statistics	_	
85-33	21087-21090	for	_	
85-34	21091-21095	ERFs	_	
85-35	21096-21097	(	_	
85-36	21097-21098	0	_	
85-37	21098-21099	-	_	
85-38	21099-21102	750	_	
85-39	21103-21115	milliseconds	_	
85-40	21115-21116	)	_	
85-41	21116-21117	;	_	
85-42	21118-21122	TFRs	_	
85-43	21123-21126	and	_	
85-44	21127-21131	ITPC	_	
85-45	21132-21137	power	_	
85-46	21138-21139	(	_	
85-47	21139-21140	1	_	
85-48	21140-21141	-	_	
85-49	21141-21143	90	_	
85-50	21144-21146	Hz	_	
85-51	21146-21147	,	_	
85-52	21148-21149	0	_	
85-53	21149-21150	-	_	
85-54	21150-21153	750	_	
85-55	21154-21166	milliseconds	_	
85-56	21167-21170	for	_	
85-57	21171-21174	TFR	_	
85-58	21175-21180	power	_	
85-59	21180-21181	,	_	
85-60	21182-21183	0	_	
85-61	21183-21184	-	_	
85-62	21184-21187	350	_	
85-63	21188-21200	milliseconds	_	
85-64	21201-21204	for	_	
85-65	21205-21209	ITPC	_	
85-66	21209-21210	,	_	
85-67	21211-21214	and	_	
85-68	21215-21217	dB	_	
85-69	21218-21224	change	_	
85-70	21225-21229	from	_	
85-71	21230-21231	a	_	
85-72	21232-21235	500	_	
85-73	21235-21236	-	_	
85-74	21236-21247	millisecond	_	
85-75	21248-21256	baseline	_	
85-76	21256-21257	)	_	
85-77	21257-21258	;	_	
85-78	21259-21267	baseline	_	
85-79	21268-21271	FFT	_	
85-80	21272-21279	spectra	_	
85-81	21280-21281	(	_	
85-82	21281-21282	1	_	
85-83	21282-21283	-	_	
85-84	21283-21285	90	_	
85-85	21286-21288	Hz	_	
85-86	21288-21289	)	_	
85-87	21289-21290	;	_	
85-88	21291-21294	and	_	
85-89	21295-21297	GC	_	
85-90	21298-21302	data	_	
85-91	21302-21303	.	_	

#Text=Type I errors were controlled by cluster statistics across time and/or frequency (eMethods in the Supplement).
86-1	21304-21308	Type	_	
86-2	21309-21310	I	_	
86-3	21311-21317	errors	_	
86-4	21318-21322	were	_	
86-5	21323-21333	controlled	_	
86-6	21334-21336	by	_	
86-7	21337-21344	cluster	_	
86-8	21345-21355	statistics	_	
86-9	21356-21362	across	_	
86-10	21363-21367	time	_	
86-11	21368-21371	and	_	
86-12	21371-21372	/	_	
86-13	21372-21374	or	_	
86-14	21375-21384	frequency	_	
86-15	21385-21386	(	_	
86-16	21386-21394	eMethods	_	
86-17	21395-21397	in	_	
86-18	21398-21401	the	_	
86-19	21402-21412	Supplement	_	
86-20	21412-21413	)	_	
86-21	21413-21414	.	_	

#Text=Finally, binary logistic regression and receiver operating characteristic curve (ROC) analyses were used to examine the association between MEG parameters and clinical outcomes in CHR-P participants (eMethods in the Supplement).
87-1	21415-21422	Finally	_	
87-2	21422-21423	,	_	
87-3	21424-21430	binary	_	
87-4	21431-21439	logistic	_	
87-5	21440-21450	regression	_	
87-6	21451-21454	and	_	
87-7	21455-21463	receiver	_	
87-8	21464-21473	operating	_	
87-9	21474-21488	characteristic	_	
87-10	21489-21494	curve	_	
87-11	21495-21496	(	_	
87-12	21496-21499	ROC	_	
87-13	21499-21500	)	_	
87-14	21501-21509	analyses	_	
87-15	21510-21514	were	_	
87-16	21515-21519	used	_	
87-17	21520-21522	to	_	
87-18	21523-21530	examine	_	
87-19	21531-21534	the	_	
87-20	21535-21546	association	_	
87-21	21547-21554	between	_	
87-22	21555-21558	MEG	_	
87-23	21559-21569	parameters	_	
87-24	21570-21573	and	_	
87-25	21574-21582	clinical	_	
87-26	21583-21591	outcomes	_	
87-27	21592-21594	in	_	
87-28	21595-21600	CHR-P	_	
87-29	21601-21613	participants	_	
87-30	21614-21615	(	_	
87-31	21615-21623	eMethods	_	
87-32	21624-21626	in	_	
87-33	21627-21630	the	_	
87-34	21631-21641	Supplement	_	
87-35	21641-21642	)	_	
87-36	21642-21643	.	_	

#Text=Results
#Text=Demographic Data
#Text=The FEP group included significantly more men than the HC (χ21 = 5.8; P = .02), CHR-N (χ21 = 6.7; P = .01), and CHR-P (χ21 = 11.6, P = .001) groups (Table).
88-1	21644-21651	Results	_	
88-2	21652-21663	Demographic	_	
88-3	21664-21668	Data	_	
88-4	21669-21672	The	_	
88-5	21673-21676	FEP	_	
88-6	21677-21682	group	_	
88-7	21683-21691	included	_	
88-8	21692-21705	significantly	_	
88-9	21706-21710	more	_	
88-10	21711-21714	men	_	
88-11	21715-21719	than	_	
88-12	21720-21723	the	_	
88-13	21724-21726	HC	_	
88-14	21727-21728	(	_	
88-15	21728-21731	χ21	_	
88-16	21732-21733	=	_	
88-17	21734-21737	5.8	_	
88-18	21737-21738	;	_	
88-19	21739-21740	P	_	
88-20	21741-21742	=	_	
88-21	21743-21746	.02	_	
88-22	21746-21747	)	_	
88-23	21747-21748	,	_	
88-24	21749-21754	CHR-N	_	
88-25	21755-21756	(	_	
88-26	21756-21759	χ21	_	
88-27	21760-21761	=	_	
88-28	21762-21765	6.7	_	
88-29	21765-21766	;	_	
88-30	21767-21768	P	_	
88-31	21769-21770	=	_	
88-32	21771-21774	.01	_	
88-33	21774-21775	)	_	
88-34	21775-21776	,	_	
88-35	21777-21780	and	_	
88-36	21781-21786	CHR-P	_	
88-37	21787-21788	(	_	
88-38	21788-21791	χ21	_	
88-39	21792-21793	=	_	
88-40	21794-21798	11.6	_	
88-41	21798-21799	,	_	
88-42	21800-21801	P	_	
88-43	21802-21803	=	_	
88-44	21804-21808	.001	_	
88-45	21808-21809	)	_	
88-46	21810-21816	groups	_	
88-47	21817-21818	(	_	
88-48	21818-21823	Table	_	
88-49	21823-21824	)	_	
88-50	21824-21825	.	_	

#Text=The BACS composite score was significantly reduced in CHR-P participants compared with HC (−0.84; 95% CI, −1.43 to −0.25; P = .004).
89-1	21826-21829	The	_	
89-2	21830-21834	BACS	_	
89-3	21835-21844	composite	_	
89-4	21845-21850	score	_	
89-5	21851-21854	was	_	
89-6	21855-21868	significantly	_	
89-7	21869-21876	reduced	_	
89-8	21877-21879	in	_	
89-9	21880-21885	CHR-P	_	
89-10	21886-21898	participants	_	
89-11	21899-21907	compared	_	
89-12	21908-21912	with	_	
89-13	21913-21915	HC	_	
89-14	21916-21917	(	_	
89-15	21917-21918	−	_	
89-16	21918-21922	0.84	_	
89-17	21922-21923	;	_	
89-18	21924-21927	95%	_	
89-19	21928-21930	CI	_	
89-20	21930-21931	,	_	
89-21	21932-21933	−	_	
89-22	21933-21937	1.43	_	
89-23	21938-21940	to	_	
89-24	21941-21942	−	_	
89-25	21942-21946	0.25	_	
89-26	21946-21947	;	_	
89-27	21948-21949	P	_	
89-28	21950-21951	=	_	
89-29	21952-21956	.004	_	
89-30	21956-21957	)	_	
89-31	21957-21958	.	_	

#Text=All clinical groups differed from HC in global assessment of functioning (GAF) scores (CHR-N, 17.7; 95% CI, 11.7 to 23.8; P < .001; CHR-P, 30.3; 95% CI, 26.3 to 34.2; P < .001; FEP, 46.6, 95% CI, 37.2 to 56.0; P < .001).
90-1	21959-21962	All	_	
90-2	21963-21971	clinical	_	
90-3	21972-21978	groups	_	
90-4	21979-21987	differed	_	
90-5	21988-21992	from	_	
90-6	21993-21995	HC	_	
90-7	21996-21998	in	_	
90-8	21999-22005	global	_	
90-9	22006-22016	assessment	_	
90-10	22017-22019	of	_	
90-11	22020-22031	functioning	_	
90-12	22032-22033	(	_	
90-13	22033-22036	GAF	_	
90-14	22036-22037	)	_	
90-15	22038-22044	scores	_	
90-16	22045-22046	(	_	
90-17	22046-22051	CHR-N	_	
90-18	22051-22052	,	_	
90-19	22053-22057	17.7	_	
90-20	22057-22058	;	_	
90-21	22059-22062	95%	_	
90-22	22063-22065	CI	_	
90-23	22065-22066	,	_	
90-24	22067-22071	11.7	_	
90-25	22072-22074	to	_	
90-26	22075-22079	23.8	_	
90-27	22079-22080	;	_	
90-28	22081-22082	P	_	
90-29	22083-22084	<	_	
90-30	22085-22089	.001	_	
90-31	22089-22090	;	_	
90-32	22091-22096	CHR-P	_	
90-33	22096-22097	,	_	
90-34	22098-22102	30.3	_	
90-35	22102-22103	;	_	
90-36	22104-22107	95%	_	
90-37	22108-22110	CI	_	
90-38	22110-22111	,	_	
90-39	22112-22116	26.3	_	
90-40	22117-22119	to	_	
90-41	22120-22124	34.2	_	
90-42	22124-22125	;	_	
90-43	22126-22127	P	_	
90-44	22128-22129	<	_	
90-45	22130-22134	.001	_	
90-46	22134-22135	;	_	
90-47	22136-22139	FEP	_	
90-48	22139-22140	,	_	
90-49	22141-22145	46.6	_	
90-50	22145-22146	,	_	
90-51	22147-22150	95%	_	
90-52	22151-22153	CI	_	
90-53	22153-22154	,	_	
90-54	22155-22159	37.2	_	
90-55	22160-22162	to	_	
90-56	22163-22167	56.0	_	
90-57	22167-22168	;	_	
90-58	22169-22170	P	_	
90-59	22171-22172	<	_	
90-60	22173-22177	.001	_	
90-61	22177-22178	)	_	
90-62	22178-22179	.	_	

#Text=Both CHR-P and CHR-N groups also differed from HC in global role and social functioning (CHR-N, −0.63; 95% CI, −0.28 to −0.99; P < .001; CHR-P,  −1.35; 95% CI, −1.05 to −1.66; P < .001).
91-1	22180-22184	Both	_	
91-2	22185-22190	CHR-P	_	
91-3	22191-22194	and	_	
91-4	22195-22200	CHR-N	_	
91-5	22201-22207	groups	_	
91-6	22208-22212	also	_	
91-7	22213-22221	differed	_	
91-8	22222-22226	from	_	
91-9	22227-22229	HC	_	
91-10	22230-22232	in	_	
91-11	22233-22239	global	_	
91-12	22240-22244	role	_	
91-13	22245-22248	and	_	
91-14	22249-22255	social	_	
91-15	22256-22267	functioning	_	
91-16	22268-22269	(	_	
91-17	22269-22274	CHR-N	_	
91-18	22274-22275	,	_	
91-19	22276-22277	−	_	
91-20	22277-22281	0.63	_	
91-21	22281-22282	;	_	
91-22	22283-22286	95%	_	
91-23	22287-22289	CI	_	
91-24	22289-22290	,	_	
91-25	22291-22292	−	_	
91-26	22292-22296	0.28	_	
91-27	22297-22299	to	_	
91-28	22300-22301	−	_	
91-29	22301-22305	0.99	_	
91-30	22305-22306	;	_	
91-31	22307-22308	P	_	
91-32	22309-22310	<	_	
91-33	22311-22315	.001	_	
91-34	22315-22316	;	_	
91-35	22317-22322	CHR-P	_	
91-36	22322-22323	,	_	
91-37	22325-22326	−	_	
91-38	22326-22330	1.35	_	
91-39	22330-22331	;	_	
91-40	22332-22335	95%	_	
91-41	22336-22338	CI	_	
91-42	22338-22339	,	_	
91-43	22340-22341	−	_	
91-44	22341-22345	1.05	_	
91-45	22346-22348	to	_	
91-46	22349-22350	−	_	
91-47	22350-22354	1.66	_	
91-48	22354-22355	;	_	
91-49	22356-22357	P	_	
91-50	22358-22359	<	_	
91-51	22360-22364	.001	_	
91-52	22364-22365	)	_	
91-53	22365-22366	.	_	

#Text=Follow-up Outcomes
#Text=We examined persistence of APS up to 12 months in CHR-P participants who met APS criteria at baseline (n = 84).
92-1	22367-22376	Follow-up	_	
92-2	22377-22385	Outcomes	_	
92-3	22386-22388	We	_	
92-4	22389-22397	examined	_	
92-5	22398-22409	persistence	_	
92-6	22410-22412	of	_	
92-7	22413-22416	APS	_	
92-8	22417-22419	up	_	
92-9	22420-22422	to	_	
92-10	22423-22425	12	_	
92-11	22426-22432	months	_	
92-12	22433-22435	in	_	
92-13	22436-22441	CHR-P	_	
92-14	22442-22454	participants	_	
92-15	22455-22458	who	_	
92-16	22459-22462	met	_	
92-17	22463-22466	APS	_	
92-18	22467-22475	criteria	_	
92-19	22476-22478	at	_	
92-20	22479-22487	baseline	_	
92-21	22488-22489	(	_	
92-22	22489-22490	n	_	
92-23	22491-22492	=	_	
92-24	22493-22495	84	_	
92-25	22495-22496	)	_	
92-26	22496-22497	.	_	

#Text=For 75 CHR-P participants, at least 1 follow-up assessment was available.
93-1	22498-22501	For	_	
93-2	22502-22504	75	_	
93-3	22505-22510	CHR-P	_	
93-4	22511-22523	participants	_	
93-5	22523-22524	,	_	
93-6	22525-22527	at	_	
93-7	22528-22533	least	_	
93-8	22534-22535	1	_	
93-9	22536-22545	follow-up	_	
93-10	22546-22556	assessment	_	
93-11	22557-22560	was	_	
93-12	22561-22570	available	_	
93-13	22570-22571	.	_	

#Text=Thirty-nine CHR-P participants continued to meet APS criteria (APS-persistent group) while 36 CHR-P participants were characterized by a remission of APS-criteria (eResults in the Supplement).
94-1	22572-22583	Thirty-nine	_	
94-2	22584-22589	CHR-P	_	
94-3	22590-22602	participants	_	
94-4	22603-22612	continued	_	
94-5	22613-22615	to	_	
94-6	22616-22620	meet	_	
94-7	22621-22624	APS	_	
94-8	22625-22633	criteria	_	
94-9	22634-22635	(	_	
94-10	22635-22649	APS-persistent	_	
94-11	22650-22655	group	_	
94-12	22655-22656	)	_	
94-13	22657-22662	while	_	
94-14	22663-22665	36	_	
94-15	22666-22671	CHR-P	_	
94-16	22672-22684	participants	_	
94-17	22685-22689	were	_	
94-18	22690-22703	characterized	_	
94-19	22704-22706	by	_	
94-20	22707-22708	a	_	
94-21	22709-22718	remission	_	
94-22	22719-22721	of	_	
94-23	22722-22734	APS-criteria	_	
94-24	22735-22736	(	_	
94-25	22736-22744	eResults	_	
94-26	22745-22747	in	_	
94-27	22748-22751	the	_	
94-28	22752-22762	Supplement	_	
94-29	22762-22763	)	_	
94-30	22763-22764	.	_	

#Text=Moreover, 9 of 119 CHR-P participants made a transition to psychosis (mean follow-up period, 17.3 months).
95-1	22765-22773	Moreover	_	
95-2	22773-22774	,	_	
95-3	22775-22776	9	_	
95-4	22777-22779	of	_	
95-5	22780-22783	119	_	
95-6	22784-22789	CHR-P	_	
95-7	22790-22802	participants	_	
95-8	22803-22807	made	_	
95-9	22808-22809	a	_	
95-10	22810-22820	transition	_	
95-11	22821-22823	to	_	
95-12	22824-22833	psychosis	_	
95-13	22834-22835	(	_	
95-14	22835-22839	mean	_	
95-15	22840-22849	follow-up	_	
95-16	22850-22856	period	_	
95-17	22856-22857	,	_	
95-18	22858-22862	17.3	_	
95-19	22863-22869	months	_	
95-20	22869-22870	)	_	
95-21	22870-22871	.	_	

#Text=Eight transitions occurred in the APS-persistent group.
96-1	22872-22877	Eight	_	
96-2	22878-22889	transitions	_	
96-3	22890-22898	occurred	_	
96-4	22899-22901	in	_	
96-5	22902-22905	the	_	
96-6	22906-22920	APS-persistent	_	
96-7	22921-22926	group	_	
96-8	22926-22927	.	_	

#Text=Task Performance
#Text=The CHR-P group was characterized by reduced response accuracy (−4.2%; 95% CI, −7.6 to −0.7; P = .01), while the patients with FEP were significantly more variable in reaction times (RTs) (27 milliseconds; 95% CI, 2 to 53; P = .03) compared with HC (Table).
97-1	22928-22932	Task	_	
97-2	22933-22944	Performance	_	
97-3	22945-22948	The	_	
97-4	22949-22954	CHR-P	_	
97-5	22955-22960	group	_	
97-6	22961-22964	was	_	
97-7	22965-22978	characterized	_	
97-8	22979-22981	by	_	
97-9	22982-22989	reduced	_	
97-10	22990-22998	response	_	
97-11	22999-23007	accuracy	_	
97-12	23008-23009	(	_	
97-13	23009-23010	−	_	
97-14	23010-23014	4.2%	_	
97-15	23014-23015	;	_	
97-16	23016-23019	95%	_	
97-17	23020-23022	CI	_	
97-18	23022-23023	,	_	
97-19	23024-23025	−	_	
97-20	23025-23028	7.6	_	
97-21	23029-23031	to	_	
97-22	23032-23033	−	_	
97-23	23033-23036	0.7	_	
97-24	23036-23037	;	_	
97-25	23038-23039	P	_	
97-26	23040-23041	=	_	
97-27	23042-23045	.01	_	
97-28	23045-23046	)	_	
97-29	23046-23047	,	_	
97-30	23048-23053	while	_	
97-31	23054-23057	the	_	
97-32	23058-23066	patients	_	
97-33	23067-23071	with	_	
97-34	23072-23075	FEP	_	
97-35	23076-23080	were	_	
97-36	23081-23094	significantly	_	
97-37	23095-23099	more	_	
97-38	23100-23108	variable	_	
97-39	23109-23111	in	_	
97-40	23112-23120	reaction	_	
97-41	23121-23126	times	_	
97-42	23127-23128	(	_	
97-43	23128-23131	RTs	_	
97-44	23131-23132	)	_	
97-45	23133-23134	(	_	
97-46	23134-23136	27	_	
97-47	23137-23149	milliseconds	_	
97-48	23149-23150	;	_	
97-49	23151-23154	95%	_	
97-50	23155-23157	CI	_	
97-51	23157-23158	,	_	
97-52	23159-23160	2	_	
97-53	23161-23163	to	_	
97-54	23164-23166	53	_	
97-55	23166-23167	;	_	
97-56	23168-23169	P	_	
97-57	23170-23171	=	_	
97-58	23172-23175	.03	_	
97-59	23175-23176	)	_	
97-60	23177-23185	compared	_	
97-61	23186-23190	with	_	
97-62	23191-23193	HC	_	
97-63	23194-23195	(	_	
97-64	23195-23200	Table	_	
97-65	23200-23201	)	_	
97-66	23201-23202	.	_	

#Text=Sensor-Level Analysis
#Text=Modulation of spectral power was characterized by early evoked activity (<approximately 250 milliseconds), which is phase locked and time locked to the onset of the stimulus and sustained induced activity that represents non–phase-locked oscillations (>250 milliseconds) (Figure 2).
98-1	23203-23215	Sensor-Level	_	
98-2	23216-23224	Analysis	_	
98-3	23225-23235	Modulation	_	
98-4	23236-23238	of	_	
98-5	23239-23247	spectral	_	
98-6	23248-23253	power	_	
98-7	23254-23257	was	_	
98-8	23258-23271	characterized	_	
98-9	23272-23274	by	_	
98-10	23275-23280	early	_	
98-11	23281-23287	evoked	_	
98-12	23288-23296	activity	_	
98-13	23297-23298	(	_	
98-14	23298-23299	<	_	
98-15	23299-23312	approximately	_	
98-16	23313-23316	250	_	
98-17	23317-23329	milliseconds	_	
98-18	23329-23330	)	_	
98-19	23330-23331	,	_	
98-20	23332-23337	which	_	
98-21	23338-23340	is	_	
98-22	23341-23346	phase	_	
98-23	23347-23353	locked	_	
98-24	23354-23357	and	_	
98-25	23358-23362	time	_	
98-26	23363-23369	locked	_	
98-27	23370-23372	to	_	
98-28	23373-23376	the	_	
98-29	23377-23382	onset	_	
98-30	23383-23385	of	_	
98-31	23386-23389	the	_	
98-32	23390-23398	stimulus	_	
98-33	23399-23402	and	_	
98-34	23403-23412	sustained	_	
98-35	23413-23420	induced	_	
98-36	23421-23429	activity	_	
98-37	23430-23434	that	_	
98-38	23435-23445	represents	_	
98-39	23446-23462	non–phase-locked	_	
98-40	23463-23475	oscillations	_	
98-41	23476-23477	(	_	
98-42	23477-23478	>	_	
98-43	23478-23481	250	_	
98-44	23482-23494	milliseconds	_	
98-45	23494-23495	)	_	
98-46	23496-23497	(	_	
98-47	23497-23503	Figure	_	
98-48	23504-23505	2	_	
98-49	23505-23506	)	_	
98-50	23506-23507	.	_	

#Text=Task-induced γ peak frequency across participants was approximately 62 Hz.
99-1	23508-23520	Task-induced	_	
99-2	23521-23522	γ	_	
99-3	23523-23527	peak	_	
99-4	23528-23537	frequency	_	
99-5	23538-23544	across	_	
99-6	23545-23557	participants	_	
99-7	23558-23561	was	_	
99-8	23562-23575	approximately	_	
99-9	23576-23578	62	_	
99-10	23579-23581	Hz	_	
99-11	23581-23582	.	_	

#Text=A main group effect (cluster F3,228 = 341.7; P < .001; 95% CI range, −0.0004 to 0.002) for 57- to 67-Hz power was found over occipital and parietal-temporal regions (Figure 2A), with no differences in any other frequency range.
100-1	23583-23584	A	_	
100-2	23585-23589	main	_	
100-3	23590-23595	group	_	
100-4	23596-23602	effect	_	
100-5	23603-23604	(	_	
100-6	23604-23611	cluster	_	
100-7	23612-23618	F3,228	_	
100-8	23619-23620	=	_	
100-9	23621-23626	341.7	_	
100-10	23626-23627	;	_	
100-11	23628-23629	P	_	
100-12	23630-23631	<	_	
100-13	23632-23636	.001	_	
100-14	23636-23637	;	_	
100-15	23638-23641	95%	_	
100-16	23642-23644	CI	_	
100-17	23645-23650	range	_	
100-18	23650-23651	,	_	
100-19	23652-23653	−	_	
100-20	23653-23659	0.0004	_	
100-21	23660-23662	to	_	
100-22	23663-23668	0.002	_	
100-23	23668-23669	)	_	
100-24	23670-23673	for	_	
100-25	23674-23676	57	_	
100-26	23676-23677	-	_	
100-27	23678-23680	to	_	
100-28	23681-23683	67	_	
100-29	23683-23684	-	_	
100-30	23684-23686	Hz	_	
100-31	23687-23692	power	_	
100-32	23693-23696	was	_	
100-33	23697-23702	found	_	
100-34	23703-23707	over	_	
100-35	23708-23717	occipital	_	
100-36	23718-23721	and	_	
100-37	23722-23739	parietal-temporal	_	
100-38	23740-23747	regions	_	
100-39	23748-23749	(	_	
100-40	23749-23755	Figure	_	
100-41	23756-23758	2A	_	
100-42	23758-23759	)	_	
100-43	23759-23760	,	_	
100-44	23761-23765	with	_	
100-45	23766-23768	no	_	
100-46	23769-23780	differences	_	
100-47	23781-23783	in	_	
100-48	23784-23787	any	_	
100-49	23788-23793	other	_	
100-50	23794-23803	frequency	_	
100-51	23804-23809	range	_	
100-52	23809-23810	.	_	

#Text=Post hoc test results revealed significantly increased γ power for CHR-N vs HC over superior occipital-parietal regions (cluster t85 = 48.4; P = .03; 95% CI range, 0.0147-0.0453) and significantly decreased γ power (cluster t73 = −50.7; P = .02; 95% CI range = 0.0143-0.0257) over inferior occipital regions for FEP compared with HC (eFigure 1 in the Supplement).
101-1	23811-23815	Post	_	
101-2	23816-23819	hoc	_	
101-3	23820-23824	test	_	
101-4	23825-23832	results	_	
101-5	23833-23841	revealed	_	
101-6	23842-23855	significantly	_	
101-7	23856-23865	increased	_	
101-8	23866-23867	γ	_	
101-9	23868-23873	power	_	
101-10	23874-23877	for	_	
101-11	23878-23883	CHR-N	_	
101-12	23884-23886	vs	_	
101-13	23887-23889	HC	_	
101-14	23890-23894	over	_	
101-15	23895-23903	superior	_	
101-16	23904-23922	occipital-parietal	_	
101-17	23923-23930	regions	_	
101-18	23931-23932	(	_	
101-19	23932-23939	cluster	_	
101-20	23940-23943	t85	_	
101-21	23944-23945	=	_	
101-22	23946-23950	48.4	_	
101-23	23950-23951	;	_	
101-24	23952-23953	P	_	
101-25	23954-23955	=	_	
101-26	23956-23959	.03	_	
101-27	23959-23960	;	_	
101-28	23961-23964	95%	_	
101-29	23965-23967	CI	_	
101-30	23968-23973	range	_	
101-31	23973-23974	,	_	
101-32	23975-23981	0.0147	_	
101-33	23981-23982	-	_	
101-34	23982-23988	0.0453	_	
101-35	23988-23989	)	_	
101-36	23990-23993	and	_	
101-37	23994-24007	significantly	_	
101-38	24008-24017	decreased	_	
101-39	24018-24019	γ	_	
101-40	24020-24025	power	_	
101-41	24026-24027	(	_	
101-42	24027-24034	cluster	_	
101-43	24035-24038	t73	_	
101-44	24039-24040	=	_	
101-45	24041-24042	−	_	
101-46	24042-24046	50.7	_	
101-47	24046-24047	;	_	
101-48	24048-24049	P	_	
101-49	24050-24051	=	_	
101-50	24052-24055	.02	_	
101-51	24055-24056	;	_	
101-52	24057-24060	95%	_	
101-53	24061-24063	CI	_	
101-54	24064-24069	range	_	
101-55	24070-24071	=	_	
101-56	24072-24078	0.0143	_	
101-57	24078-24079	-	_	
101-58	24079-24085	0.0257	_	
101-59	24085-24086	)	_	
101-60	24087-24091	over	_	
101-61	24092-24100	inferior	_	
101-62	24101-24110	occipital	_	
101-63	24111-24118	regions	_	
101-64	24119-24122	for	_	
101-65	24123-24126	FEP	_	
101-66	24127-24135	compared	_	
101-67	24136-24140	with	_	
101-68	24141-24143	HC	_	
101-69	24144-24145	(	_	
101-70	24145-24152	eFigure	_	
101-71	24153-24154	1	_	
101-72	24155-24157	in	_	
101-73	24158-24161	the	_	
101-74	24162-24172	Supplement	_	
101-75	24172-24173	)	_	
101-76	24173-24174	.	_	

#Text=Virtual Channel Analyses: TFR and ITPC Analyses
#Text=A cluster of sustained γ-band power decreases across all visual cortex ROIs (Figure 3A) for the FEP group compared with HC (TFR cluster approximately 50-75 Hz; approximately 0-750 milliseconds; cluster t73 = −791.8; P = .007; 95% CI range, 0.0033-0.0107) were observed in primary visual cortex as well as in ventral stream areas (eFigure 2A in the Supplement).
102-1	24175-24182	Virtual	_	
102-2	24183-24190	Channel	_	
102-3	24191-24199	Analyses	_	
102-4	24199-24200	:	_	
102-5	24201-24204	TFR	_	
102-6	24205-24208	and	_	
102-7	24209-24213	ITPC	_	
102-8	24214-24222	Analyses	_	
102-9	24223-24224	A	_	
102-10	24225-24232	cluster	_	
102-11	24233-24235	of	_	
102-12	24236-24245	sustained	_	
102-13	24246-24252	γ-band	_	
102-14	24253-24258	power	_	
102-15	24259-24268	decreases	_	
102-16	24269-24275	across	_	
102-17	24276-24279	all	_	
102-18	24280-24286	visual	_	
102-19	24287-24293	cortex	_	
102-20	24294-24298	ROIs	_	
102-21	24299-24300	(	_	
102-22	24300-24306	Figure	_	
102-23	24307-24309	3A	_	
102-24	24309-24310	)	_	
102-25	24311-24314	for	_	
102-26	24315-24318	the	_	
102-27	24319-24322	FEP	_	
102-28	24323-24328	group	_	
102-29	24329-24337	compared	_	
102-30	24338-24342	with	_	
102-31	24343-24345	HC	_	
102-32	24346-24347	(	_	
102-33	24347-24350	TFR	_	
102-34	24351-24358	cluster	_	
102-35	24359-24372	approximately	_	
102-36	24373-24375	50	_	
102-37	24375-24376	-	_	
102-38	24376-24378	75	_	
102-39	24379-24381	Hz	_	
102-40	24381-24382	;	_	
102-41	24383-24396	approximately	_	
102-42	24397-24398	0	_	
102-43	24398-24399	-	_	
102-44	24399-24402	750	_	
102-45	24403-24415	milliseconds	_	
102-46	24415-24416	;	_	
102-47	24417-24424	cluster	_	
102-48	24425-24428	t73	_	
102-49	24429-24430	=	_	
102-50	24431-24432	−	_	
102-51	24432-24437	791.8	_	
102-52	24437-24438	;	_	
102-53	24439-24440	P	_	
102-54	24441-24442	=	_	
102-55	24443-24447	.007	_	
102-56	24447-24448	;	_	
102-57	24449-24452	95%	_	
102-58	24453-24455	CI	_	
102-59	24456-24461	range	_	
102-60	24461-24462	,	_	
102-61	24463-24469	0.0033	_	
102-62	24469-24470	-	_	
102-63	24470-24476	0.0107	_	
102-64	24476-24477	)	_	
102-65	24478-24482	were	_	
102-66	24483-24491	observed	_	
102-67	24492-24494	in	_	
102-68	24495-24502	primary	_	
102-69	24503-24509	visual	_	
102-70	24510-24516	cortex	_	
102-71	24517-24519	as	_	
102-72	24520-24524	well	_	
102-73	24525-24527	as	_	
102-74	24528-24530	in	_	
102-75	24531-24538	ventral	_	
102-76	24539-24545	stream	_	
102-77	24546-24551	areas	_	
102-78	24552-24553	(	_	
102-79	24553-24560	eFigure	_	
102-80	24561-24563	2A	_	
102-81	24564-24566	in	_	
102-82	24567-24570	the	_	
102-83	24571-24581	Supplement	_	
102-84	24581-24582	)	_	
102-85	24582-24583	.	_	

#Text=The CHR-N and CHR-P groups did not show spectral power changes in any frequency range.
103-1	24584-24587	The	_	
103-2	24588-24593	CHR-N	_	
103-3	24594-24597	and	_	
103-4	24598-24603	CHR-P	_	
103-5	24604-24610	groups	_	
103-6	24611-24614	did	_	
103-7	24615-24618	not	_	
103-8	24619-24623	show	_	
103-9	24624-24632	spectral	_	
103-10	24633-24638	power	_	
103-11	24639-24646	changes	_	
103-12	24647-24649	in	_	
103-13	24650-24653	any	_	
103-14	24654-24663	frequency	_	
103-15	24664-24669	range	_	
103-16	24669-24670	.	_	

#Text=Differences in β/γ-band ITPC values were found for both CHR-P and FEP participants compared with HC (CHR-P: TFR-cluster approximately 21-68 Hz; approximately 125-275 milliseconds; cluster t166 = −509.1; P = .005; 95% CI range, 0.0022 to 0.0078; FEP: TFR-cluster approximately 11-57 Hz; approximately 75-325 milliseconds; cluster t73 = −633.1; P = .002; 95% CI, 0.0018-0.0022) (Figure 3B) that involved primary visual as well as ventral stream regions and that extended to dorsal stream areas in the patients with FEP (eFigure 2B in the Supplement).
104-1	24671-24682	Differences	_	
104-2	24683-24685	in	_	
104-3	24686-24687	β	_	
104-4	24687-24688	/	_	
104-5	24688-24694	γ-band	_	
104-6	24695-24699	ITPC	_	
104-7	24700-24706	values	_	
104-8	24707-24711	were	_	
104-9	24712-24717	found	_	
104-10	24718-24721	for	_	
104-11	24722-24726	both	_	
104-12	24727-24732	CHR-P	_	
104-13	24733-24736	and	_	
104-14	24737-24740	FEP	_	
104-15	24741-24753	participants	_	
104-16	24754-24762	compared	_	
104-17	24763-24767	with	_	
104-18	24768-24770	HC	_	
104-19	24771-24772	(	_	
104-20	24772-24777	CHR-P	_	
104-21	24777-24778	:	_	
104-22	24779-24790	TFR-cluster	_	
104-23	24791-24804	approximately	_	
104-24	24805-24807	21	_	
104-25	24807-24808	-	_	
104-26	24808-24810	68	_	
104-27	24811-24813	Hz	_	
104-28	24813-24814	;	_	
104-29	24815-24828	approximately	_	
104-30	24829-24832	125	_	
104-31	24832-24833	-	_	
104-32	24833-24836	275	_	
104-33	24837-24849	milliseconds	_	
104-34	24849-24850	;	_	
104-35	24851-24858	cluster	_	
104-36	24859-24863	t166	_	
104-37	24864-24865	=	_	
104-38	24866-24867	−	_	
104-39	24867-24872	509.1	_	
104-40	24872-24873	;	_	
104-41	24874-24875	P	_	
104-42	24876-24877	=	_	
104-43	24878-24882	.005	_	
104-44	24882-24883	;	_	
104-45	24884-24887	95%	_	
104-46	24888-24890	CI	_	
104-47	24891-24896	range	_	
104-48	24896-24897	,	_	
104-49	24898-24904	0.0022	_	
104-50	24905-24907	to	_	
104-51	24908-24914	0.0078	_	
104-52	24914-24915	;	_	
104-53	24916-24919	FEP	_	
104-54	24919-24920	:	_	
104-55	24921-24932	TFR-cluster	_	
104-56	24933-24946	approximately	_	
104-57	24947-24949	11	_	
104-58	24949-24950	-	_	
104-59	24950-24952	57	_	
104-60	24953-24955	Hz	_	
104-61	24955-24956	;	_	
104-62	24957-24970	approximately	_	
104-63	24971-24973	75	_	
104-64	24973-24974	-	_	
104-65	24974-24977	325	_	
104-66	24978-24990	milliseconds	_	
104-67	24990-24991	;	_	
104-68	24992-24999	cluster	_	
104-69	25000-25003	t73	_	
104-70	25004-25005	=	_	
104-71	25006-25007	−	_	
104-72	25007-25012	633.1	_	
104-73	25012-25013	;	_	
104-74	25014-25015	P	_	
104-75	25016-25017	=	_	
104-76	25018-25022	.002	_	
104-77	25022-25023	;	_	
104-78	25024-25027	95%	_	
104-79	25028-25030	CI	_	
104-80	25030-25031	,	_	
104-81	25032-25038	0.0018	_	
104-82	25038-25039	-	_	
104-83	25039-25045	0.0022	_	
104-84	25045-25046	)	_	
104-85	25047-25048	(	_	
104-86	25048-25054	Figure	_	
104-87	25055-25057	3B	_	
104-88	25057-25058	)	_	
104-89	25059-25063	that	_	
104-90	25064-25072	involved	_	
104-91	25073-25080	primary	_	
104-92	25081-25087	visual	_	
104-93	25088-25090	as	_	
104-94	25091-25095	well	_	
104-95	25096-25098	as	_	
104-96	25099-25106	ventral	_	
104-97	25107-25113	stream	_	
104-98	25114-25121	regions	_	
104-99	25122-25125	and	_	
104-100	25126-25130	that	_	
104-101	25131-25139	extended	_	
104-102	25140-25142	to	_	
104-103	25143-25149	dorsal	_	
104-104	25150-25156	stream	_	
104-105	25157-25162	areas	_	
104-106	25163-25165	in	_	
104-107	25166-25169	the	_	
104-108	25170-25178	patients	_	
104-109	25179-25183	with	_	
104-110	25184-25187	FEP	_	
104-111	25188-25189	(	_	
104-112	25189-25196	eFigure	_	
104-113	25197-25199	2B	_	
104-114	25200-25202	in	_	
104-115	25203-25206	the	_	
104-116	25207-25217	Supplement	_	
104-117	25217-25218	)	_	
104-118	25218-25219	.	_	

#Text=The CHR-N group showed intact ITPC spectral power across all visual ROIs and frequencies.
105-1	25220-25223	The	_	
105-2	25224-25229	CHR-N	_	
105-3	25230-25235	group	_	
105-4	25236-25242	showed	_	
105-5	25243-25249	intact	_	
105-6	25250-25254	ITPC	_	
105-7	25255-25263	spectral	_	
105-8	25264-25269	power	_	
105-9	25270-25276	across	_	
105-10	25277-25280	all	_	
105-11	25281-25287	visual	_	
105-12	25288-25292	ROIs	_	
105-13	25293-25296	and	_	
105-14	25297-25308	frequencies	_	
105-15	25308-25309	.	_	

#Text=Behavioral and Magnetoencephalographical Parameters Associated With APS Persistence in the CHR-P Group
#Text=Intertrial phase coherence data (30-50 Hz; 125-200 milliseconds) from 10 occipital ROIs, accuracy, RTs, and RT variability were entered into a regression model to predict persistence of APS criteria in the CHR-P group.
106-1	25310-25320	Behavioral	_	
106-2	25321-25324	and	_	
106-3	25325-25350	Magnetoencephalographical	_	
106-4	25351-25361	Parameters	_	
106-5	25362-25372	Associated	_	
106-6	25373-25377	With	_	
106-7	25378-25381	APS	_	
106-8	25382-25393	Persistence	_	
106-9	25394-25396	in	_	
106-10	25397-25400	the	_	
106-11	25401-25406	CHR-P	_	
106-12	25407-25412	Group	_	
106-13	25413-25423	Intertrial	_	
106-14	25424-25429	phase	_	
106-15	25430-25439	coherence	_	
106-16	25440-25444	data	_	
106-17	25445-25446	(	_	
106-18	25446-25448	30	_	
106-19	25448-25449	-	_	
106-20	25449-25451	50	_	
106-21	25452-25454	Hz	_	
106-22	25454-25455	;	_	
106-23	25456-25459	125	_	
106-24	25459-25460	-	_	
106-25	25460-25463	200	_	
106-26	25464-25476	milliseconds	_	
106-27	25476-25477	)	_	
106-28	25478-25482	from	_	
106-29	25483-25485	10	_	
106-30	25486-25495	occipital	_	
106-31	25496-25500	ROIs	_	
106-32	25500-25501	,	_	
106-33	25502-25510	accuracy	_	
106-34	25510-25511	,	_	
106-35	25512-25515	RTs	_	
106-36	25515-25516	,	_	
106-37	25517-25520	and	_	
106-38	25521-25523	RT	_	
106-39	25524-25535	variability	_	
106-40	25536-25540	were	_	
106-41	25541-25548	entered	_	
106-42	25549-25553	into	_	
106-43	25554-25555	a	_	
106-44	25556-25566	regression	_	
106-45	25567-25572	model	_	
106-46	25573-25575	to	_	
106-47	25576-25583	predict	_	
106-48	25584-25595	persistence	_	
106-49	25596-25598	of	_	
106-50	25599-25602	APS	_	
106-51	25603-25611	criteria	_	
106-52	25612-25614	in	_	
106-53	25615-25618	the	_	
106-54	25619-25624	CHR-P	_	
106-55	25625-25630	group	_	
106-56	25630-25631	.	_	

#Text=Only γ-band ITPC (30-50 Hz) activity contributed significantly to the model.
107-1	25632-25636	Only	_	
107-2	25637-25643	γ-band	_	
107-3	25644-25648	ITPC	_	
107-4	25649-25650	(	_	
107-5	25650-25652	30	_	
107-6	25652-25653	-	_	
107-7	25653-25655	50	_	
107-8	25656-25658	Hz	_	
107-9	25658-25659	)	_	
107-10	25660-25668	activity	_	
107-11	25669-25680	contributed	_	
107-12	25681-25694	significantly	_	
107-13	25695-25697	to	_	
107-14	25698-25701	the	_	
107-15	25702-25707	model	_	
107-16	25707-25708	.	_	

#Text=Specifically, ITPC data from the left/right cuneus and left middle occipital gyrus ROIs led to a significant model (χ23 = 14.4; P = .002) that explained 22.2% of the variance (Nagelkerke R2 = 0.222).
108-1	25709-25721	Specifically	_	
108-2	25721-25722	,	_	
108-3	25723-25727	ITPC	_	
108-4	25728-25732	data	_	
108-5	25733-25737	from	_	
108-6	25738-25741	the	_	
108-7	25742-25746	left	_	
108-8	25746-25747	/	_	
108-9	25747-25752	right	_	
108-10	25753-25759	cuneus	_	
108-11	25760-25763	and	_	
108-12	25764-25768	left	_	
108-13	25769-25775	middle	_	
108-14	25776-25785	occipital	_	
108-15	25786-25791	gyrus	_	
108-16	25792-25796	ROIs	_	
108-17	25797-25800	led	_	
108-18	25801-25803	to	_	
108-19	25804-25805	a	_	
108-20	25806-25817	significant	_	
108-21	25818-25823	model	_	
108-22	25824-25825	(	_	
108-23	25825-25828	χ23	_	
108-24	25829-25830	=	_	
108-25	25831-25835	14.4	_	
108-26	25835-25836	;	_	
108-27	25837-25838	P	_	
108-28	25839-25840	=	_	
108-29	25841-25845	.002	_	
108-30	25845-25846	)	_	
108-31	25847-25851	that	_	
108-32	25852-25861	explained	_	
108-33	25862-25867	22.2%	_	
108-34	25868-25870	of	_	
108-35	25871-25874	the	_	
108-36	25875-25883	variance	_	
108-37	25884-25885	(	_	
108-38	25885-25895	Nagelkerke	_	
108-39	25896-25898	R2	_	
108-40	25899-25900	=	_	
108-41	25901-25906	0.222	_	
108-42	25906-25907	)	_	
108-43	25907-25908	.	_	

#Text=The associated ROC curve was also significant (Figure 4A: area under the curve, 0.728; 95% CI, 0.612-0.841; P = .001) (eMethods and eResults in the Supplement).
109-1	25909-25912	The	_	
109-2	25913-25923	associated	_	
109-3	25924-25927	ROC	_	
109-4	25928-25933	curve	_	
109-5	25934-25937	was	_	
109-6	25938-25942	also	_	
109-7	25943-25954	significant	_	
109-8	25955-25956	(	_	
109-9	25956-25962	Figure	_	
109-10	25963-25965	4A	_	
109-11	25965-25966	:	_	
109-12	25967-25971	area	_	
109-13	25972-25977	under	_	
109-14	25978-25981	the	_	
109-15	25982-25987	curve	_	
109-16	25987-25988	,	_	
109-17	25989-25994	0.728	_	
109-18	25994-25995	;	_	
109-19	25996-25999	95%	_	
109-20	26000-26002	CI	_	
109-21	26002-26003	,	_	
109-22	26004-26009	0.612	_	
109-23	26009-26010	-	_	
109-24	26010-26015	0.841	_	
109-25	26015-26016	;	_	
109-26	26017-26018	P	_	
109-27	26019-26020	=	_	
109-28	26021-26025	.001	_	
109-29	26025-26026	)	_	
109-30	26027-26028	(	_	
109-31	26028-26036	eMethods	_	
109-32	26037-26040	and	_	
109-33	26041-26049	eResults	_	
109-34	26050-26052	in	_	
109-35	26053-26056	the	_	
109-36	26057-26067	Supplement	_	
109-37	26067-26068	)	_	
109-38	26068-26069	.	_	

#Text=Receiver Operating Characteristic (ROC) Curve Analysis and Granger Causality (GC) Functional Connectivity
#Text=A, On the right, ROC curve computed from prediction probabilities associated with a significant logistic regression model for predicting 12 months Comprehensive Assessment of At Risk Mental States (CAARMS; attenuated psychotic symptoms) persistence status from baseline magnetoencephalography (MEG) recordings of intertrial phase coherence (ITPC) of visual cortex responses (left and right cuneus and left middle occipital gyrus; locations shown in left panel).
110-1	26070-26078	Receiver	_	
110-2	26079-26088	Operating	_	
110-3	26089-26103	Characteristic	_	
110-4	26104-26105	(	_	
110-5	26105-26108	ROC	_	
110-6	26108-26109	)	_	
110-7	26110-26115	Curve	_	
110-8	26116-26124	Analysis	_	
110-9	26125-26128	and	_	
110-10	26129-26136	Granger	_	
110-11	26137-26146	Causality	_	
110-12	26147-26148	(	_	
110-13	26148-26150	GC	_	
110-14	26150-26151	)	_	
110-15	26152-26162	Functional	_	
110-16	26163-26175	Connectivity	_	
110-17	26176-26177	A	_	
110-18	26177-26178	,	_	
110-19	26179-26181	On	_	
110-20	26182-26185	the	_	
110-21	26186-26191	right	_	
110-22	26191-26192	,	_	
110-23	26193-26196	ROC	_	
110-24	26197-26202	curve	_	
110-25	26203-26211	computed	_	
110-26	26212-26216	from	_	
110-27	26217-26227	prediction	_	
110-28	26228-26241	probabilities	_	
110-29	26242-26252	associated	_	
110-30	26253-26257	with	_	
110-31	26258-26259	a	_	
110-32	26260-26271	significant	_	
110-33	26272-26280	logistic	_	
110-34	26281-26291	regression	_	
110-35	26292-26297	model	_	
110-36	26298-26301	for	_	
110-37	26302-26312	predicting	_	
110-38	26313-26315	12	_	
110-39	26316-26322	months	_	
110-40	26323-26336	Comprehensive	_	
110-41	26337-26347	Assessment	_	
110-42	26348-26350	of	_	
110-43	26351-26353	At	_	
110-44	26354-26358	Risk	_	
110-45	26359-26365	Mental	_	
110-46	26366-26372	States	_	
110-47	26373-26374	(	_	
110-48	26374-26380	CAARMS	_	
110-49	26380-26381	;	_	
110-50	26382-26392	attenuated	_	
110-51	26393-26402	psychotic	_	
110-52	26403-26411	symptoms	_	
110-53	26411-26412	)	_	
110-54	26413-26424	persistence	_	
110-55	26425-26431	status	_	
110-56	26432-26436	from	_	
110-57	26437-26445	baseline	_	
110-58	26446-26468	magnetoencephalography	_	
110-59	26469-26470	(	_	
110-60	26470-26473	MEG	_	
110-61	26473-26474	)	_	
110-62	26475-26485	recordings	_	
110-63	26486-26488	of	_	
110-64	26489-26499	intertrial	_	
110-65	26500-26505	phase	_	
110-66	26506-26515	coherence	_	
110-67	26516-26517	(	_	
110-68	26517-26521	ITPC	_	
110-69	26521-26522	)	_	
110-70	26523-26525	of	_	
110-71	26526-26532	visual	_	
110-72	26533-26539	cortex	_	
110-73	26540-26549	responses	_	
110-74	26550-26551	(	_	
110-75	26551-26555	left	_	
110-76	26556-26559	and	_	
110-77	26560-26565	right	_	
110-78	26566-26572	cuneus	_	
110-79	26573-26576	and	_	
110-80	26577-26581	left	_	
110-81	26582-26588	middle	_	
110-82	26589-26598	occipital	_	
110-83	26599-26604	gyrus	_	
110-84	26604-26605	;	_	
110-85	26606-26615	locations	_	
110-86	26616-26621	shown	_	
110-87	26622-26624	in	_	
110-88	26625-26629	left	_	
110-89	26630-26635	panel	_	
110-90	26635-26636	)	_	
110-91	26636-26637	.	_	

#Text=B, Results of cluster-based statistics on GC data showing range of significant effects in first-episode psychosis (FEP), clinical high-risk positive (CHR-P), and clinical high risk negative (CHR-N) groups, compared with healthy control individuals (HC).
111-1	26638-26639	B	_	
111-2	26639-26640	,	_	
111-3	26641-26648	Results	_	
111-4	26649-26651	of	_	
111-5	26652-26665	cluster-based	_	
111-6	26666-26676	statistics	_	
111-7	26677-26679	on	_	
111-8	26680-26682	GC	_	
111-9	26683-26687	data	_	
111-10	26688-26695	showing	_	
111-11	26696-26701	range	_	
111-12	26702-26704	of	_	
111-13	26705-26716	significant	_	
111-14	26717-26724	effects	_	
111-15	26725-26727	in	_	
111-16	26728-26741	first-episode	_	
111-17	26742-26751	psychosis	_	
111-18	26752-26753	(	_	
111-19	26753-26756	FEP	_	
111-20	26756-26757	)	_	
111-21	26757-26758	,	_	
111-22	26759-26767	clinical	_	
111-23	26768-26777	high-risk	_	
111-24	26778-26786	positive	_	
111-25	26787-26788	(	_	
111-26	26788-26793	CHR-P	_	
111-27	26793-26794	)	_	
111-28	26794-26795	,	_	
111-29	26796-26799	and	_	
111-30	26800-26808	clinical	_	
111-31	26809-26813	high	_	
111-32	26814-26818	risk	_	
111-33	26819-26827	negative	_	
111-34	26828-26829	(	_	
111-35	26829-26834	CHR-N	_	
111-36	26834-26835	)	_	
111-37	26836-26842	groups	_	
111-38	26842-26843	,	_	
111-39	26844-26852	compared	_	
111-40	26853-26857	with	_	
111-41	26858-26865	healthy	_	
111-42	26866-26873	control	_	
111-43	26874-26885	individuals	_	
111-44	26886-26887	(	_	
111-45	26887-26889	HC	_	
111-46	26889-26890	)	_	
111-47	26890-26891	.	_	

#Text=The main connections tested are plotted on a smoothed surface of a standard Montreal Neurological Institute brain, with red lines representing increased and blue lines decreased GC values, compared with HC.
112-1	26892-26895	The	_	
112-2	26896-26900	main	_	
112-3	26901-26912	connections	_	
112-4	26913-26919	tested	_	
112-5	26920-26923	are	_	
112-6	26924-26931	plotted	_	
112-7	26932-26934	on	_	
112-8	26935-26936	a	_	
112-9	26937-26945	smoothed	_	
112-10	26946-26953	surface	_	
112-11	26954-26956	of	_	
112-12	26957-26958	a	_	
112-13	26959-26967	standard	_	
112-14	26968-26976	Montreal	_	
112-15	26977-26989	Neurological	_	
112-16	26990-26999	Institute	_	
112-17	27000-27005	brain	_	
112-18	27005-27006	,	_	
112-19	27007-27011	with	_	
112-20	27012-27015	red	_	
112-21	27016-27021	lines	_	
112-22	27022-27034	representing	_	
112-23	27035-27044	increased	_	
112-24	27045-27048	and	_	
112-25	27049-27053	blue	_	
112-26	27054-27059	lines	_	
112-27	27060-27069	decreased	_	
112-28	27070-27072	GC	_	
112-29	27073-27079	values	_	
112-30	27079-27080	,	_	
112-31	27081-27089	compared	_	
112-32	27090-27094	with	_	
112-33	27095-27097	HC	_	
112-34	27097-27098	.	_	

#Text=For each significant connection, GC values are plotted across the frequency spectrum, separately per group (with error bars indicating standard error of the mean), and a horizontal line indicating the frequency range of significant group effects.
113-1	27099-27102	For	_	
113-2	27103-27107	each	_	
113-3	27108-27119	significant	_	
113-4	27120-27130	connection	_	
113-5	27130-27131	,	_	
113-6	27132-27134	GC	_	
113-7	27135-27141	values	_	
113-8	27142-27145	are	_	
113-9	27146-27153	plotted	_	
113-10	27154-27160	across	_	
113-11	27161-27164	the	_	
113-12	27165-27174	frequency	_	
113-13	27175-27183	spectrum	_	
113-14	27183-27184	,	_	
113-15	27185-27195	separately	_	
113-16	27196-27199	per	_	
113-17	27200-27205	group	_	
113-18	27206-27207	(	_	
113-19	27207-27211	with	_	
113-20	27212-27217	error	_	
113-21	27218-27222	bars	_	
113-22	27223-27233	indicating	_	
113-23	27234-27242	standard	_	
113-24	27243-27248	error	_	
113-25	27249-27251	of	_	
113-26	27252-27255	the	_	
113-27	27256-27260	mean	_	
113-28	27260-27261	)	_	
113-29	27261-27262	,	_	
113-30	27263-27266	and	_	
113-31	27267-27268	a	_	
113-32	27269-27279	horizontal	_	
113-33	27280-27284	line	_	
113-34	27285-27295	indicating	_	
113-35	27296-27299	the	_	
113-36	27300-27309	frequency	_	
113-37	27310-27315	range	_	
113-38	27316-27318	of	_	
113-39	27319-27330	significant	_	
113-40	27331-27336	group	_	
113-41	27337-27344	effects	_	
113-42	27344-27345	.	_	

#Text=The GC was computed for data between 250 to 750 milliseconds after stimulus onset.
114-1	27346-27349	The	_	
114-2	27350-27352	GC	_	
114-3	27353-27356	was	_	
114-4	27357-27365	computed	_	
114-5	27366-27369	for	_	
114-6	27370-27374	data	_	
114-7	27375-27382	between	_	
114-8	27383-27386	250	_	
114-9	27387-27389	to	_	
114-10	27390-27393	750	_	
114-11	27394-27406	milliseconds	_	
114-12	27407-27412	after	_	
114-13	27413-27421	stimulus	_	
114-14	27422-27427	onset	_	
114-15	27427-27428	.	_	

#Text=The directed asymmetry indices were all positive in the significant contrasts, indicating feed-forward flow of information between the nodes.
115-1	27429-27432	The	_	
115-2	27433-27441	directed	_	
115-3	27442-27451	asymmetry	_	
115-4	27452-27459	indices	_	
115-5	27460-27464	were	_	
115-6	27465-27468	all	_	
115-7	27469-27477	positive	_	
115-8	27478-27480	in	_	
115-9	27481-27484	the	_	
115-10	27485-27496	significant	_	
115-11	27497-27506	contrasts	_	
115-12	27506-27507	,	_	
115-13	27508-27518	indicating	_	
115-14	27519-27531	feed-forward	_	
115-15	27532-27536	flow	_	
115-16	27537-27539	of	_	
115-17	27540-27551	information	_	
115-18	27552-27559	between	_	
115-19	27560-27563	the	_	
115-20	27564-27569	nodes	_	
115-21	27569-27570	.	_	

#Text=AUC indicates area under curve.
116-1	27571-27574	AUC	_	
116-2	27575-27584	indicates	_	
116-3	27585-27589	area	_	
116-4	27590-27595	under	_	
116-5	27596-27601	curve	_	
116-6	27601-27602	.	_	

#Text=Regions of Interest: Baseline Power Spectra and ERF Responses
#Text=No group differences in baseline spectral power (1-90 Hz) or ERF amplitudes were observed in any visual cortex ROI (eFigures 3 and 4 in the Supplement).
117-1	27603-27610	Regions	_	
117-2	27611-27613	of	_	
117-3	27614-27622	Interest	_	
117-4	27622-27623	:	_	
117-5	27624-27632	Baseline	_	
117-6	27633-27638	Power	_	
117-7	27639-27646	Spectra	_	
117-8	27647-27650	and	_	
117-9	27651-27654	ERF	_	
117-10	27655-27664	Responses	_	
117-11	27665-27667	No	_	
117-12	27668-27673	group	_	
117-13	27674-27685	differences	_	
117-14	27686-27688	in	_	
117-15	27689-27697	baseline	_	
117-16	27698-27706	spectral	_	
117-17	27707-27712	power	_	
117-18	27713-27714	(	_	
117-19	27714-27715	1	_	
117-20	27715-27716	-	_	
117-21	27716-27718	90	_	
117-22	27719-27721	Hz	_	
117-23	27721-27722	)	_	
117-24	27723-27725	or	_	
117-25	27726-27729	ERF	_	
117-26	27730-27740	amplitudes	_	
117-27	27741-27745	were	_	
117-28	27746-27754	observed	_	
117-29	27755-27757	in	_	
117-30	27758-27761	any	_	
117-31	27762-27768	visual	_	
117-32	27769-27775	cortex	_	
117-33	27776-27779	ROI	_	
117-34	27780-27781	(	_	
117-35	27781-27789	eFigures	_	
117-36	27790-27791	3	_	
117-37	27792-27795	and	_	
117-38	27796-27797	4	_	
117-39	27798-27800	in	_	
117-40	27801-27804	the	_	
117-41	27805-27815	Supplement	_	
117-42	27815-27816	)	_	
117-43	27816-27817	.	_	

#Text=GC Connectivity
#Text=A main group effect was found for 2 connections in visual cortex (Figure 4B: calcarine [CAL] to superior occipital gyrus; approximately 50-77 Hz; cluster P = .004; 95% CI range, 0.0014-0.0066; inferior occipital gyrus [IOG] to CAL: approximately 1-14 Hz; cluster P = .02; 95% CI range, 0.0163-0.0237) and a fronto-occipital connection (medial-superior frontal [mSFG] to IOG: approximately 24-41 Hz; cluster P = .007; 95% CI range, 0.0033 to 0.0107).
118-1	27818-27820	GC	_	
118-2	27821-27833	Connectivity	_	
118-3	27834-27835	A	_	
118-4	27836-27840	main	_	
118-5	27841-27846	group	_	
118-6	27847-27853	effect	_	
118-7	27854-27857	was	_	
118-8	27858-27863	found	_	
118-9	27864-27867	for	_	
118-10	27868-27869	2	_	
118-11	27870-27881	connections	_	
118-12	27882-27884	in	_	
118-13	27885-27891	visual	_	
118-14	27892-27898	cortex	_	
118-15	27899-27900	(	_	
118-16	27900-27906	Figure	_	
118-17	27907-27909	4B	_	
118-18	27909-27910	:	_	
118-19	27911-27920	calcarine	_	
118-20	27921-27922	[	_	
118-21	27922-27925	CAL	_	
118-22	27925-27926	]	_	
118-23	27927-27929	to	_	
118-24	27930-27938	superior	_	
118-25	27939-27948	occipital	_	
118-26	27949-27954	gyrus	_	
118-27	27954-27955	;	_	
118-28	27956-27969	approximately	_	
118-29	27970-27972	50	_	
118-30	27972-27973	-	_	
118-31	27973-27975	77	_	
118-32	27976-27978	Hz	_	
118-33	27978-27979	;	_	
118-34	27980-27987	cluster	_	
118-35	27988-27989	P	_	
118-36	27990-27991	=	_	
118-37	27992-27996	.004	_	
118-38	27996-27997	;	_	
118-39	27998-28001	95%	_	
118-40	28002-28004	CI	_	
118-41	28005-28010	range	_	
118-42	28010-28011	,	_	
118-43	28012-28018	0.0014	_	
118-44	28018-28019	-	_	
118-45	28019-28025	0.0066	_	
118-46	28025-28026	;	_	
118-47	28027-28035	inferior	_	
118-48	28036-28045	occipital	_	
118-49	28046-28051	gyrus	_	
118-50	28052-28053	[	_	
118-51	28053-28056	IOG	_	
118-52	28056-28057	]	_	
118-53	28058-28060	to	_	
118-54	28061-28064	CAL	_	
118-55	28064-28065	:	_	
118-56	28066-28079	approximately	_	
118-57	28080-28081	1	_	
118-58	28081-28082	-	_	
118-59	28082-28084	14	_	
118-60	28085-28087	Hz	_	
118-61	28087-28088	;	_	
118-62	28089-28096	cluster	_	
118-63	28097-28098	P	_	
118-64	28099-28100	=	_	
118-65	28101-28104	.02	_	
118-66	28104-28105	;	_	
118-67	28106-28109	95%	_	
118-68	28110-28112	CI	_	
118-69	28113-28118	range	_	
118-70	28118-28119	,	_	
118-71	28120-28126	0.0163	_	
118-72	28126-28127	-	_	
118-73	28127-28133	0.0237	_	
118-74	28133-28134	)	_	
118-75	28135-28138	and	_	
118-76	28139-28140	a	_	
118-77	28141-28157	fronto-occipital	_	
118-78	28158-28168	connection	_	
118-79	28169-28170	(	_	
118-80	28170-28185	medial-superior	_	
118-81	28186-28193	frontal	_	
118-82	28194-28195	[	_	
118-83	28195-28199	mSFG	_	
118-84	28199-28200	]	_	
118-85	28201-28203	to	_	
118-86	28204-28207	IOG	_	
118-87	28207-28208	:	_	
118-88	28209-28222	approximately	_	
118-89	28223-28225	24	_	
118-90	28225-28226	-	_	
118-91	28226-28228	41	_	
118-92	28229-28231	Hz	_	
118-93	28231-28232	;	_	
118-94	28233-28240	cluster	_	
118-95	28241-28242	P	_	
118-96	28243-28244	=	_	
118-97	28245-28249	.007	_	
118-98	28249-28250	;	_	
118-99	28251-28254	95%	_	
118-100	28255-28257	CI	_	
118-101	28258-28263	range	_	
118-102	28263-28264	,	_	
118-103	28265-28271	0.0033	_	
118-104	28272-28274	to	_	
118-105	28275-28281	0.0107	_	
118-106	28281-28282	)	_	
118-107	28282-28283	.	_	

#Text=Post hoc comparisons revealed decreased connectivity in the FEP group in visual cortex (CAL to superior occipital gyrus: DAI = 0.04; t73 = −3.0; P = .006; 95% CI range, 0.0026 to 0.0094; IOG to CAL: DAI = 0.11; t73= −3.5; P = .004; 95% CI range, 0.0012-0.0068) but increased fronto-occipital connectivity (mSFG-to-IOG connection: DAI = 0.11; t73 = 4.5; P < .001; 95% CI range, −0.0004 to 0.002).
119-1	28284-28288	Post	_	
119-2	28289-28292	hoc	_	
119-3	28293-28304	comparisons	_	
119-4	28305-28313	revealed	_	
119-5	28314-28323	decreased	_	
119-6	28324-28336	connectivity	_	
119-7	28337-28339	in	_	
119-8	28340-28343	the	_	
119-9	28344-28347	FEP	_	
119-10	28348-28353	group	_	
119-11	28354-28356	in	_	
119-12	28357-28363	visual	_	
119-13	28364-28370	cortex	_	
119-14	28371-28372	(	_	
119-15	28372-28375	CAL	_	
119-16	28376-28378	to	_	
119-17	28379-28387	superior	_	
119-18	28388-28397	occipital	_	
119-19	28398-28403	gyrus	_	
119-20	28403-28404	:	_	
119-21	28405-28408	DAI	_	
119-22	28409-28410	=	_	
119-23	28411-28415	0.04	_	
119-24	28415-28416	;	_	
119-25	28417-28420	t73	_	
119-26	28421-28422	=	_	
119-27	28423-28424	−	_	
119-28	28424-28427	3.0	_	
119-29	28427-28428	;	_	
119-30	28429-28430	P	_	
119-31	28431-28432	=	_	
119-32	28433-28437	.006	_	
119-33	28437-28438	;	_	
119-34	28439-28442	95%	_	
119-35	28443-28445	CI	_	
119-36	28446-28451	range	_	
119-37	28451-28452	,	_	
119-38	28453-28459	0.0026	_	
119-39	28460-28462	to	_	
119-40	28463-28469	0.0094	_	
119-41	28469-28470	;	_	
119-42	28471-28474	IOG	_	
119-43	28475-28477	to	_	
119-44	28478-28481	CAL	_	
119-45	28481-28482	:	_	
119-46	28483-28486	DAI	_	
119-47	28487-28488	=	_	
119-48	28489-28493	0.11	_	
119-49	28493-28494	;	_	
119-50	28495-28498	t73	_	
119-51	28498-28499	=	_	
119-52	28500-28501	−	_	
119-53	28501-28504	3.5	_	
119-54	28504-28505	;	_	
119-55	28506-28507	P	_	
119-56	28508-28509	=	_	
119-57	28510-28514	.004	_	
119-58	28514-28515	;	_	
119-59	28516-28519	95%	_	
119-60	28520-28522	CI	_	
119-61	28523-28528	range	_	
119-62	28528-28529	,	_	
119-63	28530-28536	0.0012	_	
119-64	28536-28537	-	_	
119-65	28537-28543	0.0068	_	
119-66	28543-28544	)	_	
119-67	28545-28548	but	_	
119-68	28549-28558	increased	_	
119-69	28559-28575	fronto-occipital	_	
119-70	28576-28588	connectivity	_	
119-71	28589-28590	(	_	
119-72	28590-28601	mSFG-to-IOG	_	
119-73	28602-28612	connection	_	
119-74	28612-28613	:	_	
119-75	28614-28617	DAI	_	
119-76	28618-28619	=	_	
119-77	28620-28624	0.11	_	
119-78	28624-28625	;	_	
119-79	28626-28629	t73	_	
119-80	28630-28631	=	_	
119-81	28632-28635	4.5	_	
119-82	28635-28636	;	_	
119-83	28637-28638	P	_	
119-84	28639-28640	<	_	
119-85	28641-28645	.001	_	
119-86	28645-28646	;	_	
119-87	28647-28650	95%	_	
119-88	28651-28653	CI	_	
119-89	28654-28659	range	_	
119-90	28659-28660	,	_	
119-91	28661-28662	−	_	
119-92	28662-28668	0.0004	_	
119-93	28669-28671	to	_	
119-94	28672-28677	0.002	_	
119-95	28677-28678	)	_	
119-96	28678-28679	.	_	

#Text=Comparable long-range connectivity changes were seen in the CHR-P group (mSFG-to-IOG: DAI = 0.07; t166 = 3.19; P = .003; 95% CI range, 0.0028-0.0032).
120-1	28680-28690	Comparable	_	
120-2	28691-28701	long-range	_	
120-3	28702-28714	connectivity	_	
120-4	28715-28722	changes	_	
120-5	28723-28727	were	_	
120-6	28728-28732	seen	_	
120-7	28733-28735	in	_	
120-8	28736-28739	the	_	
120-9	28740-28745	CHR-P	_	
120-10	28746-28751	group	_	
120-11	28752-28753	(	_	
120-12	28753-28764	mSFG-to-IOG	_	
120-13	28764-28765	:	_	
120-14	28766-28769	DAI	_	
120-15	28770-28771	=	_	
120-16	28772-28776	0.07	_	
120-17	28776-28777	;	_	
120-18	28778-28782	t166	_	
120-19	28783-28784	=	_	
120-20	28785-28789	3.19	_	
120-21	28789-28790	;	_	
120-22	28791-28792	P	_	
120-23	28793-28794	=	_	
120-24	28795-28799	.003	_	
120-25	28799-28800	;	_	
120-26	28801-28804	95%	_	
120-27	28805-28807	CI	_	
120-28	28808-28813	range	_	
120-29	28813-28814	,	_	
120-30	28815-28821	0.0028	_	
120-31	28821-28822	-	_	
120-32	28822-28828	0.0032	_	
120-33	28828-28829	)	_	
120-34	28829-28830	.	_	

#Text=The CHR-N group showed decreased IOG-to-CAL connectivity (DAI = 0.11; t85 = −3.5; P = .002; 95% CI range, 0.0002-0.0038).
121-1	28831-28834	The	_	
121-2	28835-28840	CHR-N	_	
121-3	28841-28846	group	_	
121-4	28847-28853	showed	_	
121-5	28854-28863	decreased	_	
121-6	28864-28874	IOG-to-CAL	_	
121-7	28875-28887	connectivity	_	
121-8	28888-28889	(	_	
121-9	28889-28892	DAI	_	
121-10	28893-28894	=	_	
121-11	28895-28899	0.11	_	
121-12	28899-28900	;	_	
121-13	28901-28904	t85	_	
121-14	28905-28906	=	_	
121-15	28907-28908	−	_	
121-16	28908-28911	3.5	_	
121-17	28911-28912	;	_	
121-18	28913-28914	P	_	
121-19	28915-28916	=	_	
121-20	28917-28921	.002	_	
121-21	28921-28922	;	_	
121-22	28923-28926	95%	_	
121-23	28927-28929	CI	_	
121-24	28930-28935	range	_	
121-25	28935-28936	,	_	
121-26	28937-28943	0.0002	_	
121-27	28943-28944	-	_	
121-28	28944-28950	0.0038	_	
121-29	28950-28951	)	_	
121-30	28951-28952	.	_	

#Text=Correlations
#Text=Correlations were tested using linear regression models (α <.05; 2-sided; 1000-sample bootstrapping), with occipital γ power (57-67 Hz; 250-750 milliseconds) and occipital 30- to 50-Hz ITPC (125-200 milliseconds) as dependent variables.
122-1	28953-28965	Correlations	_	
122-2	28966-28978	Correlations	_	
122-3	28979-28983	were	_	
122-4	28984-28990	tested	_	
122-5	28991-28996	using	_	
122-6	28997-29003	linear	_	
122-7	29004-29014	regression	_	
122-8	29015-29021	models	_	
122-9	29022-29023	(	_	
122-10	29023-29024	α	_	
122-11	29025-29026	<	_	
122-12	29026-29029	.05	_	
122-13	29029-29030	;	_	
122-14	29031-29032	2	_	
122-15	29032-29033	-	_	
122-16	29033-29038	sided	_	
122-17	29038-29039	;	_	
122-18	29040-29044	1000	_	
122-19	29044-29045	-	_	
122-20	29045-29051	sample	_	
122-21	29052-29065	bootstrapping	_	
122-22	29065-29066	)	_	
122-23	29066-29067	,	_	
122-24	29068-29072	with	_	
122-25	29073-29082	occipital	_	
122-26	29083-29084	γ	_	
122-27	29085-29090	power	_	
122-28	29091-29092	(	_	
122-29	29092-29094	57	_	
122-30	29094-29095	-	_	
122-31	29095-29097	67	_	
122-32	29098-29100	Hz	_	
122-33	29100-29101	;	_	
122-34	29102-29105	250	_	
122-35	29105-29106	-	_	
122-36	29106-29109	750	_	
122-37	29110-29122	milliseconds	_	
122-38	29122-29123	)	_	
122-39	29124-29127	and	_	
122-40	29128-29137	occipital	_	
122-41	29138-29140	30	_	
122-42	29140-29141	-	_	
122-43	29142-29144	to	_	
122-44	29145-29147	50	_	
122-45	29147-29148	-	_	
122-46	29148-29150	Hz	_	
122-47	29151-29155	ITPC	_	
122-48	29156-29157	(	_	
122-49	29157-29160	125	_	
122-50	29160-29161	-	_	
122-51	29161-29164	200	_	
122-52	29165-29177	milliseconds	_	
122-53	29177-29178	)	_	
122-54	29179-29181	as	_	
122-55	29182-29191	dependent	_	
122-56	29192-29201	variables	_	
122-57	29201-29202	.	_	

#Text=Across all groups, γ-band power changes were positively correlated with ITPC values (unstandardized B  = 0.077; 95% CI, 0.041-0.113; standardized β coefficient = 0.274; t228 = 4.3; P < .001) and RT variance (B = 0.003; 95% CI, 0.001-0.006; β = 0.257; t228 = 2.7; P = .008), and negatively with RTs (B = −0.002; 95% CI, −0.004 to −0.001; β = −0.349; t228 = −3.6; P < .001), together explaining 13.2% of variance (R2 = 0.132).
123-1	29203-29209	Across	_	
123-2	29210-29213	all	_	
123-3	29214-29220	groups	_	
123-4	29220-29221	,	_	
123-5	29222-29228	γ-band	_	
123-6	29229-29234	power	_	
123-7	29235-29242	changes	_	
123-8	29243-29247	were	_	
123-9	29248-29258	positively	_	
123-10	29259-29269	correlated	_	
123-11	29270-29274	with	_	
123-12	29275-29279	ITPC	_	
123-13	29280-29286	values	_	
123-14	29287-29288	(	_	
123-15	29288-29302	unstandardized	_	
123-16	29303-29304	B	_	
123-17	29306-29307	=	_	
123-18	29308-29313	0.077	_	
123-19	29313-29314	;	_	
123-20	29315-29318	95%	_	
123-21	29319-29321	CI	_	
123-22	29321-29322	,	_	
123-23	29323-29328	0.041	_	
123-24	29328-29329	-	_	
123-25	29329-29334	0.113	_	
123-26	29334-29335	;	_	
123-27	29336-29348	standardized	_	
123-28	29349-29350	β	_	
123-29	29351-29362	coefficient	_	
123-30	29363-29364	=	_	
123-31	29365-29370	0.274	_	
123-32	29370-29371	;	_	
123-33	29372-29376	t228	_	
123-34	29377-29378	=	_	
123-35	29379-29382	4.3	_	
123-36	29382-29383	;	_	
123-37	29384-29385	P	_	
123-38	29386-29387	<	_	
123-39	29388-29392	.001	_	
123-40	29392-29393	)	_	
123-41	29394-29397	and	_	
123-42	29398-29400	RT	_	
123-43	29401-29409	variance	_	
123-44	29410-29411	(	_	
123-45	29411-29412	B	_	
123-46	29413-29414	=	_	
123-47	29415-29420	0.003	_	
123-48	29420-29421	;	_	
123-49	29422-29425	95%	_	
123-50	29426-29428	CI	_	
123-51	29428-29429	,	_	
123-52	29430-29435	0.001	_	
123-53	29435-29436	-	_	
123-54	29436-29441	0.006	_	
123-55	29441-29442	;	_	
123-56	29443-29444	β	_	
123-57	29445-29446	=	_	
123-58	29447-29452	0.257	_	
123-59	29452-29453	;	_	
123-60	29454-29458	t228	_	
123-61	29459-29460	=	_	
123-62	29461-29464	2.7	_	
123-63	29464-29465	;	_	
123-64	29466-29467	P	_	
123-65	29468-29469	=	_	
123-66	29470-29474	.008	_	
123-67	29474-29475	)	_	
123-68	29475-29476	,	_	
123-69	29477-29480	and	_	
123-70	29481-29491	negatively	_	
123-71	29492-29496	with	_	
123-72	29497-29500	RTs	_	
123-73	29501-29502	(	_	
123-74	29502-29503	B	_	
123-75	29504-29505	=	_	
123-76	29506-29507	−	_	
123-77	29507-29512	0.002	_	
123-78	29512-29513	;	_	
123-79	29514-29517	95%	_	
123-80	29518-29520	CI	_	
123-81	29520-29521	,	_	
123-82	29522-29523	−	_	
123-83	29523-29528	0.004	_	
123-84	29529-29531	to	_	
123-85	29532-29533	−	_	
123-86	29533-29538	0.001	_	
123-87	29538-29539	;	_	
123-88	29540-29541	β	_	
123-89	29542-29543	=	_	
123-90	29544-29545	−	_	
123-91	29545-29550	0.349	_	
123-92	29550-29551	;	_	
123-93	29552-29556	t228	_	
123-94	29557-29558	=	_	
123-95	29559-29560	−	_	
123-96	29560-29563	3.6	_	
123-97	29563-29564	;	_	
123-98	29565-29566	P	_	
123-99	29567-29568	<	_	
123-100	29569-29573	.001	_	
123-101	29573-29574	)	_	
123-102	29574-29575	,	_	
123-103	29576-29584	together	_	
123-104	29585-29595	explaining	_	
123-105	29596-29601	13.2%	_	
123-106	29602-29604	of	_	
123-107	29605-29613	variance	_	
123-108	29614-29615	(	_	
123-109	29615-29617	R2	_	
123-110	29618-29619	=	_	
123-111	29620-29625	0.132	_	
123-112	29625-29626	)	_	
123-113	29626-29627	.	_	

#Text=Thirty- to 50-Hz ITPC was positively associated with accuracy (B = 0.041; 95% CI, 0.018-0.065; β = 0.198; t228 = 3.4; P = .001) and GAF scores (B = 0.036; 95% CI, 0.024-0.047; β = 0.347; t228 = 5.9; P < .001) but negatively correlated with occipital β-band (16-22 Hz) power (B = −0.301; 95% CI, −0.562 to −0.040; β = −0.128, t228 = −2.3; P = .02) and CAARMS severity (B = −0.025; 95% CI, −0.036 to −0.013; β = −0.281; t204 = −4.2; P < .001) and explained 28.7% of variance (R2 = 0.287).
124-1	29628-29634	Thirty	_	
124-2	29634-29635	-	_	
124-3	29636-29638	to	_	
124-4	29639-29641	50	_	
124-5	29641-29642	-	_	
124-6	29642-29644	Hz	_	
124-7	29645-29649	ITPC	_	
124-8	29650-29653	was	_	
124-9	29654-29664	positively	_	
124-10	29665-29675	associated	_	
124-11	29676-29680	with	_	
124-12	29681-29689	accuracy	_	
124-13	29690-29691	(	_	
124-14	29691-29692	B	_	
124-15	29693-29694	=	_	
124-16	29695-29700	0.041	_	
124-17	29700-29701	;	_	
124-18	29702-29705	95%	_	
124-19	29706-29708	CI	_	
124-20	29708-29709	,	_	
124-21	29710-29715	0.018	_	
124-22	29715-29716	-	_	
124-23	29716-29721	0.065	_	
124-24	29721-29722	;	_	
124-25	29723-29724	β	_	
124-26	29725-29726	=	_	
124-27	29727-29732	0.198	_	
124-28	29732-29733	;	_	
124-29	29734-29738	t228	_	
124-30	29739-29740	=	_	
124-31	29741-29744	3.4	_	
124-32	29744-29745	;	_	
124-33	29746-29747	P	_	
124-34	29748-29749	=	_	
124-35	29750-29754	.001	_	
124-36	29754-29755	)	_	
124-37	29756-29759	and	_	
124-38	29760-29763	GAF	_	
124-39	29764-29770	scores	_	
124-40	29771-29772	(	_	
124-41	29772-29773	B	_	
124-42	29774-29775	=	_	
124-43	29776-29781	0.036	_	
124-44	29781-29782	;	_	
124-45	29783-29786	95%	_	
124-46	29787-29789	CI	_	
124-47	29789-29790	,	_	
124-48	29791-29796	0.024	_	
124-49	29796-29797	-	_	
124-50	29797-29802	0.047	_	
124-51	29802-29803	;	_	
124-52	29804-29805	β	_	
124-53	29806-29807	=	_	
124-54	29808-29813	0.347	_	
124-55	29813-29814	;	_	
124-56	29815-29819	t228	_	
124-57	29820-29821	=	_	
124-58	29822-29825	5.9	_	
124-59	29825-29826	;	_	
124-60	29827-29828	P	_	
124-61	29829-29830	<	_	
124-62	29831-29835	.001	_	
124-63	29835-29836	)	_	
124-64	29837-29840	but	_	
124-65	29841-29851	negatively	_	
124-66	29852-29862	correlated	_	
124-67	29863-29867	with	_	
124-68	29868-29877	occipital	_	
124-69	29878-29884	β-band	_	
124-70	29885-29886	(	_	
124-71	29886-29888	16	_	
124-72	29888-29889	-	_	
124-73	29889-29891	22	_	
124-74	29892-29894	Hz	_	
124-75	29894-29895	)	_	
124-76	29896-29901	power	_	
124-77	29902-29903	(	_	
124-78	29903-29904	B	_	
124-79	29905-29906	=	_	
124-80	29907-29908	−	_	
124-81	29908-29913	0.301	_	
124-82	29913-29914	;	_	
124-83	29915-29918	95%	_	
124-84	29919-29921	CI	_	
124-85	29921-29922	,	_	
124-86	29923-29924	−	_	
124-87	29924-29929	0.562	_	
124-88	29930-29932	to	_	
124-89	29933-29934	−	_	
124-90	29934-29939	0.040	_	
124-91	29939-29940	;	_	
124-92	29941-29942	β	_	
124-93	29943-29944	=	_	
124-94	29945-29946	−	_	
124-95	29946-29951	0.128	_	
124-96	29951-29952	,	_	
124-97	29953-29957	t228	_	
124-98	29958-29959	=	_	
124-99	29960-29961	−	_	
124-100	29961-29964	2.3	_	
124-101	29964-29965	;	_	
124-102	29966-29967	P	_	
124-103	29968-29969	=	_	
124-104	29970-29973	.02	_	
124-105	29973-29974	)	_	
124-106	29975-29978	and	_	
124-107	29979-29985	CAARMS	_	
124-108	29986-29994	severity	_	
124-109	29995-29996	(	_	
124-110	29996-29997	B	_	
124-111	29998-29999	=	_	
124-112	30000-30001	−	_	
124-113	30001-30006	0.025	_	
124-114	30006-30007	;	_	
124-115	30008-30011	95%	_	
124-116	30012-30014	CI	_	
124-117	30014-30015	,	_	
124-118	30016-30017	−	_	
124-119	30017-30022	0.036	_	
124-120	30023-30025	to	_	
124-121	30026-30027	−	_	
124-122	30027-30032	0.013	_	
124-123	30032-30033	;	_	
124-124	30034-30035	β	_	
124-125	30036-30037	=	_	
124-126	30038-30039	−	_	
124-127	30039-30044	0.281	_	
124-128	30044-30045	;	_	
124-129	30046-30050	t204	_	
124-130	30051-30052	=	_	
124-131	30053-30054	−	_	
124-132	30054-30057	4.2	_	
124-133	30057-30058	;	_	
124-134	30059-30060	P	_	
124-135	30061-30062	<	_	
124-136	30063-30067	.001	_	
124-137	30067-30068	)	_	
124-138	30069-30072	and	_	
124-139	30073-30082	explained	_	
124-140	30083-30088	28.7%	_	
124-141	30089-30091	of	_	
124-142	30092-30100	variance	_	
124-143	30101-30102	(	_	
124-144	30102-30104	R2	_	
124-145	30105-30106	=	_	
124-146	30107-30112	0.287	_	
124-147	30112-30113	)	_	
124-148	30113-30114	.	_	

#Text=Local and Long-range Oscillations in CHR-P Subgroups
#Text=We examined differences between CHR-P subgroups (CAARMS n = 34; SPI-A n = 30; CAARMS/SPI-A n = 55) in MEG activity and behavioral and clinical parameters (eResults, eFigure 6, and eTables 1-3 in the Supplement).
125-1	30115-30120	Local	_	
125-2	30121-30124	and	_	
125-3	30125-30135	Long-range	_	
125-4	30136-30148	Oscillations	_	
125-5	30149-30151	in	_	
125-6	30152-30157	CHR-P	_	
125-7	30158-30167	Subgroups	_	
125-8	30168-30170	We	_	
125-9	30171-30179	examined	_	
125-10	30180-30191	differences	_	
125-11	30192-30199	between	_	
125-12	30200-30205	CHR-P	_	
125-13	30206-30215	subgroups	_	
125-14	30216-30217	(	_	
125-15	30217-30223	CAARMS	_	
125-16	30224-30225	n	_	
125-17	30226-30227	=	_	
125-18	30228-30230	34	_	
125-19	30230-30231	;	_	
125-20	30232-30237	SPI-A	_	
125-21	30238-30239	n	_	
125-22	30240-30241	=	_	
125-23	30242-30244	30	_	
125-24	30244-30245	;	_	
125-25	30246-30252	CAARMS	_	
125-26	30252-30253	/	_	
125-27	30253-30258	SPI-A	_	
125-28	30259-30260	n	_	
125-29	30261-30262	=	_	
125-30	30263-30265	55	_	
125-31	30265-30266	)	_	
125-32	30267-30269	in	_	
125-33	30270-30273	MEG	_	
125-34	30274-30282	activity	_	
125-35	30283-30286	and	_	
125-36	30287-30297	behavioral	_	
125-37	30298-30301	and	_	
125-38	30302-30310	clinical	_	
125-39	30311-30321	parameters	_	
125-40	30322-30323	(	_	
125-41	30323-30331	eResults	_	
125-42	30331-30332	,	_	
125-43	30333-30340	eFigure	_	
125-44	30341-30342	6	_	
125-45	30342-30343	,	_	
125-46	30344-30347	and	_	
125-47	30348-30355	eTables	_	
125-48	30356-30357	1	_	
125-49	30357-30358	-	_	
125-50	30358-30359	3	_	
125-51	30360-30362	in	_	
125-52	30363-30366	the	_	
125-53	30367-30377	Supplement	_	
125-54	30377-30378	)	_	
125-55	30378-30379	.	_	

#Text=Only the combined CAARMS/SPI-A group showed a significant ITPC-deficit relative to HC (TF-cluster approximately 24-72 Hz; approximately 0-300 milliseconds; cluster P < .001; 95% CI range, −0.0004 to 0.002).
126-1	30380-30384	Only	_	
126-2	30385-30388	the	_	
126-3	30389-30397	combined	_	
126-4	30398-30404	CAARMS	_	
126-5	30404-30405	/	_	
126-6	30405-30410	SPI-A	_	
126-7	30411-30416	group	_	
126-8	30417-30423	showed	_	
126-9	30424-30425	a	_	
126-10	30426-30437	significant	_	
126-11	30438-30450	ITPC-deficit	_	
126-12	30451-30459	relative	_	
126-13	30460-30462	to	_	
126-14	30463-30465	HC	_	
126-15	30466-30467	(	_	
126-16	30467-30477	TF-cluster	_	
126-17	30478-30491	approximately	_	
126-18	30492-30494	24	_	
126-19	30494-30495	-	_	
126-20	30495-30497	72	_	
126-21	30498-30500	Hz	_	
126-22	30500-30501	;	_	
126-23	30502-30515	approximately	_	
126-24	30516-30517	0	_	
126-25	30517-30518	-	_	
126-26	30518-30521	300	_	
126-27	30522-30534	milliseconds	_	
126-28	30534-30535	;	_	
126-29	30536-30543	cluster	_	
126-30	30544-30545	P	_	
126-31	30546-30547	<	_	
126-32	30548-30552	.001	_	
126-33	30552-30553	;	_	
126-34	30554-30557	95%	_	
126-35	30558-30560	CI	_	
126-36	30561-30566	range	_	
126-37	30566-30567	,	_	
126-38	30568-30569	−	_	
126-39	30569-30575	0.0004	_	
126-40	30576-30578	to	_	
126-41	30579-30584	0.002	_	
126-42	30584-30585	)	_	
126-43	30585-30586	.	_	

#Text=The effect size (d = 1.20) was comparable with the FEP group (d = 0.93).
127-1	30587-30590	The	_	
127-2	30591-30597	effect	_	
127-3	30598-30602	size	_	
127-4	30603-30604	(	_	
127-5	30604-30605	d	_	
127-6	30606-30607	=	_	
127-7	30608-30612	1.20	_	
127-8	30612-30613	)	_	
127-9	30614-30617	was	_	
127-10	30618-30628	comparable	_	
127-11	30629-30633	with	_	
127-12	30634-30637	the	_	
127-13	30638-30641	FEP	_	
127-14	30642-30647	group	_	
127-15	30648-30649	(	_	
127-16	30649-30650	d	_	
127-17	30651-30652	=	_	
127-18	30653-30657	0.93	_	
127-19	30657-30658	)	_	
127-20	30658-30659	.	_	

#Text=The CHR-P groups showed no difference in spectral power, while CHR-P individuals with CAARMS and CAARMS/SPI-A criteria showed a selective deficit in long-range connectivity between frontal and occipital cortex (for mSFG-to-IOG connection, see eResults and eFigure 7 in the Supplement).
128-1	30660-30663	The	_	
128-2	30664-30669	CHR-P	_	
128-3	30670-30676	groups	_	
128-4	30677-30683	showed	_	
128-5	30684-30686	no	_	
128-6	30687-30697	difference	_	
128-7	30698-30700	in	_	
128-8	30701-30709	spectral	_	
128-9	30710-30715	power	_	
128-10	30715-30716	,	_	
128-11	30717-30722	while	_	
128-12	30723-30728	CHR-P	_	
128-13	30729-30740	individuals	_	
128-14	30741-30745	with	_	
128-15	30746-30752	CAARMS	_	
128-16	30753-30756	and	_	
128-17	30757-30763	CAARMS	_	
128-18	30763-30764	/	_	
128-19	30764-30769	SPI-A	_	
128-20	30770-30778	criteria	_	
128-21	30779-30785	showed	_	
128-22	30786-30787	a	_	
128-23	30788-30797	selective	_	
128-24	30798-30805	deficit	_	
128-25	30806-30808	in	_	
128-26	30809-30819	long-range	_	
128-27	30820-30832	connectivity	_	
128-28	30833-30840	between	_	
128-29	30841-30848	frontal	_	
128-30	30849-30852	and	_	
128-31	30853-30862	occipital	_	
128-32	30863-30869	cortex	_	
128-33	30870-30871	(	_	
128-34	30871-30874	for	_	
128-35	30875-30886	mSFG-to-IOG	_	
128-36	30887-30897	connection	_	
128-37	30897-30898	,	_	
128-38	30899-30902	see	_	
128-39	30903-30911	eResults	_	
128-40	30912-30915	and	_	
128-41	30916-30923	eFigure	_	
128-42	30924-30925	7	_	
128-43	30926-30928	in	_	
128-44	30929-30932	the	_	
128-45	30933-30943	Supplement	_	
128-46	30943-30944	)	_	
128-47	30944-30945	.	_	

#Text=Discussion
#Text=This study examined neural oscillations during visual processing with a state-of-the art MEG approach to investigate whether emerging psychosis is associated with aberrant oscillatory activity in visual cortex as well as the functional relevance of impaired neural oscillations.
129-1	30946-30956	Discussion	_	
129-2	30957-30961	This	_	
129-3	30962-30967	study	_	
129-4	30968-30976	examined	_	
129-5	30977-30983	neural	_	
129-6	30984-30996	oscillations	_	
129-7	30997-31003	during	_	
129-8	31004-31010	visual	_	
129-9	31011-31021	processing	_	
129-10	31022-31026	with	_	
129-11	31027-31028	a	_	
129-12	31029-31041	state-of-the	_	
129-13	31042-31045	art	_	
129-14	31046-31049	MEG	_	
129-15	31050-31058	approach	_	
129-16	31059-31061	to	_	
129-17	31062-31073	investigate	_	
129-18	31074-31081	whether	_	
129-19	31082-31090	emerging	_	
129-20	31091-31100	psychosis	_	
129-21	31101-31103	is	_	
129-22	31104-31114	associated	_	
129-23	31115-31119	with	_	
129-24	31120-31128	aberrant	_	
129-25	31129-31140	oscillatory	_	
129-26	31141-31149	activity	_	
129-27	31150-31152	in	_	
129-28	31153-31159	visual	_	
129-29	31160-31166	cortex	_	
129-30	31167-31169	as	_	
129-31	31170-31174	well	_	
129-32	31175-31177	as	_	
129-33	31178-31181	the	_	
129-34	31182-31192	functional	_	
129-35	31193-31202	relevance	_	
129-36	31203-31205	of	_	
129-37	31206-31214	impaired	_	
129-38	31215-31221	neural	_	
129-39	31222-31234	oscillations	_	
129-40	31234-31235	.	_	

#Text=Specifically, our data highlight a reduction of phase locking of high-frequency oscillations, a measure of the variability of an ongoing oscillation across trials, in visual cortices as well as impaired long-range connectivity in CHR-P participants.
130-1	31236-31248	Specifically	_	
130-2	31248-31249	,	_	
130-3	31250-31253	our	_	
130-4	31254-31258	data	_	
130-5	31259-31268	highlight	_	
130-6	31269-31270	a	_	
130-7	31271-31280	reduction	_	
130-8	31281-31283	of	_	
130-9	31284-31289	phase	_	
130-10	31290-31297	locking	_	
130-11	31298-31300	of	_	
130-12	31301-31315	high-frequency	_	
130-13	31316-31328	oscillations	_	
130-14	31328-31329	,	_	
130-15	31330-31331	a	_	
130-16	31332-31339	measure	_	
130-17	31340-31342	of	_	
130-18	31343-31346	the	_	
130-19	31347-31358	variability	_	
130-20	31359-31361	of	_	
130-21	31362-31364	an	_	
130-22	31365-31372	ongoing	_	
130-23	31373-31384	oscillation	_	
130-24	31385-31391	across	_	
130-25	31392-31398	trials	_	
130-26	31398-31399	,	_	
130-27	31400-31402	in	_	
130-28	31403-31409	visual	_	
130-29	31410-31418	cortices	_	
130-30	31419-31421	as	_	
130-31	31422-31426	well	_	
130-32	31427-31429	as	_	
130-33	31430-31438	impaired	_	
130-34	31439-31449	long-range	_	
130-35	31450-31462	connectivity	_	
130-36	31463-31465	in	_	
130-37	31466-31471	CHR-P	_	
130-38	31472-31484	participants	_	
130-39	31484-31485	.	_	

#Text=Importantly, ITPC deficits were also associated with persistent APS, providing important evidence for the role of high-frequency oscillations in clinical staging of emerging psychosis.
131-1	31486-31497	Importantly	_	
131-2	31497-31498	,	_	
131-3	31499-31503	ITPC	_	
131-4	31504-31512	deficits	_	
131-5	31513-31517	were	_	
131-6	31518-31522	also	_	
131-7	31523-31533	associated	_	
131-8	31534-31538	with	_	
131-9	31539-31549	persistent	_	
131-10	31550-31553	APS	_	
131-11	31553-31554	,	_	
131-12	31555-31564	providing	_	
131-13	31565-31574	important	_	
131-14	31575-31583	evidence	_	
131-15	31584-31587	for	_	
131-16	31588-31591	the	_	
131-17	31592-31596	role	_	
131-18	31597-31599	of	_	
131-19	31600-31614	high-frequency	_	
131-20	31615-31627	oscillations	_	
131-21	31628-31630	in	_	
131-22	31631-31639	clinical	_	
131-23	31640-31647	staging	_	
131-24	31648-31650	of	_	
131-25	31651-31659	emerging	_	
131-26	31660-31669	psychosis	_	
131-27	31669-31670	.	_	

#Text=Further evidence for the functional relevance of β/γ-band phase locking are significant correlations with RTs, severity of APS, and the combination of SPI-A/CAARMS criteria as well as GAF-scores across participants.
132-1	31671-31678	Further	_	
132-2	31679-31687	evidence	_	
132-3	31688-31691	for	_	
132-4	31692-31695	the	_	
132-5	31696-31706	functional	_	
132-6	31707-31716	relevance	_	
132-7	31717-31719	of	_	
132-8	31720-31721	β	_	
132-9	31721-31722	/	_	
132-10	31722-31728	γ-band	_	
132-11	31729-31734	phase	_	
132-12	31735-31742	locking	_	
132-13	31743-31746	are	_	
132-14	31747-31758	significant	_	
132-15	31759-31771	correlations	_	
132-16	31772-31776	with	_	
132-17	31777-31780	RTs	_	
132-18	31780-31781	,	_	
132-19	31782-31790	severity	_	
132-20	31791-31793	of	_	
132-21	31794-31797	APS	_	
132-22	31797-31798	,	_	
132-23	31799-31802	and	_	
132-24	31803-31806	the	_	
132-25	31807-31818	combination	_	
132-26	31819-31821	of	_	
132-27	31822-31827	SPI-A	_	
132-28	31827-31828	/	_	
132-29	31828-31834	CAARMS	_	
132-30	31835-31843	criteria	_	
132-31	31844-31846	as	_	
132-32	31847-31851	well	_	
132-33	31852-31854	as	_	
132-34	31855-31865	GAF-scores	_	
132-35	31866-31872	across	_	
132-36	31873-31885	participants	_	
132-37	31885-31886	.	_	

#Text=In addition, β/γ-band ITPC was associated with induced γ-band power, highlighting the importance of the integrity of early visual processing for large-scale cognition and functioning.
133-1	31887-31889	In	_	
133-2	31890-31898	addition	_	
133-3	31898-31899	,	_	
133-4	31900-31901	β	_	
133-5	31901-31902	/	_	
133-6	31902-31908	γ-band	_	
133-7	31909-31913	ITPC	_	
133-8	31914-31917	was	_	
133-9	31918-31928	associated	_	
133-10	31929-31933	with	_	
133-11	31934-31941	induced	_	
133-12	31942-31948	γ-band	_	
133-13	31949-31954	power	_	
133-14	31954-31955	,	_	
133-15	31956-31968	highlighting	_	
133-16	31969-31972	the	_	
133-17	31973-31983	importance	_	
133-18	31984-31986	of	_	
133-19	31987-31990	the	_	
133-20	31991-32000	integrity	_	
133-21	32001-32003	of	_	
133-22	32004-32009	early	_	
133-23	32010-32016	visual	_	
133-24	32017-32027	processing	_	
133-25	32028-32031	for	_	
133-26	32032-32043	large-scale	_	
133-27	32044-32053	cognition	_	
133-28	32054-32057	and	_	
133-29	32058-32069	functioning	_	
133-30	32069-32070	.	_	

#Text=These data are consistent with previous findings that have identified associations between compromised sensory processing, impaired functioning, and cognitive deficits in schizophrenia.
134-1	32071-32076	These	_	
134-2	32077-32081	data	_	
134-3	32082-32085	are	_	
134-4	32086-32096	consistent	_	
134-5	32097-32101	with	_	
134-6	32102-32110	previous	_	
134-7	32111-32119	findings	_	
134-8	32120-32124	that	_	
134-9	32125-32129	have	_	
134-10	32130-32140	identified	_	
134-11	32141-32153	associations	_	
134-12	32154-32161	between	_	
134-13	32162-32173	compromised	_	
134-14	32174-32181	sensory	_	
134-15	32182-32192	processing	_	
134-16	32192-32193	,	_	
134-17	32194-32202	impaired	_	
134-18	32203-32214	functioning	_	
134-19	32214-32215	,	_	
134-20	32216-32219	and	_	
134-21	32220-32229	cognitive	_	
134-22	32230-32238	deficits	_	
134-23	32239-32241	in	_	
134-24	32242-32255	schizophrenia	_	
134-25	32255-32256	.	_	

#Text=Comparisons between FEP and CHR-P groups revealed overlapping and distinct oscillatory signatures.
135-1	32257-32268	Comparisons	_	
135-2	32269-32276	between	_	
135-3	32277-32280	FEP	_	
135-4	32281-32284	and	_	
135-5	32285-32290	CHR-P	_	
135-6	32291-32297	groups	_	
135-7	32298-32306	revealed	_	
135-8	32307-32318	overlapping	_	
135-9	32319-32322	and	_	
135-10	32323-32331	distinct	_	
135-11	32332-32343	oscillatory	_	
135-12	32344-32354	signatures	_	
135-13	32354-32355	.	_	

#Text=Induced γ-band oscillations were prominently impaired in the FEP group in visual areas, which was not observed in CHR-P participants.
136-1	32356-32363	Induced	_	
136-2	32364-32370	γ-band	_	
136-3	32371-32383	oscillations	_	
136-4	32384-32388	were	_	
136-5	32389-32400	prominently	_	
136-6	32401-32409	impaired	_	
136-7	32410-32412	in	_	
136-8	32413-32416	the	_	
136-9	32417-32420	FEP	_	
136-10	32421-32426	group	_	
136-11	32427-32429	in	_	
136-12	32430-32436	visual	_	
136-13	32437-32442	areas	_	
136-14	32442-32443	,	_	
136-15	32444-32449	which	_	
136-16	32450-32453	was	_	
136-17	32454-32457	not	_	
136-18	32458-32466	observed	_	
136-19	32467-32469	in	_	
136-20	32470-32475	CHR-P	_	
136-21	32476-32488	participants	_	
136-22	32488-32489	.	_	

#Text=Both groups were characterized by impaired long-range connectivity between visual and frontal cortices while the FEP group also showed reduced visual cortex connectivity.
137-1	32490-32494	Both	_	
137-2	32495-32501	groups	_	
137-3	32502-32506	were	_	
137-4	32507-32520	characterized	_	
137-5	32521-32523	by	_	
137-6	32524-32532	impaired	_	
137-7	32533-32543	long-range	_	
137-8	32544-32556	connectivity	_	
137-9	32557-32564	between	_	
137-10	32565-32571	visual	_	
137-11	32572-32575	and	_	
137-12	32576-32583	frontal	_	
137-13	32584-32592	cortices	_	
137-14	32593-32598	while	_	
137-15	32599-32602	the	_	
137-16	32603-32606	FEP	_	
137-17	32607-32612	group	_	
137-18	32613-32617	also	_	
137-19	32618-32624	showed	_	
137-20	32625-32632	reduced	_	
137-21	32633-32639	visual	_	
137-22	32640-32646	cortex	_	
137-23	32647-32659	connectivity	_	
137-24	32659-32660	.	_	

#Text=An influential model in schizophrenia has been the disconnectivity hypothesis as well as the notion of reduced cognitive control mediated by frontal cortices.
138-1	32661-32663	An	_	
138-2	32664-32675	influential	_	
138-3	32676-32681	model	_	
138-4	32682-32684	in	_	
138-5	32685-32698	schizophrenia	_	
138-6	32699-32702	has	_	
138-7	32703-32707	been	_	
138-8	32708-32711	the	_	
138-9	32712-32727	disconnectivity	_	
138-10	32728-32738	hypothesis	_	
138-11	32739-32741	as	_	
138-12	32742-32746	well	_	
138-13	32747-32749	as	_	
138-14	32750-32753	the	_	
138-15	32754-32760	notion	_	
138-16	32761-32763	of	_	
138-17	32764-32771	reduced	_	
138-18	32772-32781	cognitive	_	
138-19	32782-32789	control	_	
138-20	32790-32798	mediated	_	
138-21	32799-32801	by	_	
138-22	32802-32809	frontal	_	
138-23	32810-32818	cortices	_	
138-24	32818-32819	.	_	

#Text=Our GC data are consistent with these hypotheses, suggesting a shared feature of both FEP and at-risk participants is the presence of impaired connectivity between sensory regions and frontal cortices.
139-1	32820-32823	Our	_	
139-2	32824-32826	GC	_	
139-3	32827-32831	data	_	
139-4	32832-32835	are	_	
139-5	32836-32846	consistent	_	
139-6	32847-32851	with	_	
139-7	32852-32857	these	_	
139-8	32858-32868	hypotheses	_	
139-9	32868-32869	,	_	
139-10	32870-32880	suggesting	_	
139-11	32881-32882	a	_	
139-12	32883-32889	shared	_	
139-13	32890-32897	feature	_	
139-14	32898-32900	of	_	
139-15	32901-32905	both	_	
139-16	32906-32909	FEP	_	
139-17	32910-32913	and	_	
139-18	32914-32921	at-risk	_	
139-19	32922-32934	participants	_	
139-20	32935-32937	is	_	
139-21	32938-32941	the	_	
139-22	32942-32950	presence	_	
139-23	32951-32953	of	_	
139-24	32954-32962	impaired	_	
139-25	32963-32975	connectivity	_	
139-26	32976-32983	between	_	
139-27	32984-32991	sensory	_	
139-28	32992-32999	regions	_	
139-29	33000-33003	and	_	
139-30	33004-33011	frontal	_	
139-31	33012-33020	cortices	_	
139-32	33020-33021	.	_	

#Text=Impairments in high-frequency oscillations showed a considerable degree of specificity.
140-1	33022-33033	Impairments	_	
140-2	33034-33036	in	_	
140-3	33037-33051	high-frequency	_	
140-4	33052-33064	oscillations	_	
140-5	33065-33071	showed	_	
140-6	33072-33073	a	_	
140-7	33074-33086	considerable	_	
140-8	33087-33093	degree	_	
140-9	33094-33096	of	_	
140-10	33097-33108	specificity	_	
140-11	33108-33109	.	_	

#Text=First, ITPC impairments were only found for activity in the β/γ-band range but not for lower frequencies.
141-1	33110-33115	First	_	
141-2	33115-33116	,	_	
141-3	33117-33121	ITPC	_	
141-4	33122-33133	impairments	_	
141-5	33134-33138	were	_	
141-6	33139-33143	only	_	
141-7	33144-33149	found	_	
141-8	33150-33153	for	_	
141-9	33154-33162	activity	_	
141-10	33163-33165	in	_	
141-11	33166-33169	the	_	
141-12	33170-33171	β	_	
141-13	33171-33172	/	_	
141-14	33172-33178	γ-band	_	
141-15	33179-33184	range	_	
141-16	33185-33188	but	_	
141-17	33189-33192	not	_	
141-18	33193-33196	for	_	
141-19	33197-33202	lower	_	
141-20	33203-33214	frequencies	_	
141-21	33214-33215	.	_	

#Text=Together with the large reductions in induced γ-band activity in the FEP group, these data highlight the unique contribution of high-frequency oscillations toward circuit impairments in emerging psychosis.
142-1	33216-33224	Together	_	
142-2	33225-33229	with	_	
142-3	33230-33233	the	_	
142-4	33234-33239	large	_	
142-5	33240-33250	reductions	_	
142-6	33251-33253	in	_	
142-7	33254-33261	induced	_	
142-8	33262-33268	γ-band	_	
142-9	33269-33277	activity	_	
142-10	33278-33280	in	_	
142-11	33281-33284	the	_	
142-12	33285-33288	FEP	_	
142-13	33289-33294	group	_	
142-14	33294-33295	,	_	
142-15	33296-33301	these	_	
142-16	33302-33306	data	_	
142-17	33307-33316	highlight	_	
142-18	33317-33320	the	_	
142-19	33321-33327	unique	_	
142-20	33328-33340	contribution	_	
142-21	33341-33343	of	_	
142-22	33344-33358	high-frequency	_	
142-23	33359-33371	oscillations	_	
142-24	33372-33378	toward	_	
142-25	33379-33386	circuit	_	
142-26	33387-33398	impairments	_	
142-27	33399-33401	in	_	
142-28	33402-33410	emerging	_	
142-29	33411-33420	psychosis	_	
142-30	33420-33421	.	_	

#Text=Second, the CHR-N group showed intact behavioral task parameters as well normal power and phase of high-frequency oscillations in visual cortices and long-range connectivity with only evidence for a circumscribed impairment in local connectivity in visual cortex.
143-1	33422-33428	Second	_	
143-2	33428-33429	,	_	
143-3	33430-33433	the	_	
143-4	33434-33439	CHR-N	_	
143-5	33440-33445	group	_	
143-6	33446-33452	showed	_	
143-7	33453-33459	intact	_	
143-8	33460-33470	behavioral	_	
143-9	33471-33475	task	_	
143-10	33476-33486	parameters	_	
143-11	33487-33489	as	_	
143-12	33490-33494	well	_	
143-13	33495-33501	normal	_	
143-14	33502-33507	power	_	
143-15	33508-33511	and	_	
143-16	33512-33517	phase	_	
143-17	33518-33520	of	_	
143-18	33521-33535	high-frequency	_	
143-19	33536-33548	oscillations	_	
143-20	33549-33551	in	_	
143-21	33552-33558	visual	_	
143-22	33559-33567	cortices	_	
143-23	33568-33571	and	_	
143-24	33572-33582	long-range	_	
143-25	33583-33595	connectivity	_	
143-26	33596-33600	with	_	
143-27	33601-33605	only	_	
143-28	33606-33614	evidence	_	
143-29	33615-33618	for	_	
143-30	33619-33620	a	_	
143-31	33621-33634	circumscribed	_	
143-32	33635-33645	impairment	_	
143-33	33646-33648	in	_	
143-34	33649-33654	local	_	
143-35	33655-33667	connectivity	_	
143-36	33668-33670	in	_	
143-37	33671-33677	visual	_	
143-38	33678-33684	cortex	_	
143-39	33684-33685	.	_	

#Text=Thus, EEG/MEG readouts could potentially inform clinical decision-making and search for novel treatment opportunities.
144-1	33686-33690	Thus	_	
144-2	33690-33691	,	_	
144-3	33692-33695	EEG	_	
144-4	33695-33696	/	_	
144-5	33696-33699	MEG	_	
144-6	33700-33708	readouts	_	
144-7	33709-33714	could	_	
144-8	33715-33726	potentially	_	
144-9	33727-33733	inform	_	
144-10	33734-33742	clinical	_	
144-11	33743-33758	decision-making	_	
144-12	33759-33762	and	_	
144-13	33763-33769	search	_	
144-14	33770-33773	for	_	
144-15	33774-33779	novel	_	
144-16	33780-33789	treatment	_	
144-17	33790-33803	opportunities	_	
144-18	33803-33804	.	_	

#Text=The search for biomarkers that have prognostic utility and could guide treatments in emerging psychosis is an important objective of research.
145-1	33805-33808	The	_	
145-2	33809-33815	search	_	
145-3	33816-33819	for	_	
145-4	33820-33830	biomarkers	_	
145-5	33831-33835	that	_	
145-6	33836-33840	have	_	
145-7	33841-33851	prognostic	_	
145-8	33852-33859	utility	_	
145-9	33860-33863	and	_	
145-10	33864-33869	could	_	
145-11	33870-33875	guide	_	
145-12	33876-33886	treatments	_	
145-13	33887-33889	in	_	
145-14	33890-33898	emerging	_	
145-15	33899-33908	psychosis	_	
145-16	33909-33911	is	_	
145-17	33912-33914	an	_	
145-18	33915-33924	important	_	
145-19	33925-33934	objective	_	
145-20	33935-33937	of	_	
145-21	33938-33946	research	_	
145-22	33946-33947	.	_	

#Text=This study highlights that impaired γ-band ITPC differentiates between CHR-P individuals who have a high likelihood of persistent APS and transition to psychosis vs CHR-P individuals who show more benign APS.
146-1	33948-33952	This	_	
146-2	33953-33958	study	_	
146-3	33959-33969	highlights	_	
146-4	33970-33974	that	_	
146-5	33975-33983	impaired	_	
146-6	33984-33990	γ-band	_	
146-7	33991-33995	ITPC	_	
146-8	33996-34010	differentiates	_	
146-9	34011-34018	between	_	
146-10	34019-34024	CHR-P	_	
146-11	34025-34036	individuals	_	
146-12	34037-34040	who	_	
146-13	34041-34045	have	_	
146-14	34046-34047	a	_	
146-15	34048-34052	high	_	
146-16	34053-34063	likelihood	_	
146-17	34064-34066	of	_	
146-18	34067-34077	persistent	_	
146-19	34078-34081	APS	_	
146-20	34082-34085	and	_	
146-21	34086-34096	transition	_	
146-22	34097-34099	to	_	
146-23	34100-34109	psychosis	_	
146-24	34110-34112	vs	_	
146-25	34113-34118	CHR-P	_	
146-26	34119-34130	individuals	_	
146-27	34131-34134	who	_	
146-28	34135-34139	show	_	
146-29	34140-34144	more	_	
146-30	34145-34151	benign	_	
146-31	34152-34155	APS	_	
146-32	34155-34156	.	_	

#Text=On the other hand, reductions in induced γ-band power emerged as a specific signature of FEP, suggesting that impaired γ-band oscillations could serve as a biomarker for established psychosis that warrants more aggressive treatments, such as antipsychotic medications.
147-1	34157-34159	On	_	
147-2	34160-34163	the	_	
147-3	34164-34169	other	_	
147-4	34170-34174	hand	_	
147-5	34174-34175	,	_	
147-6	34176-34186	reductions	_	
147-7	34187-34189	in	_	
147-8	34190-34197	induced	_	
147-9	34198-34204	γ-band	_	
147-10	34205-34210	power	_	
147-11	34211-34218	emerged	_	
147-12	34219-34221	as	_	
147-13	34222-34223	a	_	
147-14	34224-34232	specific	_	
147-15	34233-34242	signature	_	
147-16	34243-34245	of	_	
147-17	34246-34249	FEP	_	
147-18	34249-34250	,	_	
147-19	34251-34261	suggesting	_	
147-20	34262-34266	that	_	
147-21	34267-34275	impaired	_	
147-22	34276-34282	γ-band	_	
147-23	34283-34295	oscillations	_	
147-24	34296-34301	could	_	
147-25	34302-34307	serve	_	
147-26	34308-34310	as	_	
147-27	34311-34312	a	_	
147-28	34313-34322	biomarker	_	
147-29	34323-34326	for	_	
147-30	34327-34338	established	_	
147-31	34339-34348	psychosis	_	
147-32	34349-34353	that	_	
147-33	34354-34362	warrants	_	
147-34	34363-34367	more	_	
147-35	34368-34378	aggressive	_	
147-36	34379-34389	treatments	_	
147-37	34389-34390	,	_	
147-38	34391-34395	such	_	
147-39	34396-34398	as	_	
147-40	34399-34412	antipsychotic	_	
147-41	34413-34424	medications	_	
147-42	34424-34425	.	_	

#Text=Our observations of increased variability in the timing of β/γ-band oscillations is consistent with formulations that have implicated aberrant glutamatergic and GABAergic neurotransmission as key mechanism for circuit dysfunctions in psychotic disorders.
148-1	34426-34429	Our	_	
148-2	34430-34442	observations	_	
148-3	34443-34445	of	_	
148-4	34446-34455	increased	_	
148-5	34456-34467	variability	_	
148-6	34468-34470	in	_	
148-7	34471-34474	the	_	
148-8	34475-34481	timing	_	
148-9	34482-34484	of	_	
148-10	34485-34486	β	_	
148-11	34486-34487	/	_	
148-12	34487-34493	γ-band	_	
148-13	34494-34506	oscillations	_	
148-14	34507-34509	is	_	
148-15	34510-34520	consistent	_	
148-16	34521-34525	with	_	
148-17	34526-34538	formulations	_	
148-18	34539-34543	that	_	
148-19	34544-34548	have	_	
148-20	34549-34559	implicated	_	
148-21	34560-34568	aberrant	_	
148-22	34569-34582	glutamatergic	_	
148-23	34583-34586	and	_	
148-24	34587-34596	GABAergic	_	
148-25	34597-34614	neurotransmission	_	
148-26	34615-34617	as	_	
148-27	34618-34621	key	_	
148-28	34622-34631	mechanism	_	
148-29	34632-34635	for	_	
148-30	34636-34643	circuit	_	
148-31	34644-34656	dysfunctions	_	
148-32	34657-34659	in	_	
148-33	34660-34669	psychotic	_	
148-34	34670-34679	disorders	_	
148-35	34679-34680	.	_	

#Text=Specifically, an increase in variability of neuronal responses can be elicited by N-methyl-d-aspartate receptor hypofunction, suggesting that elevated excitability in sensory regions during the early stages of psychosis may lead to favorable conditions for altered network dynamics to emerge.
149-1	34681-34693	Specifically	_	
149-2	34693-34694	,	_	
149-3	34695-34697	an	_	
149-4	34698-34706	increase	_	
149-5	34707-34709	in	_	
149-6	34710-34721	variability	_	
149-7	34722-34724	of	_	
149-8	34725-34733	neuronal	_	
149-9	34734-34743	responses	_	
149-10	34744-34747	can	_	
149-11	34748-34750	be	_	
149-12	34751-34759	elicited	_	
149-13	34760-34762	by	_	
149-14	34763-34783	N-methyl-d-aspartate	_	
149-15	34784-34792	receptor	_	
149-16	34793-34805	hypofunction	_	
149-17	34805-34806	,	_	
149-18	34807-34817	suggesting	_	
149-19	34818-34822	that	_	
149-20	34823-34831	elevated	_	
149-21	34832-34844	excitability	_	
149-22	34845-34847	in	_	
149-23	34848-34855	sensory	_	
149-24	34856-34863	regions	_	
149-25	34864-34870	during	_	
149-26	34871-34874	the	_	
149-27	34875-34880	early	_	
149-28	34881-34887	stages	_	
149-29	34888-34890	of	_	
149-30	34891-34900	psychosis	_	
149-31	34901-34904	may	_	
149-32	34905-34909	lead	_	
149-33	34910-34912	to	_	
149-34	34913-34922	favorable	_	
149-35	34923-34933	conditions	_	
149-36	34934-34937	for	_	
149-37	34938-34945	altered	_	
149-38	34946-34953	network	_	
149-39	34954-34962	dynamics	_	
149-40	34963-34965	to	_	
149-41	34966-34972	emerge	_	
149-42	34972-34973	.	_	

#Text=Moreover, deficits in high-frequency oscillations highlight the contribution of specific GABAergic interneurons, such as parvalbumin or somatostatin-expressing interneurons that are impaired in visual areas in schizophrenia.
150-1	34974-34982	Moreover	_	
150-2	34982-34983	,	_	
150-3	34984-34992	deficits	_	
150-4	34993-34995	in	_	
150-5	34996-35010	high-frequency	_	
150-6	35011-35023	oscillations	_	
150-7	35024-35033	highlight	_	
150-8	35034-35037	the	_	
150-9	35038-35050	contribution	_	
150-10	35051-35053	of	_	
150-11	35054-35062	specific	_	
150-12	35063-35072	GABAergic	_	
150-13	35073-35085	interneurons	_	
150-14	35085-35086	,	_	
150-15	35087-35091	such	_	
150-16	35092-35094	as	_	
150-17	35095-35106	parvalbumin	_	
150-18	35107-35109	or	_	
150-19	35110-35133	somatostatin-expressing	_	
150-20	35134-35146	interneurons	_	
150-21	35147-35151	that	_	
150-22	35152-35155	are	_	
150-23	35156-35164	impaired	_	
150-24	35165-35167	in	_	
150-25	35168-35174	visual	_	
150-26	35175-35180	areas	_	
150-27	35181-35183	in	_	
150-28	35184-35197	schizophrenia	_	
150-29	35197-35198	.	_	

#Text=In addition to the pharmacologic correction of aberrant circuit dynamics, it is also conceivable that interventions that improve the fidelity of sensory processing through cognitive remediation or brain stimulation could potentially prevent the progression of circuit dysfunctions from sensory areas to more extended networks.
151-1	35199-35201	In	_	
151-2	35202-35210	addition	_	
151-3	35211-35213	to	_	
151-4	35214-35217	the	_	
151-5	35218-35231	pharmacologic	_	
151-6	35232-35242	correction	_	
151-7	35243-35245	of	_	
151-8	35246-35254	aberrant	_	
151-9	35255-35262	circuit	_	
151-10	35263-35271	dynamics	_	
151-11	35271-35272	,	_	
151-12	35273-35275	it	_	
151-13	35276-35278	is	_	
151-14	35279-35283	also	_	
151-15	35284-35295	conceivable	_	
151-16	35296-35300	that	_	
151-17	35301-35314	interventions	_	
151-18	35315-35319	that	_	
151-19	35320-35327	improve	_	
151-20	35328-35331	the	_	
151-21	35332-35340	fidelity	_	
151-22	35341-35343	of	_	
151-23	35344-35351	sensory	_	
151-24	35352-35362	processing	_	
151-25	35363-35370	through	_	
151-26	35371-35380	cognitive	_	
151-27	35381-35392	remediation	_	
151-28	35393-35395	or	_	
151-29	35396-35401	brain	_	
151-30	35402-35413	stimulation	_	
151-31	35414-35419	could	_	
151-32	35420-35431	potentially	_	
151-33	35432-35439	prevent	_	
151-34	35440-35443	the	_	
151-35	35444-35455	progression	_	
151-36	35456-35458	of	_	
151-37	35459-35466	circuit	_	
151-38	35467-35479	dysfunctions	_	
151-39	35480-35484	from	_	
151-40	35485-35492	sensory	_	
151-41	35493-35498	areas	_	
151-42	35499-35501	to	_	
151-43	35502-35506	more	_	
151-44	35507-35515	extended	_	
151-45	35516-35524	networks	_	
151-46	35524-35525	.	_	

#Text=Limitations
#Text=This study has several limitations.
152-1	35526-35537	Limitations	_	
152-2	35538-35542	This	_	
152-3	35543-35548	study	_	
152-4	35549-35552	has	_	
152-5	35553-35560	several	_	
152-6	35561-35572	limitations	_	
152-7	35572-35573	.	_	

#Text=Although we can predict the persistence of subthreshold psychotic symptoms through MEG data in our CHR-P cohort, further follow-up data are required to test whether abnormalities in high-frequency oscillations can predict transition to psychosis as well as the persistence of Cognitive Disturbances and Cognitive-Perceptive Basic Symptoms criteria.
153-1	35574-35582	Although	_	
153-2	35583-35585	we	_	
153-3	35586-35589	can	_	
153-4	35590-35597	predict	_	
153-5	35598-35601	the	_	
153-6	35602-35613	persistence	_	
153-7	35614-35616	of	_	
153-8	35617-35629	subthreshold	_	
153-9	35630-35639	psychotic	_	
153-10	35640-35648	symptoms	_	
153-11	35649-35656	through	_	
153-12	35657-35660	MEG	_	
153-13	35661-35665	data	_	
153-14	35666-35668	in	_	
153-15	35669-35672	our	_	
153-16	35673-35678	CHR-P	_	
153-17	35679-35685	cohort	_	
153-18	35685-35686	,	_	
153-19	35687-35694	further	_	
153-20	35695-35704	follow-up	_	
153-21	35705-35709	data	_	
153-22	35710-35713	are	_	
153-23	35714-35722	required	_	
153-24	35723-35725	to	_	
153-25	35726-35730	test	_	
153-26	35731-35738	whether	_	
153-27	35739-35752	abnormalities	_	
153-28	35753-35755	in	_	
153-29	35756-35770	high-frequency	_	
153-30	35771-35783	oscillations	_	
153-31	35784-35787	can	_	
153-32	35788-35795	predict	_	
153-33	35796-35806	transition	_	
153-34	35807-35809	to	_	
153-35	35810-35819	psychosis	_	
153-36	35820-35822	as	_	
153-37	35823-35827	well	_	
153-38	35828-35830	as	_	
153-39	35831-35834	the	_	
153-40	35835-35846	persistence	_	
153-41	35847-35849	of	_	
153-42	35850-35859	Cognitive	_	
153-43	35860-35872	Disturbances	_	
153-44	35873-35876	and	_	
153-45	35877-35897	Cognitive-Perceptive	_	
153-46	35898-35903	Basic	_	
153-47	35904-35912	Symptoms	_	
153-48	35913-35921	criteria	_	
153-49	35921-35922	.	_	

#Text=Moreover, these data are only cross-sectional.
154-1	35923-35931	Moreover	_	
154-2	35931-35932	,	_	
154-3	35933-35938	these	_	
154-4	35939-35943	data	_	
154-5	35944-35947	are	_	
154-6	35948-35952	only	_	
154-7	35953-35968	cross-sectional	_	
154-8	35968-35969	.	_	

#Text=Accordingly, further studies are required to examine the longitudinal course of oscillatory deficits during emerging psychosis.
155-1	35970-35981	Accordingly	_	
155-2	35981-35982	,	_	
155-3	35983-35990	further	_	
155-4	35991-35998	studies	_	
155-5	35999-36002	are	_	
155-6	36003-36011	required	_	
155-7	36012-36014	to	_	
155-8	36015-36022	examine	_	
155-9	36023-36026	the	_	
155-10	36027-36039	longitudinal	_	
155-11	36040-36046	course	_	
155-12	36047-36049	of	_	
155-13	36050-36061	oscillatory	_	
155-14	36062-36070	deficits	_	
155-15	36071-36077	during	_	
155-16	36078-36086	emerging	_	
155-17	36087-36096	psychosis	_	
155-18	36096-36097	.	_	

#Text=Conclusions
#Text=In summary, this advanced MEG analysis provides, to our knowledge, the first comprehensive investigation into the oscillatory signatures during different stages of early psychosis.
156-1	36098-36109	Conclusions	_	
156-2	36110-36112	In	_	
156-3	36113-36120	summary	_	
156-4	36120-36121	,	_	
156-5	36122-36126	this	_	
156-6	36127-36135	advanced	_	
156-7	36136-36139	MEG	_	
156-8	36140-36148	analysis	_	
156-9	36149-36157	provides	_	
156-10	36157-36158	,	_	
156-11	36159-36161	to	_	
156-12	36162-36165	our	_	
156-13	36166-36175	knowledge	_	
156-14	36175-36176	,	_	
156-15	36177-36180	the	_	
156-16	36181-36186	first	_	
156-17	36187-36200	comprehensive	_	
156-18	36201-36214	investigation	_	
156-19	36215-36219	into	_	
156-20	36220-36223	the	_	
156-21	36224-36235	oscillatory	_	
156-22	36236-36246	signatures	_	
156-23	36247-36253	during	_	
156-24	36254-36263	different	_	
156-25	36264-36270	stages	_	
156-26	36271-36273	of	_	
156-27	36274-36279	early	_	
156-28	36280-36289	psychosis	_	
156-29	36289-36290	.	_	

#Text=Specifically, we can show that the timing of high-frequency oscillations in visual cortices is the first impairment to emerge in CHR-P participants in combination with abnormal long-range connectivity.
157-1	36291-36303	Specifically	_	
157-2	36303-36304	,	_	
157-3	36305-36307	we	_	
157-4	36308-36311	can	_	
157-5	36312-36316	show	_	
157-6	36317-36321	that	_	
157-7	36322-36325	the	_	
157-8	36326-36332	timing	_	
157-9	36333-36335	of	_	
157-10	36336-36350	high-frequency	_	
157-11	36351-36363	oscillations	_	
157-12	36364-36366	in	_	
157-13	36367-36373	visual	_	
157-14	36374-36382	cortices	_	
157-15	36383-36385	is	_	
157-16	36386-36389	the	_	
157-17	36390-36395	first	_	
157-18	36396-36406	impairment	_	
157-19	36407-36409	to	_	
157-20	36410-36416	emerge	_	
157-21	36417-36419	in	_	
157-22	36420-36425	CHR-P	_	
157-23	36426-36438	participants	_	
157-24	36439-36441	in	_	
157-25	36442-36453	combination	_	
157-26	36454-36458	with	_	
157-27	36459-36467	abnormal	_	
157-28	36468-36478	long-range	_	
157-29	36479-36491	connectivity	_	
157-30	36491-36492	.	_	

#Text=Patients with FEP were characterized by a pronounced reduction in the power of induced γ-band oscillations in combination with reduced β/γ-band ITPC as well as local and long-range connectivity.
158-1	36493-36501	Patients	_	
158-2	36502-36506	with	_	
158-3	36507-36510	FEP	_	
158-4	36511-36515	were	_	
158-5	36516-36529	characterized	_	
158-6	36530-36532	by	_	
158-7	36533-36534	a	_	
158-8	36535-36545	pronounced	_	
158-9	36546-36555	reduction	_	
158-10	36556-36558	in	_	
158-11	36559-36562	the	_	
158-12	36563-36568	power	_	
158-13	36569-36571	of	_	
158-14	36572-36579	induced	_	
158-15	36580-36586	γ-band	_	
158-16	36587-36599	oscillations	_	
158-17	36600-36602	in	_	
158-18	36603-36614	combination	_	
158-19	36615-36619	with	_	
158-20	36620-36627	reduced	_	
158-21	36628-36629	β	_	
158-22	36629-36630	/	_	
158-23	36630-36636	γ-band	_	
158-24	36637-36641	ITPC	_	
158-25	36642-36644	as	_	
158-26	36645-36649	well	_	
158-27	36650-36652	as	_	
158-28	36653-36658	local	_	
158-29	36659-36662	and	_	
158-30	36663-36673	long-range	_	
158-31	36674-36686	connectivity	_	
158-32	36686-36687	.	_	

#Text=Importantly, impaired γ-band IPTC-values were associated with the persistence of subthreshold psychotic experiences, suggesting that γ-band oscillations could constitute a possible biomarker for clinical staging of emerging psychosis.
159-1	36688-36699	Importantly	_	
159-2	36699-36700	,	_	
159-3	36701-36709	impaired	_	
159-4	36710-36716	γ-band	_	
159-5	36717-36728	IPTC-values	_	
159-6	36729-36733	were	_	
159-7	36734-36744	associated	_	
159-8	36745-36749	with	_	
159-9	36750-36753	the	_	
159-10	36754-36765	persistence	_	
159-11	36766-36768	of	_	
159-12	36769-36781	subthreshold	_	
159-13	36782-36791	psychotic	_	
159-14	36792-36803	experiences	_	
159-15	36803-36804	,	_	
159-16	36805-36815	suggesting	_	
159-17	36816-36820	that	_	
159-18	36821-36827	γ-band	_	
159-19	36828-36840	oscillations	_	
159-20	36841-36846	could	_	
159-21	36847-36857	constitute	_	
159-22	36858-36859	a	_	
159-23	36860-36868	possible	_	
159-24	36869-36878	biomarker	_	
159-25	36879-36882	for	_	
159-26	36883-36891	clinical	_	
159-27	36892-36899	staging	_	
159-28	36900-36902	of	_	
159-29	36903-36911	emerging	_	
159-30	36912-36921	psychosis	_	
159-31	36921-36922	.	_	

#Text=Future studies and preclinical research should therefore focus on the circuit-mechanisms mediating precise coordinated neural responses that could offer targets for preventive approaches.
160-1	36923-36929	Future	_	
160-2	36930-36937	studies	_	
160-3	36938-36941	and	_	
160-4	36942-36953	preclinical	_	
160-5	36954-36962	research	_	
160-6	36963-36969	should	_	
160-7	36970-36979	therefore	_	
160-8	36980-36985	focus	_	
160-9	36986-36988	on	_	
160-10	36989-36992	the	_	
160-11	36993-37011	circuit-mechanisms	_	
160-12	37012-37021	mediating	_	
160-13	37022-37029	precise	_	
160-14	37030-37041	coordinated	_	
160-15	37042-37048	neural	_	
160-16	37049-37058	responses	_	
160-17	37059-37063	that	_	
160-18	37064-37069	could	_	
160-19	37070-37075	offer	_	
160-20	37076-37083	targets	_	
160-21	37084-37087	for	_	
160-22	37088-37098	preventive	_	
160-23	37099-37109	approaches	_	
160-24	37109-37110	.	_	

#Text=References
#Text=Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties
#Text=Gamma-band synchronization in visual cortex predicts speed of change detection
#Text=Prefrontal parvalbumin neurons in control of attention
#Text=Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology
#Text=Abnormal neural synchrony in schizophrenia
#Text=Gamma frequency-range abnormalities to auditory stimulation in schizophrenia
#Text=MEG-measured visually induced gamma-band oscillations in chronic schizophrenia: Evidence for impaired generation of rhythmic activity in ventral stream regions
#Text=Abnormalities of neuronal oscillations and temporal integration to low- and high-frequency auditory stimulation in schizophrenia
#Text=Impaired midline theta power and connectivity during proactive cognitive control in schizophrenia
#Text=Neuronal dynamics and neuropsychiatric disorders: toward a translational paradigm for dysfunctional large-scale networks
#Text=Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?
161-1	37111-37121	References	_	
161-2	37122-37133	Oscillatory	_	
161-3	37134-37143	responses	_	
161-4	37144-37146	in	_	
161-5	37147-37150	cat	_	
161-6	37151-37157	visual	_	
161-7	37158-37164	cortex	_	
161-8	37165-37172	exhibit	_	
161-9	37173-37187	inter-columnar	_	
161-10	37188-37203	synchronization	_	
161-11	37204-37209	which	_	
161-12	37210-37218	reflects	_	
161-13	37219-37225	global	_	
161-14	37226-37234	stimulus	_	
161-15	37235-37245	properties	_	
161-16	37246-37256	Gamma-band	_	
161-17	37257-37272	synchronization	_	
161-18	37273-37275	in	_	
161-19	37276-37282	visual	_	
161-20	37283-37289	cortex	_	
161-21	37290-37298	predicts	_	
161-22	37299-37304	speed	_	
161-23	37305-37307	of	_	
161-24	37308-37314	change	_	
161-25	37315-37324	detection	_	
161-26	37325-37335	Prefrontal	_	
161-27	37336-37347	parvalbumin	_	
161-28	37348-37355	neurons	_	
161-29	37356-37358	in	_	
161-30	37359-37366	control	_	
161-31	37367-37369	of	_	
161-32	37370-37379	attention	_	
161-33	37380-37386	Neural	_	
161-34	37387-37396	synchrony	_	
161-35	37397-37399	in	_	
161-36	37400-37405	brain	_	
161-37	37406-37415	disorders	_	
161-38	37415-37416	:	_	
161-39	37417-37426	relevance	_	
161-40	37427-37430	for	_	
161-41	37431-37440	cognitive	_	
161-42	37441-37453	dysfunctions	_	
161-43	37454-37457	and	_	
161-44	37458-37473	pathophysiology	_	
161-45	37474-37482	Abnormal	_	
161-46	37483-37489	neural	_	
161-47	37490-37499	synchrony	_	
161-48	37500-37502	in	_	
161-49	37503-37516	schizophrenia	_	
161-50	37517-37522	Gamma	_	
161-51	37523-37538	frequency-range	_	
161-52	37539-37552	abnormalities	_	
161-53	37553-37555	to	_	
161-54	37556-37564	auditory	_	
161-55	37565-37576	stimulation	_	
161-56	37577-37579	in	_	
161-57	37580-37593	schizophrenia	_	
161-58	37594-37606	MEG-measured	_	
161-59	37607-37615	visually	_	
161-60	37616-37623	induced	_	
161-61	37624-37634	gamma-band	_	
161-62	37635-37647	oscillations	_	
161-63	37648-37650	in	_	
161-64	37651-37658	chronic	_	
161-65	37659-37672	schizophrenia	_	
161-66	37672-37673	:	_	
161-67	37674-37682	Evidence	_	
161-68	37683-37686	for	_	
161-69	37687-37695	impaired	_	
161-70	37696-37706	generation	_	
161-71	37707-37709	of	_	
161-72	37710-37718	rhythmic	_	
161-73	37719-37727	activity	_	
161-74	37728-37730	in	_	
161-75	37731-37738	ventral	_	
161-76	37739-37745	stream	_	
161-77	37746-37753	regions	_	
161-78	37754-37767	Abnormalities	_	
161-79	37768-37770	of	_	
161-80	37771-37779	neuronal	_	
161-81	37780-37792	oscillations	_	
161-82	37793-37796	and	_	
161-83	37797-37805	temporal	_	
161-84	37806-37817	integration	_	
161-85	37818-37820	to	_	
161-86	37821-37824	low	_	
161-87	37824-37825	-	_	
161-88	37826-37829	and	_	
161-89	37830-37844	high-frequency	_	
161-90	37845-37853	auditory	_	
161-91	37854-37865	stimulation	_	
161-92	37866-37868	in	_	
161-93	37869-37882	schizophrenia	_	
161-94	37883-37891	Impaired	_	
161-95	37892-37899	midline	_	
161-96	37900-37905	theta	_	
161-97	37906-37911	power	_	
161-98	37912-37915	and	_	
161-99	37916-37928	connectivity	_	
161-100	37929-37935	during	_	
161-101	37936-37945	proactive	_	
161-102	37946-37955	cognitive	_	
161-103	37956-37963	control	_	
161-104	37964-37966	in	_	
161-105	37967-37980	schizophrenia	_	
161-106	37981-37989	Neuronal	_	
161-107	37990-37998	dynamics	_	
161-108	37999-38002	and	_	
161-109	38003-38019	neuropsychiatric	_	
161-110	38020-38029	disorders	_	
161-111	38029-38030	:	_	
161-112	38031-38037	toward	_	
161-113	38038-38039	a	_	
161-114	38040-38053	translational	_	
161-115	38054-38062	paradigm	_	
161-116	38063-38066	for	_	
161-117	38067-38080	dysfunctional	_	
161-118	38081-38092	large-scale	_	
161-119	38093-38101	networks	_	
161-120	38102-38112	Excitation	_	
161-121	38112-38113	,	_	
161-122	38114-38124	inhibition	_	
161-123	38124-38125	,	_	
161-124	38126-38131	local	_	
161-125	38132-38144	oscillations	_	
161-126	38144-38145	,	_	
161-127	38146-38148	or	_	
161-128	38149-38160	large-scale	_	
161-129	38161-38166	loops	_	
161-130	38166-38167	:	_	
161-131	38168-38172	what	_	
161-132	38173-38179	causes	_	
161-133	38180-38183	the	_	
161-134	38184-38192	symptoms	_	
161-135	38193-38195	of	_	
161-136	38196-38209	schizophrenia	_	
161-137	38209-38210	?	_	

#Text=Synchronization in networks of excitatory and inhibitory neurons with sparse, random connectivity
#Text=Parvalbumin neurons and gamma rhythms enhance cortical circuit performance
#Text=Dynamic circuit motifs underlying rhythmic gain control, gating and integration
#Text=Neurophysiological and computational principles of cortical rhythms in cognition
#Text=Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia
#Text=Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
#Text=GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder
#Text=Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy
#Text=The psychosis high-risk state: a comprehensive state-of-the-art review
#Text=Prevention of mental disorders
#Text=Biomarkers and clinical staging in psychiatry
#Text=Differential alterations of auditory gamma oscillatory responses between pre-onset high-risk individuals and first-episode schizophrenia
#Text=Early auditory gamma-band responses in patients at clinical high risk for schizophrenia
#Text=Visual gamma oscillations: the effects of stimulus type, visual field coverage and stimulus motion on MEG and EEG recordings
#Text=Measuring the cortical correlation structure of spontaneous oscillatory activity with EEG and MEG
#Text=Investigating the electrophysiological basis of resting state networks using magnetoencephalography
#Text=Disorders of attention and perception in early schizophrenia
#Text=Perceptual anomalies in schizophrenia: integrating phenomenology and cognitive neuroscience
#Text=Diagnosing schizophrenia in the initial prodromal phase
#Text=Rapid feature selective neuronal synchronization through correlated latency shifting
#Text=Alpha-beta and gamma rhythms subserve feedback and feedforward influences among human visual cortical areas
#Text=Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis
#Text=Neurocognitive function as a possible marker for remission from clinical high risk for psychosis
#Text=Schizophrenia: a disconnection syndrome?
162-1	38211-38226	Synchronization	_	
162-2	38227-38229	in	_	
162-3	38230-38238	networks	_	
162-4	38239-38241	of	_	
162-5	38242-38252	excitatory	_	
162-6	38253-38256	and	_	
162-7	38257-38267	inhibitory	_	
162-8	38268-38275	neurons	_	
162-9	38276-38280	with	_	
162-10	38281-38287	sparse	_	
162-11	38287-38288	,	_	
162-12	38289-38295	random	_	
162-13	38296-38308	connectivity	_	
162-14	38309-38320	Parvalbumin	_	
162-15	38321-38328	neurons	_	
162-16	38329-38332	and	_	
162-17	38333-38338	gamma	_	
162-18	38339-38346	rhythms	_	
162-19	38347-38354	enhance	_	
162-20	38355-38363	cortical	_	
162-21	38364-38371	circuit	_	
162-22	38372-38383	performance	_	
162-23	38384-38391	Dynamic	_	
162-24	38392-38399	circuit	_	
162-25	38400-38406	motifs	_	
162-26	38407-38417	underlying	_	
162-27	38418-38426	rhythmic	_	
162-28	38427-38431	gain	_	
162-29	38432-38439	control	_	
162-30	38439-38440	,	_	
162-31	38441-38447	gating	_	
162-32	38448-38451	and	_	
162-33	38452-38463	integration	_	
162-34	38464-38482	Neurophysiological	_	
162-35	38483-38486	and	_	
162-36	38487-38500	computational	_	
162-37	38501-38511	principles	_	
162-38	38512-38514	of	_	
162-39	38515-38523	cortical	_	
162-40	38524-38531	rhythms	_	
162-41	38532-38534	in	_	
162-42	38535-38544	cognition	_	
162-43	38545-38550	Novel	_	
162-44	38551-38559	findings	_	
162-45	38560-38564	from	_	
162-46	38565-38569	CNVs	_	
162-47	38570-38579	implicate	_	
162-48	38580-38590	inhibitory	_	
162-49	38591-38594	and	_	
162-50	38595-38605	excitatory	_	
162-51	38606-38615	signaling	_	
162-52	38616-38625	complexes	_	
162-53	38626-38628	in	_	
162-54	38629-38642	schizophrenia	_	
162-55	38643-38651	Cortical	_	
162-56	38652-38663	parvalbumin	_	
162-57	38664-38676	interneurons	_	
162-58	38677-38680	and	_	
162-59	38681-38690	cognitive	_	
162-60	38691-38702	dysfunction	_	
162-61	38703-38705	in	_	
162-62	38706-38719	schizophrenia	_	
162-63	38720-38729	GABAergic	_	
162-64	38730-38742	interneurons	_	
162-65	38742-38743	:	_	
162-66	38744-38756	implications	_	
162-67	38757-38760	for	_	
162-68	38761-38774	understanding	_	
162-69	38775-38788	schizophrenia	_	
162-70	38789-38792	and	_	
162-71	38793-38800	bipolar	_	
162-72	38801-38809	disorder	_	
162-73	38810-38818	Elevated	_	
162-74	38819-38829	prefrontal	_	
162-75	38830-38836	cortex	_	
162-76	38837-38851	γ-aminobutyric	_	
162-77	38852-38856	acid	_	
162-78	38857-38860	and	_	
162-79	38861-38880	glutamate-glutamine	_	
162-80	38881-38887	levels	_	
162-81	38888-38890	in	_	
162-82	38891-38904	schizophrenia	_	
162-83	38905-38913	measured	_	
162-84	38914-38916	in	_	
162-85	38917-38921	vivo	_	
162-86	38922-38926	with	_	
162-87	38927-38933	proton	_	
162-88	38934-38942	magnetic	_	
162-89	38943-38952	resonance	_	
162-90	38953-38965	spectroscopy	_	
162-91	38966-38969	The	_	
162-92	38970-38979	psychosis	_	
162-93	38980-38989	high-risk	_	
162-94	38990-38995	state	_	
162-95	38995-38996	:	_	
162-96	38997-38998	a	_	
162-97	38999-39012	comprehensive	_	
162-98	39013-39029	state-of-the-art	_	
162-99	39030-39036	review	_	
162-100	39037-39047	Prevention	_	
162-101	39048-39050	of	_	
162-102	39051-39057	mental	_	
162-103	39058-39067	disorders	_	
162-104	39068-39078	Biomarkers	_	
162-105	39079-39082	and	_	
162-106	39083-39091	clinical	_	
162-107	39092-39099	staging	_	
162-108	39100-39102	in	_	
162-109	39103-39113	psychiatry	_	
162-110	39114-39126	Differential	_	
162-111	39127-39138	alterations	_	
162-112	39139-39141	of	_	
162-113	39142-39150	auditory	_	
162-114	39151-39156	gamma	_	
162-115	39157-39168	oscillatory	_	
162-116	39169-39178	responses	_	
162-117	39179-39186	between	_	
162-118	39187-39196	pre-onset	_	
162-119	39197-39206	high-risk	_	
162-120	39207-39218	individuals	_	
162-121	39219-39222	and	_	
162-122	39223-39236	first-episode	_	
162-123	39237-39250	schizophrenia	_	
162-124	39251-39256	Early	_	
162-125	39257-39265	auditory	_	
162-126	39266-39276	gamma-band	_	
162-127	39277-39286	responses	_	
162-128	39287-39289	in	_	
162-129	39290-39298	patients	_	
162-130	39299-39301	at	_	
162-131	39302-39310	clinical	_	
162-132	39311-39315	high	_	
162-133	39316-39320	risk	_	
162-134	39321-39324	for	_	
162-135	39325-39338	schizophrenia	_	
162-136	39339-39345	Visual	_	
162-137	39346-39351	gamma	_	
162-138	39352-39364	oscillations	_	
162-139	39364-39365	:	_	
162-140	39366-39369	the	_	
162-141	39370-39377	effects	_	
162-142	39378-39380	of	_	
162-143	39381-39389	stimulus	_	
162-144	39390-39394	type	_	
162-145	39394-39395	,	_	
162-146	39396-39402	visual	_	
162-147	39403-39408	field	_	
162-148	39409-39417	coverage	_	
162-149	39418-39421	and	_	
162-150	39422-39430	stimulus	_	
162-151	39431-39437	motion	_	
162-152	39438-39440	on	_	
162-153	39441-39444	MEG	_	
162-154	39445-39448	and	_	
162-155	39449-39452	EEG	_	
162-156	39453-39463	recordings	_	
162-157	39464-39473	Measuring	_	
162-158	39474-39477	the	_	
162-159	39478-39486	cortical	_	
162-160	39487-39498	correlation	_	
162-161	39499-39508	structure	_	
162-162	39509-39511	of	_	
162-163	39512-39523	spontaneous	_	
162-164	39524-39535	oscillatory	_	
162-165	39536-39544	activity	_	
162-166	39545-39549	with	_	
162-167	39550-39553	EEG	_	
162-168	39554-39557	and	_	
162-169	39558-39561	MEG	_	
162-170	39562-39575	Investigating	_	
162-171	39576-39579	the	_	
162-172	39580-39600	electrophysiological	_	
162-173	39601-39606	basis	_	
162-174	39607-39609	of	_	
162-175	39610-39617	resting	_	
162-176	39618-39623	state	_	
162-177	39624-39632	networks	_	
162-178	39633-39638	using	_	
162-179	39639-39661	magnetoencephalography	_	
162-180	39662-39671	Disorders	_	
162-181	39672-39674	of	_	
162-182	39675-39684	attention	_	
162-183	39685-39688	and	_	
162-184	39689-39699	perception	_	
162-185	39700-39702	in	_	
162-186	39703-39708	early	_	
162-187	39709-39722	schizophrenia	_	
162-188	39723-39733	Perceptual	_	
162-189	39734-39743	anomalies	_	
162-190	39744-39746	in	_	
162-191	39747-39760	schizophrenia	_	
162-192	39760-39761	:	_	
162-193	39762-39773	integrating	_	
162-194	39774-39787	phenomenology	_	
162-195	39788-39791	and	_	
162-196	39792-39801	cognitive	_	
162-197	39802-39814	neuroscience	_	
162-198	39815-39825	Diagnosing	_	
162-199	39826-39839	schizophrenia	_	
162-200	39840-39842	in	_	
162-201	39843-39846	the	_	
162-202	39847-39854	initial	_	
162-203	39855-39864	prodromal	_	
162-204	39865-39870	phase	_	
162-205	39871-39876	Rapid	_	
162-206	39877-39884	feature	_	
162-207	39885-39894	selective	_	
162-208	39895-39903	neuronal	_	
162-209	39904-39919	synchronization	_	
162-210	39920-39927	through	_	
162-211	39928-39938	correlated	_	
162-212	39939-39946	latency	_	
162-213	39947-39955	shifting	_	
162-214	39956-39966	Alpha-beta	_	
162-215	39967-39970	and	_	
162-216	39971-39976	gamma	_	
162-217	39977-39984	rhythms	_	
162-218	39985-39993	subserve	_	
162-219	39994-40002	feedback	_	
162-220	40003-40006	and	_	
162-221	40007-40018	feedforward	_	
162-222	40019-40029	influences	_	
162-223	40030-40035	among	_	
162-224	40036-40041	human	_	
162-225	40042-40048	visual	_	
162-226	40049-40057	cortical	_	
162-227	40058-40063	areas	_	
162-228	40064-40075	Persistence	_	
162-229	40076-40078	or	_	
162-230	40079-40089	recurrence	_	
162-231	40090-40092	of	_	
162-232	40093-40106	non-psychotic	_	
162-233	40107-40115	comorbid	_	
162-234	40116-40122	mental	_	
162-235	40123-40132	disorders	_	
162-236	40133-40143	associated	_	
162-237	40144-40148	with	_	
162-238	40149-40150	6	_	
162-239	40150-40151	-	_	
162-240	40151-40155	year	_	
162-241	40156-40160	poor	_	
162-242	40161-40171	functional	_	
162-243	40172-40180	outcomes	_	
162-244	40181-40183	in	_	
162-245	40184-40192	patients	_	
162-246	40193-40195	at	_	
162-247	40196-40201	ultra	_	
162-248	40202-40206	high	_	
162-249	40207-40211	risk	_	
162-250	40212-40215	for	_	
162-251	40216-40225	psychosis	_	
162-252	40226-40240	Neurocognitive	_	
162-253	40241-40249	function	_	
162-254	40250-40252	as	_	
162-255	40253-40254	a	_	
162-256	40255-40263	possible	_	
162-257	40264-40270	marker	_	
162-258	40271-40274	for	_	
162-259	40275-40284	remission	_	
162-260	40285-40289	from	_	
162-261	40290-40298	clinical	_	
162-262	40299-40303	high	_	
162-263	40304-40308	risk	_	
162-264	40309-40312	for	_	
162-265	40313-40322	psychosis	_	
162-266	40323-40336	Schizophrenia	_	
162-267	40336-40337	:	_	
162-268	40338-40339	a	_	
162-269	40340-40353	disconnection	_	
162-270	40354-40362	syndrome	_	
162-271	40362-40363	?	_	

#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
#Text=The Youth Mental Health Risk and Resilience Study (YouR-Study)
#Text=Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia
#Text=Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States
#Text=
#Text=
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
#Text=Localizing human visual gamma-band activity in frequency, time and space
#Text=FieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data
#Text=Tangential derivative mapping of axial MEG applied to event-related desynchronization research
#Text=Dynamic imaging of coherent sources: Studying neural interactions in the human brain
#Text=Stimulus specificity of phase-locked and non-phase-locked 40 Hz visual responses in human
#Text=Visual areas exert feedforward and feedback influences through distinct frequency channels
#Text=Early sensory contributions to contextual encoding deficits in schizophrenia
#Text=Contribution of impaired early-stage visual processing to working memory dysfunction in adolescents with schizophrenia: a study with event-related potentials and functional magnetic resonance imaging
#Text=Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia
#Text=General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance
#Text=Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model
#Text=Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
#Text=NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia
#Text=Cortical gamma band synchronization through somatostatin interneurons
#Text=Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia
#Text=Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia
#Text=Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia
163-1	40364-40377	Dysconnection	_	
163-2	40378-40380	in	_	
163-3	40381-40394	schizophrenia	_	
163-4	40394-40395	:	_	
163-5	40396-40400	from	_	
163-6	40401-40409	abnormal	_	
163-7	40410-40418	synaptic	_	
163-8	40419-40429	plasticity	_	
163-9	40430-40432	to	_	
163-10	40433-40441	failures	_	
163-11	40442-40444	of	_	
163-12	40445-40460	self-monitoring	_	
163-13	40461-40464	The	_	
163-14	40465-40470	Youth	_	
163-15	40471-40477	Mental	_	
163-16	40478-40484	Health	_	
163-17	40485-40489	Risk	_	
163-18	40490-40493	and	_	
163-19	40494-40504	Resilience	_	
163-20	40505-40510	Study	_	
163-21	40511-40512	(	_	
163-22	40512-40522	YouR-Study	_	
163-23	40522-40523	)	_	
163-24	40524-40529	Acute	_	
163-25	40530-40538	ketamine	_	
163-26	40539-40551	dysregulates	_	
163-27	40552-40564	task-related	_	
163-28	40565-40575	gamma-band	_	
163-29	40576-40588	oscillations	_	
163-30	40589-40591	in	_	
163-31	40592-40608	thalamo-cortical	_	
163-32	40609-40617	circuits	_	
163-33	40618-40620	in	_	
163-34	40621-40634	schizophrenia	_	
163-35	40635-40642	Mapping	_	
163-36	40643-40646	the	_	
163-37	40647-40652	onset	_	
163-38	40653-40655	of	_	
163-39	40656-40665	psychosis	_	
163-40	40665-40666	:	_	
163-41	40667-40670	the	_	
163-42	40671-40684	Comprehensive	_	
163-43	40685-40695	Assessment	_	
163-44	40696-40698	of	_	
163-45	40699-40706	At-Risk	_	
163-46	40707-40713	Mental	_	
163-47	40714-40720	States	_	
163-48	40723-40726	The	_	
163-49	40727-40735	positive	_	
163-50	40736-40739	and	_	
163-51	40740-40748	negative	_	
163-52	40749-40757	syndrome	_	
163-53	40758-40763	scale	_	
163-54	40764-40765	(	_	
163-55	40765-40770	PANSS	_	
163-56	40770-40771	)	_	
163-57	40772-40775	for	_	
163-58	40776-40789	schizophrenia	_	
163-59	40790-40793	The	_	
163-60	40794-40799	Brief	_	
163-61	40800-40810	Assessment	_	
163-62	40811-40813	of	_	
163-63	40814-40823	Cognition	_	
163-64	40824-40826	in	_	
163-65	40827-40840	Schizophrenia	_	
163-66	40840-40841	:	_	
163-67	40842-40853	reliability	_	
163-68	40853-40854	,	_	
163-69	40855-40866	sensitivity	_	
163-70	40866-40867	,	_	
163-71	40868-40871	and	_	
163-72	40872-40882	comparison	_	
163-73	40883-40887	with	_	
163-74	40888-40889	a	_	
163-75	40890-40898	standard	_	
163-76	40899-40913	neurocognitive	_	
163-77	40914-40921	battery	_	
163-78	40922-40932	Localizing	_	
163-79	40933-40938	human	_	
163-80	40939-40945	visual	_	
163-81	40946-40956	gamma-band	_	
163-82	40957-40965	activity	_	
163-83	40966-40968	in	_	
163-84	40969-40978	frequency	_	
163-85	40978-40979	,	_	
163-86	40980-40984	time	_	
163-87	40985-40988	and	_	
163-88	40989-40994	space	_	
163-89	40995-41004	FieldTrip	_	
163-90	41004-41005	:	_	
163-91	41006-41010	open	_	
163-92	41011-41017	source	_	
163-93	41018-41026	software	_	
163-94	41027-41030	for	_	
163-95	41031-41039	advanced	_	
163-96	41040-41048	analysis	_	
163-97	41049-41051	of	_	
163-98	41052-41055	MEG	_	
163-99	41055-41056	,	_	
163-100	41057-41060	EEG	_	
163-101	41060-41061	,	_	
163-102	41062-41065	and	_	
163-103	41066-41074	invasive	_	
163-104	41075-41095	electrophysiological	_	
163-105	41096-41100	data	_	
163-106	41101-41111	Tangential	_	
163-107	41112-41122	derivative	_	
163-108	41123-41130	mapping	_	
163-109	41131-41133	of	_	
163-110	41134-41139	axial	_	
163-111	41140-41143	MEG	_	
163-112	41144-41151	applied	_	
163-113	41152-41154	to	_	
163-114	41155-41168	event-related	_	
163-115	41169-41186	desynchronization	_	
163-116	41187-41195	research	_	
163-117	41196-41203	Dynamic	_	
163-118	41204-41211	imaging	_	
163-119	41212-41214	of	_	
163-120	41215-41223	coherent	_	
163-121	41224-41231	sources	_	
163-122	41231-41232	:	_	
163-123	41233-41241	Studying	_	
163-124	41242-41248	neural	_	
163-125	41249-41261	interactions	_	
163-126	41262-41264	in	_	
163-127	41265-41268	the	_	
163-128	41269-41274	human	_	
163-129	41275-41280	brain	_	
163-130	41281-41289	Stimulus	_	
163-131	41290-41301	specificity	_	
163-132	41302-41304	of	_	
163-133	41305-41317	phase-locked	_	
163-134	41318-41321	and	_	
163-135	41322-41338	non-phase-locked	_	
163-136	41339-41341	40	_	
163-137	41342-41344	Hz	_	
163-138	41345-41351	visual	_	
163-139	41352-41361	responses	_	
163-140	41362-41364	in	_	
163-141	41365-41370	human	_	
163-142	41371-41377	Visual	_	
163-143	41378-41383	areas	_	
163-144	41384-41389	exert	_	
163-145	41390-41401	feedforward	_	
163-146	41402-41405	and	_	
163-147	41406-41414	feedback	_	
163-148	41415-41425	influences	_	
163-149	41426-41433	through	_	
163-150	41434-41442	distinct	_	
163-151	41443-41452	frequency	_	
163-152	41453-41461	channels	_	
163-153	41462-41467	Early	_	
163-154	41468-41475	sensory	_	
163-155	41476-41489	contributions	_	
163-156	41490-41492	to	_	
163-157	41493-41503	contextual	_	
163-158	41504-41512	encoding	_	
163-159	41513-41521	deficits	_	
163-160	41522-41524	in	_	
163-161	41525-41538	schizophrenia	_	
163-162	41539-41551	Contribution	_	
163-163	41552-41554	of	_	
163-164	41555-41563	impaired	_	
163-165	41564-41575	early-stage	_	
163-166	41576-41582	visual	_	
163-167	41583-41593	processing	_	
163-168	41594-41596	to	_	
163-169	41597-41604	working	_	
163-170	41605-41611	memory	_	
163-171	41612-41623	dysfunction	_	
163-172	41624-41626	in	_	
163-173	41627-41638	adolescents	_	
163-174	41639-41643	with	_	
163-175	41644-41657	schizophrenia	_	
163-176	41657-41658	:	_	
163-177	41659-41660	a	_	
163-178	41661-41666	study	_	
163-179	41667-41671	with	_	
163-180	41672-41685	event-related	_	
163-181	41686-41696	potentials	_	
163-182	41697-41700	and	_	
163-183	41701-41711	functional	_	
163-184	41712-41720	magnetic	_	
163-185	41721-41730	resonance	_	
163-186	41731-41738	imaging	_	
163-187	41739-41745	Social	_	
163-188	41746-41756	perception	_	
163-189	41757-41759	as	_	
163-190	41760-41761	a	_	
163-191	41762-41770	mediator	_	
163-192	41771-41773	of	_	
163-193	41774-41777	the	_	
163-194	41778-41787	influence	_	
163-195	41788-41790	of	_	
163-196	41791-41796	early	_	
163-197	41797-41803	visual	_	
163-198	41804-41814	processing	_	
163-199	41815-41817	on	_	
163-200	41818-41828	functional	_	
163-201	41829-41835	status	_	
163-202	41836-41838	in	_	
163-203	41839-41852	schizophrenia	_	
163-204	41853-41860	General	_	
163-205	41861-41864	and	_	
163-206	41865-41873	specific	_	
163-207	41874-41884	functional	_	
163-208	41885-41897	connectivity	_	
163-209	41898-41910	disturbances	_	
163-210	41911-41913	in	_	
163-211	41914-41927	first-episode	_	
163-212	41928-41941	schizophrenia	_	
163-213	41942-41948	during	_	
163-214	41949-41958	cognitive	_	
163-215	41959-41966	control	_	
163-216	41967-41978	performance	_	
163-217	41979-41986	Linking	_	
163-218	41987-41999	microcircuit	_	
163-219	42000-42011	dysfunction	_	
163-220	42012-42014	to	_	
163-221	42015-42024	cognitive	_	
163-222	42025-42035	impairment	_	
163-223	42035-42036	:	_	
163-224	42037-42044	effects	_	
163-225	42045-42047	of	_	
163-226	42048-42061	disinhibition	_	
163-227	42062-42072	associated	_	
163-228	42073-42077	with	_	
163-229	42078-42091	schizophrenia	_	
163-230	42092-42094	in	_	
163-231	42095-42096	a	_	
163-232	42097-42105	cortical	_	
163-233	42106-42113	working	_	
163-234	42114-42120	memory	_	
163-235	42121-42126	model	_	
163-236	42127-42140	Circuit-based	_	
163-237	42141-42150	framework	_	
163-238	42151-42154	for	_	
163-239	42155-42168	understanding	_	
163-240	42169-42185	neurotransmitter	_	
163-241	42186-42189	and	_	
163-242	42190-42194	risk	_	
163-243	42195-42199	gene	_	
163-244	42200-42212	interactions	_	
163-245	42213-42215	in	_	
163-246	42216-42229	schizophrenia	_	
163-247	42230-42234	NMDA	_	
163-248	42235-42246	antagonists	_	
163-249	42247-42255	recreate	_	
163-250	42256-42271	signal-to-noise	_	
163-251	42272-42277	ratio	_	
163-252	42278-42281	and	_	
163-253	42282-42288	timing	_	
163-254	42289-42302	perturbations	_	
163-255	42303-42310	present	_	
163-256	42311-42313	in	_	
163-257	42314-42327	schizophrenia	_	
163-258	42328-42336	Cortical	_	
163-259	42337-42342	gamma	_	
163-260	42343-42347	band	_	
163-261	42348-42363	synchronization	_	
163-262	42364-42371	through	_	
163-263	42372-42384	somatostatin	_	
163-264	42385-42397	interneurons	_	
163-265	42398-42407	Conserved	_	
163-266	42408-42416	regional	_	
163-267	42417-42425	patterns	_	
163-268	42426-42428	of	_	
163-269	42429-42441	GABA-related	_	
163-270	42442-42452	transcript	_	
163-271	42453-42463	expression	_	
163-272	42464-42466	in	_	
163-273	42467-42470	the	_	
163-274	42471-42480	neocortex	_	
163-275	42481-42483	of	_	
163-276	42484-42492	subjects	_	
163-277	42493-42497	with	_	
163-278	42498-42511	schizophrenia	_	
163-279	42512-42521	Cognitive	_	
163-280	42522-42535	interventions	_	
163-281	42536-42545	targeting	_	
163-282	42546-42551	brain	_	
163-283	42552-42562	plasticity	_	
163-284	42563-42565	in	_	
163-285	42566-42569	the	_	
163-286	42570-42579	prodromal	_	
163-287	42580-42583	and	_	
163-288	42584-42589	early	_	
163-289	42590-42596	phases	_	
163-290	42597-42599	of	_	
163-291	42600-42613	schizophrenia	_	
163-292	42614-42619	Early	_	
163-293	42620-42635	neuromodulation	_	
163-294	42636-42644	prevents	_	
163-295	42645-42648	the	_	
163-296	42649-42660	development	_	
163-297	42661-42663	of	_	
163-298	42664-42669	brain	_	
163-299	42670-42673	and	_	
163-300	42674-42684	behavioral	_	
163-301	42685-42698	abnormalities	_	
163-302	42699-42701	in	_	
163-303	42702-42703	a	_	
163-304	42704-42710	rodent	_	
163-305	42711-42716	model	_	
163-306	42717-42719	of	_	
163-307	42720-42733	schizophrenia	_	
